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ABSTRACT 
Weston James Smith: The Role of Cobalamin in Biological Photochemistry 
(Under the direction of David Lawrence) 
 
This dissertation is divided into two parts.  The first part describes the development of small 
molecule drug delivery systems that exploit human erythrocytes as drug carriers and photolabile cobalamin-
drug complexes as light activated “switches”.  These complexes are activated by energy transfers from long 
wavelength fluorophores that act as antennae receptive to wavelengths of light that reside in the optical 
window of tissue.  The first of these delivery systems takes advantage of hydrophobic anchors to bind 
fluorescent antennae and cobalamin complexes to the exterior of erythrocyte membranes and allows the 
two to interact by free association.  The second of these systems appends the fluorophores directly to the 
cobalamin-drug complexes and these delivery units are loaded to the interior of the red blood cell through 
hypotonic pore formation.  Upon irradiation, these red blood cells release chemotherapeutics.   
 The second half of this dissertation describes cobalamin complexes designed for the study of 
cellular signal transduction.  First, a peptide substrate for the proto-oncogene tyrosine kinase Src is 
complexed with a cobalamin based membrane anchor, sequestering it inside of the glycocalyx of 
erythrocyte ghosts.  Photoactivation of the substrate with green light allows the substrate to diffuse away 
from the membrane allowing phosphorylation by Src.  This proof of concept demonstrates that membrane 
sequestration could be a viable means of sampling endogenous kinase activity in intracellular 
environments.  The second cobalamin based signaling tool is a “caged” cAMP dependent protein kinase 
that is inactive until illuminated with ≤ 577 nm light.  Such enzymes have been used in the past to study the 
effect of targeted bursts of enzyme activity in living cells.  We hope that our light activated enzyme will lead 
to technologies that allow multiple enzymes to be controlled in sequential order. 
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Chapter 1:  The Development of Photoactivated Molecules for Biological Study and the Promise of 
Cobalamin for the Future of the Field. 
 
1.1.  A Brief History of the Practice of Biomolecular Photoactivation 
In the years leading up to 1978, Joseph Hoffman realized that a significant barrier to studying 
enzymatic activity in intracellular environments would be the need to deliver bioactive molecules into a 
functionally complete system in such a way that they would be functionally inert until a measurement could 
be made1.  Previous work dating back to the 1960’s had used light to expose key functional groups of 
various small biomolecules2,3.  By appending one of these photoprotecting groups to the γ-phosphate of 
adenosine triphosphate (ATP), Hoffman generated what he called “caged ATP” wherein the molecule was 
rendered unusable to an ATP dependent Na, K ion channel until he irradiated it with 340 nm UV light 
(Scheme 1.1).  Demonstrating this further caged ATP was encapsulated in erythrocyte ghosts and 
photolyzed to instantly activate the membrane bound ion channels “upon command”, a feat that could not 
have been accomplished without the aid of photochemistry1.  This demonstration of exquisite temporal 
control would open up a new field of biology that would allow chemists to directly control the systems they 
wanted to study using rapid photochemical reactions. 
One year later Menasche Nass and Bernard Erlanger would move the field of biological 
photochemistry beyond the realm of proof of principle reactions when they used an azobenzene moiety to 
probe the mechanism of inhibition neural ion channel.  Using a photoisomerizable azobenzene inhibitor that 
was only bioactive in a cis configuration, researchers were effectively able to “instantaneously dose” an ion 
channel with an inhibitor due to the short time scales of the photochemical reaction that allowed researchers 
to selectively study open vs closed states an ion channel.  By activating the inhibitor when the channel was 
in its brief “open” state, they were able to selectively probe the channel in that configuration and determine 
a whether acetylcholine type inhibitors bound to the open or closed conformation of the channel4.  Without 
the precise temporal control offered by light, it would have been impossible to selectively probe the open 
vs closed state of the ion channel.  
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Scheme 1.1.  Hoffman synthesized a bio-orthogonal form of ATP by appending a ortho-nitrobenzyl moiety 
to the γ-phosphate of ATP.  Upon exposure to 340 nm light the photoprotecting group was cleaved away 
leaving a bioactive ATP, a substrate for many enzymes.  Mechanism shown in scheme 1.2. 
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Scheme 1.2.   Mechanism of o-nitrobenzyl cleavage.  X is eliminated via a Norrish type II mechanism.5  
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Figure 1.1.  (a) A photoisomerizable inhibitor of a Na+ channel is inactive in its relaxed trans configuration.  
Upon excitation with 360 nm light, the azobenzene moiety transitions into a cis configuration on the ms time 
scale.  (b)  By exciting when the ion channel was active the researchers confirmed that the inhibitor could 
bind to the open channel.  If the mechanism of binding had been stabilization of the closed confirmation, 
photolysis would have not caused a change in voltage of an active channel4. 
 
 
Reprinted with permission from Lester, H.; Krouse, M; Nass. M; Wassermann, N.; Erlanger, B. Light-
activated drug confirms a mechanism of ion channel blockade. Nature. 1979 280 (9), 509-510..© 1979 
Nature Publishing Group. 
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 A very short time after azobenzene derivatives were found to be useful in the study of membrane 
action potentials, “caged” ATP also found biological relevance in the study of muscle contraction.  Muscle 
fibers were stripped of their membranes and incubated with “caged” ATP.  The bio-orthogonal nature of the 
non-photolyzed construct allowed full equilibrium to be reached within muscular myofibrils.  Brief flashes 
with lasers rapidly “uncaged” significant amounts of ATP within the fibers, which must hydrolyze it in order 
to relax.  Thus upon photolysis, the muscle fiber would relax until the researchers washed away ATP and 
replaced it with the “caged” derivative.  By allowing the researchers to choose time T0 for their experiments 
there were no artifacts in their measurements from the rate of diffusion and they could effectively gauge the 
rates of muscular relaxation and contraction due to consumption of ATP6 (Figure 1.2). 
Half a decade after its inception in the late seventies, the field of biological photochemistry was still 
limited to one photocleavable molecule and a small class of photoisomerizable inhibitors that were largely 
restricted to studying ion channels.  The early successes of “caged” ATP and azobenzene inhibitors  had 
proven the utility of being able to “instantaneously dose” a biological system with a desired reagent.   It was 
well known that cellular signal transduction often happened through instantaneous and transient “bursts” of 
ions or small molecules.  The desire to mimic these characteristic would lead to the first light controlled 
signaling pathways7. 
 In 1984, the nitrobenzyl caging strategy was applied to cyclic AMP and cyclic GMP (Figure 1.3).  
The photochemical reaction involved in photolysis of these new reagents was nearly equivalent to their 
ATP counterparts.  However biochemically the step was more profound.  Instead of needing to generate 
half a millimolar or more of ATP in order to see a physiological change, spikes of a few µM could lead to 
drastic cellular consequences.  These caged cyclic nucleotides were cell permeable giving them the 
advantage of being applicable in cell culture without microinjection.  Flash photolysis of cells incubated with 
these “caged” cyclic nucleotides showed an increase in ion channel activity that was dependent on cell 
type8.     
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Figure 1.2.  Muscle fibers were incubated with 5 mM ATP to keep them in a relaxed state.  After washing 
away ATP and replacing it with “caged” ATP, the fibers stiffened (top) and the contractile force of the muscle 
increased (bottom).  Because muscle fibers consume ATP in order to relax, a laser pulse in the presence 
of 5 mM “caged” ATP triggered the fiber to relax and the kinetics of this process could be properly studied.  
Surprisingly, in the presence of calcium, the laser pulse triggered the opposite effect and intense transient 
contractile force was generated6.  Without the ability to permeate the fiber with quiescent form of ATP, the 
tissue would move differentially at the rate of perfusion, creating an artificial motion that had nothing to do 
with its biological design. 
  
 
Reprinted with permission from Goldman, Y.; Hibberd, M.; Trentham D. Relaxation of rabbit psoas muscle 
fibres from rigor by photochemical generation of adenosine-5'-triphosphate. J Physiol Lond. 1984 354, 605-
624.© 1984 The Physiological Society. 
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 Two years later, Roger Tsien and Robert Zucker described a calcium chelator with a 160 nM affinity  
for calcium ions that showed a 40 fold drop in binding affinity upon photolysis.  Calcium is normally 
sequestered in intracellular organelles such as the endoplasmic reticulum.  Previously used methods relied 
on secondary effects of cell stimulus or toxins to release calcium into the cytoplasm or ionophores to carry 
calcium across the outer membrane (also toxic).  Tsien was able to microinject calcium bound to his 
photolabile chelator and create a bio-orthogonal reservoir of calcium that remained inactive until exposed 
to light (Figure 1.3).   This gave biologists absolute control over spikes in intracellular calcium that more 
accurately resembled a biological cascade9.  Both Tsien and Zucker would go on to describe other 
examples of neurological activation using this elegant approach that could mimic the cell’s own signaling 
mechanisms as opposed to previously utilized ion channel blockers and other toxins10,11. 
In 1989 Timothy Mitchison decided to use the nitrobenzyl moiety to create profluorescent molecules 
that could only be visualized via flash photolysis, inventing a new method for visualizing intracellular motion.  
Before photoactivation of fluorescence (PAF) imaging, movement was visualized by photobleaching 
fluorescently labeled biomolecules and monitoring for the reappearance of fluorescence over time.  PAF 
allowed one to visualize a small portion of fluorescently labeled biomolecules to observe against a dark 
background, allowing the researcher to track their movements with far greater signal to noise ratios than 
previously possible.  These were of great use in studying tubulin12,13 and actin14 dynamics in living cells 
(Figure 1.4).  These studies mark one of the first exploitations of both spatial and temporal control afforded 
by photoactivation. 
By the early nineties the field of biological photochemistry had seen an explosion in the number of 
photoprotecting groups used in the service of “caging” biomolecules15.   Chemists sought to eliminate the 
need to disentangle the kinetics from their photoprotecting groups from processes they wished to study.  
Attempts were made to double quantum yields by placing two nitrobenzyl derivatives on the same leaving 
group16.  Some photoprotecting groups never gained much traction because their synthesis was non-trivial17 
or suffered undesirable side reactions that negatively impacted the yield of photolytic release of the desired 
biological agent18.  Many caging agents produce reactive species that were damaging to the systems being 
studied7,15.  However, the new diversity in the photochemical tool kit was beginning to allow researchers to 
tailor their caging strategy for optimal performance in the systems they wished to study (Figure 1.5).  
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Figure 1.3.  (Left) “Caged” cAMP migrates across lipid bilayers of cells and remains largely inactive until 
exposure to 360 nm light in analogous fashion to caged ATP (Scheme 1.1)8.  (Right) The chelator is not 
cleaved with light but makes use of the photochemical changes to the nitrobenzyl moiety itself.  The subtle 
changes in orientation and molecular orbitals were enough to decrease affinity to calcium by 40 fold9. 
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Figure 1.4.  (top) Phase contrast image of neural axon.  (middle) Photolyzed fluorescein labeled tubulin 
polymerized into microtubules.  Tubulin is seen migrating down the axon toward the dendrite body of the 
neuron (time after photolysis is marked on the figure in minutes).  (bottom) Structure and photolysis of 
“caged” fluorescein. 
 
 
 
Reprinted with permission from Reinsch, S.; Mitchison, T.; Kirschner, M.  Microtubule polymer assembly 
and transport during axonal elongation.  J Cell Biol.  1991, 115 (2), 365-379. © 1991 Rockefeller University 
Press. 
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Figure 1.5.  Although structurally diverse, each caging group has at least two common properties.  They 
each release a heteroatom of one form or another and they all require UV light to trigger the release of their 
cargo15,19. 
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Despite the growing number of photoactivating groups, the popularity of the nitrobenzyl caging 
group became more wide spread due to the simplicity of the chemistry involved, the predictable and reliable 
photochemistry, and the fact that other caging groups offered little improvement.  Regardless of whether 
one wanted to deprotect using a nitrene18 or end up with an indole19 the wavelength of activation was always 
limited to 350-365 nm (or even shorter)15.   This was not such a draw in the 90’s as whole animal 
experiments were not as common place as they are today.  The lack of tissue penetration afforded by UV 
light was not yet of great concern and the number of nitrobenzyl mediated caged compounds ballooned.    
Over 10 years after the first signaling molecules were caged (cAMP and cGMP) the literature was becoming 
populated with a diverse array of caged signal transduction agonists, some of which are represented in 
Figure 1.620.  It was becoming clear that photoactivation of enzymatic agonists was the closest analogue 
to their natural release in biological systems. 
 The 90’s saw a blossoming of biological photochemistry into a field that could make real 
contributions in the elucidation of biological mechanism and function within living cells.  Hoffmann’s caging 
principle was finding broad utility in the study of signaling pathways.  The increased availability of 
microscopes that could selectively photolyze part of a cell allowed more researchers to exploit the potential 
of spatial control of photoactivation15,21.  The increased accessibility and scope of solid phase peptide 
synthesis would allow for kinase and protease substrates that were inactive until photolyzed and light 
mediated peptide protein interactions. A nitrobenzyl moiety can be appended onto an amino acid either on 
a side chain22 or as part of the backbone23 and be incorporated into the peptide without any significant 
deviation in synthetic procedure22-24 (Figure 1.7).  Together these two innovations would bring the field of 
biological photochemistry into the modern era.  
1.2.  The Problem with Ultraviolet Light 
 Despite their great versatility, nitrobenzyl derivatives are limited by the fact that they all require 
UV light to change the biological activity of a biomolecule.  Many have seen this limitation as a benefit in 
that cells can be monitored using visual wavelengths without any effect on caged molecules12.  While this 
is a great convenience to the cellular biologist, it ties the hands of those who wish to do in vivo work or 
simply study cells in any environment closely resembling living tissue.  It is well established that only  
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Figure 1.6.  A sample of bioactive molecules that were “caged” in the 90’s.  The nitrobenzyl moiety is, as 
of this writing, by far the most commonly used chemical group for photoactivation20. 
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Figure 1.7.   Prominent examples of peptide photochemistry.  (a) Kinase substrates can be unavailable for 
phosphorylation until illuminated with UV light by appending a nitrobenzyl moiety on the site of phosphoryl 
transfer25.  (b) A nitrobenzyl moiety attached to the fmoc-protected amine of an amino acid will protect the 
resulting peptide backbone from proteolysis23.  (c)  A nitrobenzylic amino acid can be incorporated into a 
peptide to make a photocleavable backbone26. 
  
a) 
b) 
c) 
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longer wavelengths of light have the ability to penetrate deeper into living tissue due to light scattering and 
the inner filter effect of biomolecules at short wavelength.  This is known as the optical window of tissue.  
Shorter wavelengths are absorbed and scattered while wavelengths longer than 1000 nm are absorbed by 
water27 (Figure 1.8).  Furthermore this inner filter effect is not simply a benign nuisance that can be 
compensated for by increasing the power of the light source.  Molecules excited by UV light can produce 
radicals that damage cellular components or simply become bleached and useless to their host, thus 
perturbing the system in uncontrolled ways28.  The desire to avoid unintentional perturbations is what leads 
many to use caged compounds in the first place.  
In an attempt follow the leading edge of research into living animals, there has been an extensive 
effort to add to the usable wavelengths of photolysis to the molecular biologist’s toolkit for caging 
compounds.  One such method is use of “two-photon” chemistry that focuses an intense beam of light so 
concentrated that a molecule can absorb two photons nearly simultaneously.  When this happens it has the 
effect of absorbing one photon of half the wavelength.  What this means is that a nitrobenzyl group that 
absorbs maximally at 350 nm could be excited using a very intense beam of 700 nm light.  This is done by 
applying short bursts of very high intensity light (typically each pulse has a power of over 1000 W) and 
focusing the light on as small an area as possible.  This creates a small three dimensional space within 
which a molecule of interest can be excited.  Unfortunately not every molecule has a usable two photon 
cross section and the most commonly used caging agents function poorly under these conditions so new 
photoprotecting groups have had to be synthesized.  The kinetics of photo release mediated by two photon 
processes are not as easy to control as the relationship between increased illumination power and 
photolysis is non-linear.  As a result significant single photon sample heating is often observed with this 
method29,30. 
1.3.  Attempts to Red Shift the Wavelengths of Photoactivation  
 Similarly, there has been an effort in the single photon realm to push the wavelength of activation 
for caging groups farther red.  One of the first widely used family of caging groups that took advantage of 
visible light were the coumarin derivatives (2002)31.  These groups were useful in extending the 
wavelengths of photolysis into the visible spectrum (400-450 nm).  Another class of blue light caging groups 
are the ruthenium bipyridyl complexes, which spontaneously expel ligands at 450 nm illumination (2006)32.    
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Figure 1.8.  Visualization of the optical window of tissue.  The visible and Near Infrared (NIR) absorbance 
of a 1 cm barrier of blood (blue line), deoxygenated blood (red line), fat (green), and water (orange dots). 
 
 
Reprinted with permission from Quek, C.; Leong, K.  Near-Infrared Fluorescent Nanoprobes for in Vivo 
Optical Imaging.  Nanomaterials.  2012, 2, 92-112.   © 2012 MDPI AG (Basel, Switzerland). 
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Figure 1.9.  Selected visible wavelength caging groups.  (a)  Coumarin caged GDP (b) red light sensitive 
azobenzene ion channel gate (c) Bodipy release of histamine at 500 nm (d) an alternative Bodipy cage that 
functions more like a coumarin (e) A cyanine dye that releases fluorescent coumarin as it photobleaches.  
Of these, only the coumarin have been used in independent biological studies that go beyond a proof of 
concept. 
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Wooley and colleagues recently discovered that ortho substituents on the azobenzene photosystem extend 
its isomerization potential into the red (2014)33.  Bodipy fluorophores have been shown to release functional 
groups similarly to the coumarin derivatives using green light (2014)34,35.  Cyanine dyes have recently been 
shown to photobleach in a manner that can deprotect functional groups using red light (2014)36.  Finally the 
recently discovered upconverting nanoparticles have made it possible to excite a system with 960 nm light 
and emit photons in the UV spectrum.  Researchers recently used this phenomenon to use infrared light to 
release an HIV drug using nitrobenzyl derivatives (2014)37. 
1.4.  Cobalamin Photochemistry 
As far as we know, Vitamin B12 (or cobalamin) is essential for every living animal on earth.  The 
species that do not synthesize it must get it from their diet38.  It is the most complicated of all the essential 
vitamins and is used primarily for carbon skeletal rearrangements.  As such it is used by life as a controlled 
source of carbon centered radicals (Figure 1.10).  In biology these are generated in sudden conformational 
changes in the enzymes containing the cofactor39.  However, a convenient side effect of this is a willingness 
to undergo homolytic cleavage of the cobalt carbon bond upon excitation with any light that the cobalamin 
can absorb.  At the time our work began, the longest wavelength anyone had reported for photocleavage 
of a caging group was around 450 nm40. Since alkyl cobalamins absorb at wavelengths as long as 577 nm, 
they seemed like an attractive option for extending the wavelengths of photoactivation out of the blue 
spectrum. 
 Given the complexity of the B12 complex, it is surprisingly simple to functionalize.  Reduction with 
zinc creates a nucleophilic Co(I) species that reacts very readily with alkyl halides.  Activation by carbonyl 
ditriazole allows amines to be linked to the 5’ –OH of the cobalamin ribose, forming a carbamate.  Anything 
attached via the Co-C bond is cleaved away upon irradiation with light, and anything attached to ribose 
remains attached to the cobalamin.  These two simple reactions form the basis of all of the caged 
compounds we have been able to create. 
1.5.  The Principle of Cobalamin Regulated Biological Activity 
The term “cage” implies an image of “trapped” activity.  Thus far, that has been an adequate 
description of photoactivatable molecules.  Whether it is a photoisomerization that toggles a molecule from 
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Figure 1.10.  The role of cobalamin in the mechanism of methylmalonyl coenzyme A mutase.39 
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bio-orthogonal to bioactive or a key functional group modification that is reversed upon photolysis, one can 
think of a caged molecule as inactive or quiescent.  Looking at Figure 1.11, we see the work of Dr. Thomas 
Shell et al. in the attempt to “cage” doxorubicin, cAMP, and a Bodipy fluorophore41.  One would think that 
the size of the appended B12 alone would be sufficient to disrupt the interaction between the small molecule 
and any endogenous targets.  However, it was found that cAMP tethered to cobalamin is still capable of 
activating PKA.  However, none of these three molecules is able to achieve their biological function in cell 
culture in the absence of photolysis because of the sequestration effects of cobalamin trafficking inside 
cells38.   
Cobalamin remains inside of endosomes in living cells until removed via active transport, which 
may or may not recognize a particular modified cobalamin42,43.  Therefore each of these compounds were 
trapped, endosomally, away from their targets until illumination caused the Co-C bond to break.  So instead 
of caging the compounds, cobalamin sequesters them by dominating their cellular fate until photolysis 
releases them from the endosomal compartment they were trapped inside of.  So in this sense we have not 
made cobalamin into a caging group but a photolabile sequestering group.  As such we had to think beyond 
the old caging group paradigm in order to find practical applications for our new system. 
This begs the question of why go to the trouble of using a system that operates on a fundamentally 
different principle than all previous photoprotecting groups?  What is the advantage in generating a carbon 
based radical over heterolytic cleavage of an oxygen or a thiol?  For one, radicals can do things that anions 
(the typical leaving group in a caged compound) cannot.  Alkyl radicals can abstract a hydrogen from their 
environment to release alkyl chains instead of heteroatoms.  We have found that in a biological context this 
happens for the majority of cleavage events and have shown that this is a useful function in the release of 
small hydrophobic drugs such as colchicine44.  Homolytic cleavage can cause damage, which can be 
negligible45 or devastating46 depending on how the concentration of radicals and the photolysis conditions 
(factors controlled by the researcher).  However, beyond radical generation, the true gain of this system is 
the fluorescent antenna effect. 
1.6.  Cobalamin Allows Access to the Opitical Window of Tissue 
Work done by Shell et al. revealed that energy transfers between cobalamin and fluorophores could 
greatly accelerate the rate of photolysis (presumably because fluorophores typically have far higher  
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Figure 1.11.  Cobalamin sequestered small molecules.  (top) The structure of three cobalamin sequestered 
small molecules: Doxorubicin, cAMP, and Bodipy 650.  (a) HeLa cells in the presence of Cbl sequestered 
cAMP.  (b)  HeLa cells after photolysis of Cbl sequestered cAMP.  (c)  Bopidy trapped in endosomes before 
photolysis.  (d)  Bodipy migrates to mitochondria after photolysis. 
 
 
 
Reprinted with permission from Shell, T.; Shell, J.; Rodgers Z.; Lawrence, D. Tunable Visible and Near-IR 
Photoactivation of Light-Responsive Compounds by Using Fluorophores as Light-Capturing Antennas  
Angew Chem Int Ed Engl. 2014 53 (3), 875-878.  © 2014 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim 
a b c 
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extinction coefficient than cobalamin by itself).  Additionally, appending a fluorophore that is excited in the 
near IR region can cause cleavage to occur at wavelengths where cobalamin does not absorb light at all41.  
An energy transfer, the mechanism of which is not understood, from the fluorophore to the cobalamin results 
in cleavage of the β-axial ligand of cobalamin.  This phenomenon allows photoactivation at any wavelength 
of light capable of exciting the appended fluorochrome and affords access to the entire spectrum of the 
optical window of tissue. 
 In the following chapters it will be demonstrated how cobalamin can function to modulate the activity 
of small molecule drugs, peptide substrates, and whole enzymes.  We demonstrate that cobalamins can 
function in human blood, an important step in whole animal studies.  These works will hopefully convince 
the reader of the great promise that cobalamin has in the field of biological photochemistry. 
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Chapter 2: Membrane Mediated Assembly of Near IR Activated Phototherapeutics 
(Reproduced with permission from Smith, W. J.; Oien, N. P.; Hughes, R. M.; Marvin, C. M.; Rodgers, Z. L.; 
Lee, J.; Lawrence, D. S. Cell-Mediated Assembly of Phototherapeutics. Angew. Chemie - Int. Ed. 2014, 
10945–10948.  © 2014 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim) 
2.1.  Background 
The use of light to activate therapeutic agents at disease sites offers  the  advantage  of  aggressive  
treatment  with  exquisite spatial  control,  thereby  reducing  potential  deleterious  side effects at unintended 
sites. An excellent example of this concept is  photodynamic  therapy,  which  employs  the  delivery  of  a 
photosensitizer  to  the  tissue  of  interest.1  Upon  excitation  with the  appropriate wavelength  of  light  
and,  in  the  presence  of oxygen,  cytotoxic  reactive  oxygen  species  are  generated, resulting  in  
destruction  of  the  target  cells.  This  minimally invasive  procedure  furnishes  control  over  where  and  
when  the reactive oxygen species are produced. However, a more general strategy  that  can  control  the  
delivery  of  any  drug  could profoundly  influence  the  treatment  of  a  variety  of  disorders, including  
cancer,  diabetes,  and  autoimmune  and  vascular diseases.   
A  major  challenge  in  this  regard  is  the  so-called “optical  window  of  tissue”,  the  wavelength  
of  light  that  enjoys maximal tissue penetration, which lies in the range of 600 – 900 nm (see Figure 1.8 
for detail)2.  Wavelengths  less  than  600  nm  are  absorbed  by hemoglobin  in  the  circulatory  system  
and  melanin  in  the  skin whereas  water  interferes  with  light  penetrance  >900  nm.   Unfortunately, 
nearly all light-activatable pro-drugs described to date respond to short wavelengths <450 nm3,4.  This 
limitation is responsible for the intense  interest  in  two-photon5 and up converting6 technologies.  However, 
as  discussed  in recent reviews,5,6 both  technologies  must  overcome  daunting challenges before potential 
therapeutic applications are realized.  We recently described the long wavelength (>600 nm) photolysis of 
alkylcobalamins (alkyl-Cbl)7.  We now report the cell-mediated assembly of lipid-Cbl-drug and lipid-
fluorophore conjugates in which  the  latter  serve  as long  wavelength light capturing antennas that promote 
drug release. 
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Figure 2.1.  An a priori selected wavelength of drug release  strategy.  Anti-inflammatory drugs are 
covalently  appended  to  cobalamin  via a  weak  photolabile Co-C bond.  Lipidated-cobalamin and 
fluorophore constructs assemble on the plasma membrane of human erythrocytes. The fluorophore serves 
as an antenna, capturing long wavelength light and transmitting the energy to the Cbl-drug, resulting in drug 
release from the erythrocyte carrier.  The photolysis  wavelength is selected a priori by the experimenter 
through selection of a fluorophore with a desirable excitation spectrum.  Alternatively the cobalamin itself 
can be directly excited with wavelengths ≤ 577 nm. 
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Erythrocytes  have  been  called  the  “champions  of  drug delivery”  due  to  their  biocompatibility,  
their  long  life  span  (120 days), and their size, which allows large quantities of drug to be conveyed relative 
to other carriers8.  However, “practically useful controlled release from carrier RBC (red blood cells) remains 
an elusive goal”.  Our strategy to address this issue is depicted in Figure 2.1.  Based  on  a  previously  
demonstrated  energy  transfer between  fluorophores  and  Cbls  in  covalently  appended  Cbl-fluorophore 
conjugates7, we decided to explore the premise that a  cell-mediated  assembly of  C18-Cbl-drug  and  C18-
fluorophore conjugates could  act  in  concert  as  a  photo-responsive  drug delivery  system.  Illumination  
of  the  fluorophore  antenna  at  its λmax and  subsequent  energy  transfer  to  the  Cbl-drug  moiety should  
result  in  cleavage  of  the  weak  Co-C  bond7,9,10,11,12, thereby liberating the drug. 
2.2.  Design and Synthesis of Anchored Compounds 
 A  series  of  lipid anchored cobalamins  (C18-Cbl)  and  C18–fluorophore derivatives  were  prepared  
(Figure  2.2  and  Figure 2.3 and Schemes 2.3-2.10). In the case of the cobalamin derivatives, the C18 
moiety was appended to the 5ʹ ribose –OH of cobalamin using octadecylamine (ODA) and carbonyl-di-
triazole (CDT).  Subsequent  alkylation of the Co furnished an amine or carboxylic acid handle, upon which 
drugs and fluorescent  reporters were covalently attached (Figure 2.2). These species include the anti-
inflammatories  methotrexate (MTX),  colchicine  (COL),  and  dexamethasone  (DEX),  and  the fluorescent  
reporters  tetramethylrhodamine  (TAM)  and fluorescein  (FAM).  The C18–fluorophore  derivatives  were 
prepared via direct condensation of the activated carboxylate of the fluorophore with the amine of 
octadecylamine.   
2.3.  Measuring a Light Dependent Change in Hydrophilicity of Lipid Tethered Molecules 
 Our  initial  studies  sought  to  explore  the  premise  of  Figure  2.1  strategy  by  establishing  light-
triggered  movement  of drugs  and  reporters  from  a  hydrophobic  environment  to  an aqueous  one.  
For these preliminary  experiments  we  directly photolyzed C18-Cbl-drug and C18-Cbl-reporter conjugates 
at the cobalamin  absorbance  wavelength  (525 nm) in an octanol / water partition.  As expected,  both 
C18- Cbl-TAM and C18-Cbl-MTX are soluble in octanol. Illumination at 525  nm  cleaved  the C18-Cbl-TAM  
cobalt-carbon bond  and  promoted migration  of  TAM  from  octanol  to  water  as hydrophilicity assessed  
by fluorescence as seen in Figure 2.4.  In an analogous fashion, 525  nm  illumination  of C18-Cbl-MTX  
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Figure 2.2. Lipidated  Cbl-reporters,  TAM  (C18-Cbl-TAM) and FAM (C18-Cbl-FAM) and lipidated Cbl-drug 
conjugates, MTX (C18-Cbl-MTX), COL (C18-Cbl-COL), and DEX (C18-Cbl-DEX). 
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Figure 2.3.  Structure of C18 conjugated fluorophores used in this study.  Their ʎmax excitation wavelengths 
are: C18-Cy5, 646 nm; C18-AF700, 700 nm, C18-Cy7, ʎmax : 747 nm; and C18-DY800, ʎmax : 784 nm. 
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Figure 2.4.  Light induced migration of TAM from octanol to water monitored by fluorescence of the aqueous 
layer.  C18-Cbl-TAM (primarily soluble in the octanol layer) in a water/octanol partition was photolyzed at 
525 nm.  Fluorescence of TAM in the water layer ʎex: 555 nm ʎem: 585 nm. Photolysis time: 0 (red), 1 
(orange), 2 (yellow), 3 (green), and 10 min (blue). The inset shows the emission spectrum of aqueous TAM 
(570 nm – 600 nm).  Data are represented as averages with standard errors of three independent 
experiments. 
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Figure 2.5.  Light induced migration of MTX from octanol to water as quantified by the MTX LC-MS assay.  
C18-Cbl-MTX (primarily soluble in the octanol layer) was photolyzed using 525 nm LEDs.  Migration is 
represented as the mole percent of total amount of MTX found in the aqueous layer.  Data are represented 
as averages with standard errors of three independent experiments. 
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triggered  the  release  of MTX  into  the  aqueous  phase  as  demonstrated  by  LC-MS  (Figure  2.5).  We  
subsequently  explored  the  light triggered  transfer  of  drug/reporter  from  the  lipophilic  plasma membrane 
of erythrocytes to the aqueous milieu.  
2.4.  Demonstration of Small Molecule Loading and Release From Erythrocyte Membranes 
First, exposure of  erythrocytes  to C18-Cbl-TAM revealed  even  and  extensive loading  as  
assessed  by  widefield  fluorescence  microscopy.  The act of imaging the loaded erythrocytes was 
sufficient to cleave the fluorophore from the membrane.  In addition, given the established photolytic 
sensitivity of the Co-C bond,7,9,13 we  were  not  surprised  to  find  that  20 ms exposure of C18-Cbl-TAM to 
570 nm light on erythrocytes results in the rapid migration (<1 s) of TAM fluorescence  from  erythrocytes 
into solution (Figure 2.6).   
C18-Cbl-MTX, C18-Cbl-COL, and C18-Cbl-DEX were loaded onto intact human erythrocytes with 
minimal lysis (ca. 5% at 5 mM C18-Cbl-drug, Figure 2.7.  The amount of drug that could be loaded onto 
erythrocyte membranes was a linear function of the loading concentration (within a range of 1 to 10 µM).  
Loading capcity was remarkably similar for C18-Cbl-MTX and C18-Cbl-COL with slightly more efficient 
loading observed with C18-Cbl-DEX (Figure 2.8).  A typical loading concentration for the Cbl-Drug carriers  
was 4 µM cobalamin complex.  At that loading concentration, the amount of C18-Cbl-drug loaded per red 
blood cell was 0.3–1.0 fmol.  Subsequent photorelease of the drug was quantitative for C18-Cbl-COL and 
C18-Cbl-DEX and 35% for C18-Cbl-MTX (Figure 2.9).  We were able to accurately measure the 
concentrations of liberated drug with LC-MS analysis and comparison to known standards (Figure 2.10).   
LC-MS analysis revealed that photolysis of erythrocyte-anchored C18-Cbl-MTX primarily furnishes 
N-propylamide MTX (Figure 2.11; Scheme 2.1, and Tables 2.1–2.2). Consistent with the established 
structure–activity relationship of MTX derivatives,14,15 the photolyzed product of C18-Cbl-MTX serves as an 
effective inhibitor of dihydrofolate reductase (DHFR, Figure 2.12).   N-butanoyl COL is the primary 
photoproduct of C18-Cbl-COL loaded erythrocytes (Figure 2.11; Scheme 2.1, Tables 2.1–2.2).  DEX is the 
observed product from photolysis of C18-Cbl-DEX loaded erythrocytes, instead of one or more of the 
expected photoproducts (Figure 2.11 and Tables 2.1 – 2.2). The 21-esters of DEX are pro-drugs that are  
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Figure 2.6.  Erythrocytes loaded with 10 µM C18-Cbl-TAM and visualized at (a) long wavelength (λex= 650 
nm, λem= 684 nm) to prevent photo-cleavage of the Co-TAM bond.  Visualization and photolysis of C18-
Cbl-TAM at (b) λex= 570 nm, λem= 590 nm, with 20 ms exposure times. Photolysis occurred within the 
first time frame. Images were taken every 1/3 s.  After the first exposure, the fluorophore is nearly completely 
dissociated from the erythrocyte membrane and only present in solution.  All images were acquired using 
an Olympus IX-81 widefield fluorescence microscope with a 60x oil immersion objective.  
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Figure 2.7. Structural integrity of erythrocytes exposed to various concentrations of lipidated drug 
conjugates for 14 h. Leaked heme was measured by optical density at 550 nm minus the optical density of 
a DMSO control (7 ± 1%) and divided by the absorbance of a 100% lysed control (0.05% SDS). In this way, 
only hemolysis due to compounds was measured. Data are represented as averages with standard errors 
of three independent experiments. C18-Cbl-MTX (blue), C18-Cbl-COL (orange), and C18-Cbl-DEX (grey). 
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Figures 2.8.  Drug loading onto and release from human erythrocytes.  The figure shows the amount of 
drug photo-released from erythrocytes as a function of C18-Cbl-Drug loading concentration.  Samples were 
photolyzed to completion using 525 nm LEDs exposure for 2 h. Concentrations were determined by LC-
MS assays described for each drug. Data are represented as averages with standard errors of three 
independent experiments. C18-Cbl-MTX (blue), C18-Cbl-COL (orange), and C18-Cbl-DEX (grey).  Drug 
release quantity determined by comparison to known standards (Figure 2.10).   
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Figure 2.9.  Quantification of drug loading and photo-release. Erythrocytes (200 µL, 5% hematocrit) were 
incubated with 4 µM of each Cbl drug conjugate for 30 min. At the end of this time, three washes were 
performed in which the erythrocytes were spun down at 1000 g and the PBS buffer was exchanged. 
Supernatants were collected, pooled, photolyzed for 30 min at 525 nm, and then analyzed by the various 
LC-MS assays described for each drug (Figure 2.10).  This provided a measure of the C18-Cbl-drug that did 
not bind to the membranes.  The erythrocytes were resuspended at 200 µL and photolyzed for 1 h at 525 
nm and the supernatant was analyzed by the drug specific LC-MS assays (Fig. 2.10).  Black bars represent 
the total amount of drug loaded onto erythrocytes at 5% hematocrit in 200 µL.  Conversion of the y-axis 
values to fmol of C18-Cbl-Drug per RBC was calculated from the experimentally derived value of 2.3 ± 0.1 
x 107 RBC/mL (5% hematocrit): 0.28 ± 0.04 fmol of C18-Cbl-DEX/RBC,1.03 ± 0.03 fmol of C18-Cbl-
COL/RBC, and 0.57 ± 0.01 fmol of C18-Cbl-MTX/RBC.  White bars represent the amount of drug liberated 
from photolysis into the supernatant. Data are represented as averages of three independent experiments. 
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Figure 2.10.  (a) The standard curve 
used with MTX LC-MS assay was 
generated by titration of known 
amounts of commercially available 
MTX and subsequent analysis of the 
area under the curve by UV-Vis (300 
nm) via LC-MS; concentrations used 
were 1.0 µM, 0.5 µM, 0.1 µM, 0.05 µM, 
and 0.01 µM. Data are represented as 
averages of three independent 
experiments.  (b) standard curve used 
with COL LC-MS assay was generated 
by titration of known amounts of 
commercially available COL and 
subsequent analysis of the area under 
the curve by UV-Vis (365 nm) via LC-
MS. Concentrations used were 5 µM, 
1 µM, 0.5 µM, 0.1 µM. Data are 
represented as averages of three 
independent experiments; (c) 
standard curve used with DEX LC-MS 
assay was generated by titration of 
known amounts of commercially 
available DEX and subsequent 
analysis of the area under the curve by 
UV-Vis (239 nm) via LC-MS; 
concentrations used were 5.0 µM, 2.5 
µM, 1 µM, 0.5 µM, and 0.1 µM. Data 
are represented as averages of three 
independent experiments. 
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Products of C18-Cbl-Drug Photolysis 
 
Scheme 2.1.  Mechanism and products of alkyl cobalamin photolysis.  Photolysis results in the homolytic 
cleavage of the cobalt carbon bond producing a primary carbon centered radical and a cobalt II species.  
In the absence of oxygen, recombination dominates and the parent compound is restored.  In aerobic 
environments, the alkyl radical reacts with oxygen to form a peroxy radical.  This is believed to react with 
cob(II)alamin to generate the final products of photolysis.  When this process takes place on a biological 
membrane, which could act as a radical trap, hydrogen abstraction likely plays a pivotal role in the 
determination of these products. 
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Figure 2.11.  Erythrocyte-released photoproducts of C18-Cbl-MTX, C18-Cbl-COL and C18-Cbl-DEX. In the 
case of C18-Cbl-DEX, DEX is observed, instead of the possible photoproducts (X = H, OH, or =O). 
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C18-Cbl-Drug 
Elution Time 
(min) 
Predicted Masses 
(M + 2H+) z=2  
m/z 
Detected Masses 
(M + 2H+) z=2 
 m/z 
C18-Cbl-MTX 6.8 1060.0 1060.3 
C18-Cbl-COL 7.3 1026.0 1026.5 
C18-Cbl-DEX 7.5 1079.1 1079.3 
 
Table 2.1.  Elution times and predicted/detected masses of intact C18-Cbl-MTX, C18-Cbl-COL, and C18-
Cbl-DEX when analyzed by their various LC-MS assays using the gradient from Table 2.8. 
 
 
 
Elution Time (min) Yield (mole fraction) 
 
X = H X = OH X = O C18-Cbl X = H 
Other 
Products 
C18-Cbl-MTX 3.3 2.9 3.1 6.8 0.83 0.17 
Mass 494.2 510.2 528 812.8 
 
 
C18-Cbl-COL 4.7 4.4 4.4 6.7 0.20 0.80 
Mass 426.1 442 460 812.7 
 
 
C18-Cbl-DEX 5.5 5.5 5.5 6.7 n/a n/a 
Mass 514.3 533 532 812.7 
 
 
 
 
 
Table 2.2.  Elution times and detected masses of the photocleavage products for C18-Cbl-MTX, C18-Cbl-
COL, and C18-Cbl-DEX after illumination at 525 nm light for 20 min in PBS buffer, pH 7.4. These products 
are described in detail in Scheme 2.1. Detection was performed using the MTX, COL, and DEX LC-MS 
assays. The solvent gradient is described in Table 2.8. Note that the aldehyde (X=O) byproducts are 
detected in the hydrated form for cleaved MTX and COL but not for DEX. 
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Figure 2.12.  Inhibition of DHFR by MTX (circles) and photolyzed erythrocyte-bound C18-Cbl-MTX 
(triangles). 
  
43 
 
hydrolyzed to DEX in vivo.16,17 The possible presence of blood esterases18 may explain the formation of 
DEX once freed from the RBC surface. 
2.6.  Delivery of Drugs Via Photolysis from Erythrocyte Membranes 
Red blood cells were co-incubated with HeLa cells.  Photolyzed C18-Cbl-COL disrupts microtubules 
in HeLa cells as effectively as COL itself (Figures 2.14 and 2.15).   In addition, photoreleased MTX from 
erythrocyte-anchored C18-Cbl-MTX binds to DHFR in HeLa cells (Figure 2.13).  Photo-release of DEX from 
C18-Cbl-DEX-loaded erythrocytes co-cultured with HeLa cells results in the migration of glucocorticoid 
receptor α (GRα) from the cytosol to the nucleus in HeLa cells (Figures 2.16 – 2.17). We note that, in the 
absence of illumination, C18-Cbl-MTX, C18-Cbl-COL, and C18-Cbl-DEX loaded erythrocytes do not cause a 
phenotypical change in HeLa cells (Figures 2.14, 2.16, 2.18). 
2.7.  Demonstration that C18-Cbl-Drugs do not “Jump“ from Erythrocytes. 
We also examined whether C18-Cbl-drugs transfer from erythrocytes to HeLa cells in the absence 
of light. HeLa cells were incubated with C18-Cbl-DEX-loaded erythrocytes and, subsequently, the adherent 
HeLa cells were washed to remove the red blood cells. If C18-Cbl-DEX had migrated to HeLa membranes 
during the incubation process, illumination at 525 nm should result in DEX release, uptake, and GRα 
migration. However, we did not observe receptor relocation to the nucleus, suggesting that C18-Cbl-DEX is 
retained by erythrocytes in the dark (Figure 2.18). 
2.8.  The Utility of Longer Wavelength Photolysis 
With the biological efficacy of the light triggered release of drugs from erythrocytes established, we 
turned our attention to the assembly of photo-responsive constructs that (1) operate within the optical 
window of tissue and (2) are encoded to respond to specific wavelengths. Our choice of anti-inflammatory 
drugs is based upon their role in the treatment of rheumatoid arthritis (RA). The long-term administration of 
anti-inflammatory agents produce moderate to severe side effects, such as weight gain, osteoporosis, 
diabetes mellitus, hypertension, skin fragility and infections arising from being systemically 
immunocompromised.19,20 Not surprisingly, there is significant interest in the development of therapeutics 
that can be selectively delivered to RA joints.21,22,23 With this in mind, we prepared C18 derivatives of Cy5  
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Figure 2.13. Assessment of MTX photo-release (@ 525 nm) from C18-Cbl-MTX-loaded erythrocytes via 
the cellular thermal shift assay (CETSA). In the absence of MTX (“Dark”, “No Treatment”, and “‘-‘MTX“) no 
DHFR is detected from HeLa cells following incubation of HeLa cells at 52 °C. By contrast, exposure of 
HeLa cells to C18-Cbl-MTX-loaded erythrocytes with increasing illumination times (10, 20, and 30 min) leads 
to increasing amounts of DHFR stable to 52 °C. Loading control: GAPDH. 
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Figure 2.14.  Effect of COL on microtubules in HeLa cells. COL was added to HeLa cell culture and allowed 
to incubate for 1 h before the cells were fixed and stained for tubulin to visualize microtubule networks. (a) 
DMSO only (b) 250 nM (c) 500 nM (d) 1 µM (e) 2 µM (f) 4 µM. At 2 µM COL well structured microtubules 
disappear and pools of depolymerized tubulin are visible at the cell periphery.  
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Figure 2.15. Effect of photo-released (@ 525 nm) COL from erythrocyte-bound C18-Cbl-COL on 
microtubules in HeLa cells. Human erythrocytes were loaded with C18-Cbl-COL (5% hematocrit, 6 µM).  (a) 
20 min photolysis at 525 nm, (b) dark, (c) no erythrocytes and dark, (d) no erythrocytes and 20 min 
photolysis at 525 nm. Disruption of microtubule networks from photolyzed C18-Cbl-COL (1.2 µM release 
according to Figure S6) is shown in panel a. 
 
 
a) b) 
c) d) 
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Figure 2.16. Effect of DEX on the subcellular location of GRα in HeLa cells. HeLa cells were stained with 
Alexa488 antiRabbit/anti-GRα (green) and HOESCHT 33342 (blue). (a) In HeLa cells treated with DMSO, 
GRα is largely cytosolic and does not co-localize with (b) nuclear HOESCHT 33342 stain. (c) In HeLa cells 
treated with 250 nM DEX, GRα migrates to the nucleus and (d) co-stains with HOESCHT 33342.   
 
 
Figure 2.17. Effect of photo-released (@ 525 nm) DEX from erythrocyte-bound C18-Cbl-DEX on the 
subcellular location of GRα in HeLa cells. (a) HeLa cells were treated with erythrocytes loaded with 1 µM 
C18-Cbl-DEX without photolysis. (b) HeLa cells were treated with erythrocytes loaded with 1 µM C18-Cbl-
DEX with 10 min photolysis at 525 nm. HeLa cells were stained with Alexa488 antiRabbit/anti-GRα. 
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Figure 2.18.  Assessment of C18-Cbl-DEX transfer between the erythrocyte and HeLa cell membranes. 
Erythrocytes were loaded with C18-Cbl-DEX (1 µM at 5% hematocrit). A 525 nm LED light source was used 
for all illumination experiments. (a) HeLa cells were exposed to C18-Cbl-DEX loaded erythrocytes in the 
dark for 1 h followed by removal of the erythrocytes via washing prior to photolysis and then fixed and 
stained for GRα. (b) HeLa cells were exposed to C18-Cbl-DEX loaded erythrocytes in the dark for 1 h 
followed by removal of the erythrocytes via washing; without photolysis; fixed and stained for GRα. (c) HeLa 
cells were not exposed to erythrocytes but were washed and illuminated; and then fixed and stained for 
GRα. In all instances, GRα remained cytosolic, indicating that DEX was not released from the erythrocytes. 
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(C18-Cy5; λex 646 nm), Alexa Fluor 700 (C18-AF700; λex 700 nm), Cy7 (C18-Cy7; λex 747 nm), and a 
DyLight 800 analog (C18-DY800; λex 784 nm) and examined whether they are capable of serving as long 
wavelength antennas for drug release. Photolysis experiments employed in-house constructed LED 
circuit boards centered at 660 nm (Cy5), 725 nm (AF700 and Cy7), and 780 nm (DY800) (Figure 2.19 
and Table 2.3). 
2.9.  Fluorophore Release from Erythrocytes by Long Wavelength Energy Transfer  
Our initial studies employed C18-Cbl-TAM in the presence of the C18-fluorophores, since the photo-
release of TAM from C18-Cbl-TAM labelled erythrocytes is readily monitored by fluorescence. In order to 
identify optimal energy transfer conditions, we first exposed erythrocytes to various relative concentrations 
of C18-Cbl-TAM and C18-Cy5. After washing the erythrocytes to remove any unbound C18-Cbl-TAM and 
C18-Cy5, the loaded RBCs were illuminated at 660 nm. The carrier erythrocytes were subsequently pelleted 
via centrifugation and TAM fluorescence in the supernatant measured. Although the most efficient TAM 
release was observed with erythrocytes exposed to 1 µM:10 µM of C18-Cbl-TAM:C18-Cy5 (Figure 2.20), we 
employed a 1 µM:5 µM ratio to keep disruption of the erythrocyte’s structural integrity at an absolute 
minimum. In addition to the C18-Cy5 @ 660 nm antenna, the photo-release of TAM from C18-Cbl-TAM-
loaded erythrocytes can be triggered at longer wavelengths in the presence of other antennas [C18-Cy7 @ 
725 nm, C18-Cy7 @ 725 nm, C18-DY800 @ 780 nm]. Figure 2.21 compares the fraction of TAM released 
as a function of (a) antenna wavelength, (b) power of the different LEDs, and (c) photon density. An 
analogous set of experiments with similar results was performed with C18-Cbl-FAM/C18-fluorophores 
(Figure 2.22). Erythrocytes in the dark do not release TAM or FAM and, erythrocytes lacking a fluorophore 
antenna do not release FAM or TAM at wavelengths longer than those absorbed by Cbl (Figures 2.23, 2.24, 
2.25). Finally, confocal microscopy revealed that the structural integrity of erythrocytes is not altered by the 
addition of the C18-fluorophores (Figure 2.26). 
2.10.  Drug Release from Erythrocytes by Long Wavelength Energy Transfer 
 
We subsequently examined drug photo-release from the erythrocyte-assembled drug/antenna 
array. C18-Cbl-MTX, C18-Cbl-COL, and C18-Cbl-DEX were each paired with C18-fluorophores and 
illuminated. LC-MS confirmed the release of MTX, COL, and DEX at the wavelength absorbed by the  
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Figure 2.19.  LED boards. All boards were powered with a 12V DC power supply.  LEDs were wired in 
units of 4 LEDs in series with a 100 Ω resistor in parallel.   
 
LED Wavelength 
(nm) 
Power 
(mW/cm2) 
Photon Flux 
(µmol photon/s-m2) 
525 1.50 ± 0.03 66 ± 1 
660 3.30 ± 0.02 183 ± 1 
725 6.00 ± 0.05 365 ± 3 
780 3.30 ± 0.02 216 ± 1 
 
Table 2.3. Power output of each of the LED arrays (Figure 2.20) after filters were applied to cut off 
wavelengths shorter than those specified. MacNan colored film gels (Aqua, Blue, Green, Magenta, and 
Red) were used in combination as filters for the following LEDs: 525 nm (Green), 660 nm (Red and 
Magenta), 725 nm (Red and Magenta), and 780 nm (Blue, Green, and Aqua). 
725 nm 780 nm 525 nm 660 nm 
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Figure 2.20.  Heat map of TAM release from erythrocytes (5% hematocrit) exposed to variable 
concentrations of C18-Cbl-TAM and C18-Cy5 followed by photolysis (30 min with 660 nm). The most efficient 
release (yellow/orange/red) is observed at low C18-Cbl-TAM:C18-Cy5 ratios. Given that lipid concentrations 
>10 µM begin to compromise erythrocyte structural integrity according to the Hemolysis Assay, we chose 
to employ 1 µM:5 µM Cbl-Drug:C18-fluorophore ratios in our initial studies. 
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Figure 2.21.  Photo-release of TAM from C18-Cbl-TAM/C18-fluorophore-loaded erythrocytes. LED arrays 
centered at 660 nm (Cy5), 725 nm (AF700 and Cy7), and 780 nm (DY800) were employed as the light 
sources. TAM release is displayed as the fraction liberated from erythrocytes. Total erythrocyte bound C18-
Cbl-TAM was determined via a time study where 3 h of illumination generated maximal TAM release. 
Unfilled bars: fraction of TAM release; Black bars: fraction of TAM release normalized by the power of the 
different light sources; Grey bars: fraction of TAM release normalized by photon density produced by the 
light sources; n = 3 for all experiments.  Power was normalized to C18-Cy5 by multiplying the fraction 
released (white bar) by a ratio of the power output of the LED board used to the output of the 660 board 
used for C18-Cy5 (Table 2.3).  Photon density normalization was carried out in a similar fashion with photon 
flux values reported in Table 2.3.  Data are represented as averages with standard errors of three 
independent experiments.   
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Figure 2.22. Release of FAM from erythrocytes loaded with C18-Cbl-FAM/C18-fluorophores (1 µM/5 µM) 
after 30 min illumination. Release is displayed as the fraction of FAM liberated out of the total amount of 
FAM bound. Total FAM bound was determined by measuring the concentration of FAM in the supernatant 
after 3 h of photolysis (@ 525 nm). The light sources employed were arrays of LEDs (shown in Figure 2.20) 
centered at 660 nm (Cy5), 725 nm (AF700 and Cy7), and 780 nm (DY800). The fraction of FAM released 
(white), the fraction of FAM release normalized by the power of the different light sources (black), and the 
fraction of FAM released normalized by photon density produced by the various light sources (grey). Power 
was normalized to C18-Cy5 by multiplying the fraction released (white bar) by a ratio of the power output of 
the LED board used to the output of the 660 board used for C18-Cy5 (Table 2.3).  Photon density 
normalization was carried out in a similar fashion with photon flux values reported in Table 2.3.  Data are 
represented as averages with standard errors of three independent experiments.   
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Figure 2.23. Release of TAM from erythrocytes loaded with C18-Cbl-TAM/C18-fluorophores (1 µM/5 µM) 
after 30 min of illumination. Release is displayed as the fraction of TAM liberated. The light sources 
employed are the LED arrays shown in Figure S18. In the absence of a long wavelength fluorescent 
antenna, illumination at 660, 725, or 780 nm fails to release membrane-tethered TAM. Data are represented 
as averages with standard errors of three independent experiments.   
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Figure 2.24. Release of TAM from erythrocytes loaded with C18-Cbl-TAM (1 µM) as a function of photolysis 
time. Release is displayed as the fraction of TAM liberated.  All samples were analyzed at 1 h. The light 
sources employed are the LED arrays (shown in Figure 2.19) centered at 525 nm (circles) and 660 nm 
(triangles). Data are represented as averages with standard errors of three independent experiments.   
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Figure 2.25.  Release of FAM from erythrocytes loaded with C18-Cbl-FAM (1 µM) as a function of photolysis 
time. Release is displayed as the fraction of FAM liberated.  All samples were analyzed at 1 h. The light 
sources employed were arrays of LEDs (shown in Figure 2.19) centered at 525 nm (circle) and 660 nm 
(triangle). Data are represented as averages with standard errors of three independent experiments.   
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Figure 2.26.  Confocal images of erythrocytes loaded with C18-Cy5. C18-Cy5 (5 µM) was added to 10% 
hematocrit erythrocytes. Following incubation, erythrocytes were washed, plated at 0.1% hematocrit, and 
imaged by confocal microscopy. DIC (left) Cy-5 fluorescence (middle), and overlay (right). Bar length = 5 
µm. 
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Elution Times (min) Yield (mole fraction) 
 
X = H X = OH X = O C18-Cbl X = H 
Other 
Products 
C18-Cbl-MTX  
 
     
525 nm 3.4 2.9 3 n/a 0.76 0.24 
660 nm (Cy5) 3.4 2.9 3 n/a 0.80 0.20 
725 nm (AF700) 3.3 2.9 3 n/a 0.80 0.20 
725 nm (Cy7) 3.4 n/a 3 n/a 0.80 0.20 
780 nm (DY800) 3.4 2.9 n/a n/a 0.80 0.20 
 
      
C18-Cbl-COL  
 
     
525 nm 4.6 4.3 4.3 n/a 0.91 0.09 
660 nm (Cy5) 4.5 n/a n/a n/a <0.94 
 
780 nm (DY800) 4.5 n/a n/a n/a <0.90 
 
 
 
Table 2.4.  Elution times for the products of C18-Cbl-MTX and C18-Cbl-COL after fluorophore assisted, 
photocleavage from erythrocytes. C18-Cbl-MTX was loaded with a 1:5 C18-Cbl-Drug:C18-fluorophore ratio. 
C18-Cbl-COL and C18-Cbl-DEX were loaded with a 1:1 C18-Cbl-Drug:C18-fluorophore. C18-Cbl-DEX is not 
listed in the table as the ester of the cleaved product is hydrolyzed upon photo-release (possibly due to the 
presence of esterases) and only DEX was recovered. Photolysis times were all 30 min at the wavelengths 
indicated. These products are described in detail in Scheme 2.1. Detection was performed using the MTX, 
COL, and DEX LC-MS assays. The solvent gradient is described in Table 2.8.   
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Figure 2.27. Release of MTX from C18-Cbl-MTX/C18-fluorophore-loaded erythrocytes. (a) MTX release was 
measured by the LC-MS MTX Assay following photolysis at the ʎex of each fluorophore. LED arrays (Figure 
2.20) were centered at 660 nm (Cy5), 725 nm (AF700 and Cy7), and 780 nm (DY800). Data are represented 
as averages with standard errors of three independent experiments. In the presence (white column) and 
absence of illumination (black columns). (b) The relative efficiency of MTX release. The total nmols of MTX 
released from photolyzed RBC MTX mixtures in (a) was divided by the total number of photons that fell on 
the cross sectional surface area of those mixtures during 30 min of illumination time. The relative efficiency 
of the release of MTX for each of the various fluorescent antennae is given in nmol MTX released/µmol 
photons-cm2. LED arrays (Figure 2.19) were centered at 660 nm (C18-Cy5), 725 nm (C18-AF700 and C18-
Cy7), and 780 nm (C18-DY800).   
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Figure 2.28. (a) Release of COL and (b) DEX from C18-Cbl-COL/C18-fluorophore-loaded erythrocytes and 
C18-Cbl-DEX/C18-fluorophore-loaded erythrocytes, respectively. Drug release was measured by the LC-MS 
COL or DEX Assays (white columns) following illumination at 660 nm (C18-Cy5) or 780 nm (C18-DY800). 
Control experiments in the dark were performed in parallel (black columns). Data are represented as 
averages with standard errors of three independent experiments. (c) The relative efficiency of drug release. 
The total nmols of drug released from photolyzed RBC drug mixtures in (a) and (b) was divided by the total 
number of photons that fell on the cross sectional surface area of those mixtures during 30 min of 
illumination time. The relative efficiency of drug release for each of the various fluorescent antennae is 
given in nmol drug released/µmol photons-cm2. LED arrays (Figure 2.20) were centered at 660 nm (C18-
Cy5).  
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partner C18-fluorophore (Figures 2.27 – 2.28 and Table 2.4).  Our results indicate that fewer oxidative side 
products result from long wavelength photolysis of Cbl-Drug complexes, providing added incentive to 
release the compounds in this manner. 
2.11.  Using Long Wavelength Light to Release Drugs into HeLa Cells 
C18-Cbl-DEX/C18-Cy5: DEX is released from C18-Cbl-DEX/C18-Cy5-loaded erythrocytes in culture 
with HeLa cells upon 660 nm exposure. As a consequence, GRα in HeLa cells migrates from the cytoplasm 
to the nucleus (Figure 2.29). By contrast, C18-Cbl-DEX loaded erythrocytes lacking a long wavelength 
absorbing antenna fail to trigger GRα migration when exposed to long wavelengths (e.g. 780 nm; Figures 
2.30 – 2.31). C18-Cbl-COL/C18-DY800: 780 nm elicits COL release from erythrocyte-anchored C18-Cbl-
COL/C18-DY800, which induces microtubule depolymerization in the plated HeLa cells (Figure 2.33, Figure 
2.34).  C18-Cbl-MTX/C18-Cy7: MTX is released from C18-Cbl-MTX/C18-Cy7-loaded erythrocytes upon 725 
nm exposure. The MTX photo-product associates with endogenous DHFR in the co-cultured HeLa cells as 
assessed by the cellular thermal shift assay (Figure 2.35).24 
2.12.  Conclusion 
In summary, we’ve described the cell-mediated assembly of photo-responsive drug release 
constructs. Release is triggered upon exposure to far-red and near-IR light that falls well within the optical 
window of tissue. Furthermore, drug release is wavelength-encodable; enabling the action wavelength to 
be chosen in advance based upon the known excitation properties of a given fluorophore. Finally, although 
this study focused on erythrocytes as drug carriers, the strategy described herein should prove applicable 
to nanoparticle drug carriers as well.25,26,27 
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Figure 2.29. DEX release from C18-Cbl-DEX/C18-Cy5-loaded erythrocytes at 660 nm triggers HeLa cell 
GRα nuclear localization, where (a) is dark and (b) 660 nm. HeLa GRα visualized with Alexa488 
antiRabbit/anti-GRα.  Bar = 5 µm 
 
Figure 2.30. Wavelength selective release of DEX from erythrocyte-bound C18-Cbl-DEX and the effect on 
GRα subcellular location. (a) HeLa cells treated with DMSO. (b) HeLa cells treated with erythrocyte-bound 
C18-Cbl-DEX in the dark. (c) HeLa cells treated with erythrocyte-bound C18-Cbl-DEX and illuminated at 780 
nm. (d) HeLa cells treated with erythrocyte-bound C18-Cbl-DEX and illuminated at 525 nm. GRα in HeLa 
cells was visualized using Alexa488 antiRabbit/anti-GRα. 
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Figure 2.31.  Quantitation of the effect of DEX release from C18-Cbl-DEX/C18-Cy5-loaded erythrocytes on 
GRα subcellular location in HeLa cells. Analysis of data from Figure 5. GRα is shown in green and 
HOESCHT 33342 nuclear staining in blue. (a) HeLa cells treated with C18-Cbl-DEX/C18-Cy5-loaded 
erythrocytes and illuminated at 660 nm. (b) HeLa cells treated with C18-Cbl-DEX/C18-Cy5-loaded 
erythrocytes in the dark. Lines indicate where cross-sectional fluorescent intensity is measured.  A plot of 
two of these cross sections showing fluorescent intensities of GRα (green) and Hoescht (blue) is shown in 
(c, light)  and (d, dark).  (e) The correlation between HOESCHT and FITC fluorescence from (c). (f) The 
absence of correlation between HOESCHT and FITC fluorescence from (d). R2 values for HOESCHT/FITC 
correlations for light (0.90 ± 0.01, n = 6) and dark (0.49 ± 0.09, n = 6) samples. 
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Figure 2.32.  COL release from Cbl-COL/C18-DY800 erythrocytes at 780 nm initiates HeLa microtubule 
depolymerization, where (a) is dark and (b) 780 nm. HeLa microtubules visualized with Alexa488 
antiMouse/anti-tubulin.  
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Figure 2.33. Long wavelength release of COL from erythrocytes. (a) Untreated HeLa cells, (b) HeLa cells 
treated with C18-Cbl-COL/C18-Cy5-loaded erythrocytes in the dark, (c) HeLa cells treated with C18-Cbl-
COL/C18-Cy5-loaded erythrocytes and illuminated at 660 nm.  Bar = 5 µm. 
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Figure 2.34.  MTX release from C18-Cbl-MTX/C18-Cy7-loaded erythrocytes at 725 nm shifts the thermal 
stability of DHFR where left 3 lanes (dark) and right 3 lanes (725 nm). GAPDH used as loading control.  
MTX release from C18-Cbl-MTX/C18-Cy7 loaded erythrocytes at 725 nm shifts the thermal stability of DHFR.  
(a)  Western blot staining (anti-DHFR and anti-GAPDH antibodies) of HeLa cell extracts created from 
cultures exposed to loaded erythrocytes with and without 725 nm light.  (b) Average band intensities of 
DHFR from (a). 
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2.13.  Materials and Methods 
Cyanocobalamin was purchased from Lalilab Inc. Alexa Fluor 700 carboxylic acid succinimidyl ester was 
purchased from Life Technologies. All other chemical reagents were purchased from Sigma Aldrich.  8x10 
Color Film Gels were manufactured by MacNan and supplied by Amazon. 525 nm and 660 nm LEDs were 
purchased from LED Supply. 725 nm and 780 nm LEDs were purchased from Techmark.  Erythrocytes 
were purchased from Allcells.  HRMS data was acquired on a Thermo Scientific electrospray linear trap 
quadrupole fourier transform mass spectrometer (LT-QFT). 
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Scheme 2.2.  The structure and synthesis of C18-modified Cbls 2a, 2b, and 2c. 
 
C18-Cbl (2a, Scheme 2.2). Cyanocobalamin (CN-Cbl, 200 mg, 148 µmol) was dissolved in 10 mL 
anhydrous dimethylsulfoxide (DMSO) and carbonylditriazole (CDT, 121 mg, 740 µmol) was added. The 
solution was rapidly stirred for 45 min.  To this solution octadecylamine (ODA, 398 mg, 1.48 mmol) was 
added. The resulting mixture was stirred for 1 h before being added to 90 mL ether/chloroform. The resulting 
precipitate was collected by centrifugation and decantation. The pellet was dried under vacuum and 10 mL 
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EtOH was added. A CDT-mediated ODA dimer formed as a white precipitate, and was removed by 
centrifugation. The Cbl product was precipitated in 40 mL ether/chloroform (1:1) and collected by 
centrifugation and decantation.  The pellet was dissolved in EtOH and purified on a 100 g Biotage KP-C18-
HS flash column with a linear gradient of H2O:MeOH from 100% H2O to 100% MeOH in 8 column volumes. 
2a eluted at 100% MeOH and, upon removal of MeOH furnished a red solid in 75% yield.  1H NMR (DMSO-
d6 ,400MHz): δ = 7.50 - 7.75 (m, 4 H), 7.35 (br. s., 1 H), 7.27 (br. s., 1 H), 7.17 (d, J=17.6 Hz, 2 H), 7.04 (d, 
J=10.6 Hz, 2 H), 6.77 (br. s., 1 H), 6.71 (br. s., 1 H), 6.51 (br. s., 1 H), 6.46 (s, 1 H), 6.24 (br. s., 2 H), 5.92 
(s, 1 H), 4.62 - 4.80 (m, 2 H), 4.33 - 4.42 (m, 1 H), 4.18 - 4.30 (m, 1 H), 3.90 - 4.15 (m, 4 H), 3.67 - 3.76 (m, 
2 H), 3.08 (d, J=11.0 Hz, 1 H), 2.95 (d, J=6.3 Hz, 2 H), 2.72 - 2.86 (m, 2 H), 2.54 (s, 2 H), 2.48 (br. s., 2 H), 
2.42 (s, 2 H), 2.25 (d, J=5.5 Hz, 2 H), 2.17 (br. s., 4 H), 2.07 (br. s., 3 H), 1.58 - 1.84 (m, 6 H), 1.46 - 1.57 
(m, 2 H), 1.38 (d, J=5.9 Hz, 2 H), 1.33 (br. s., 2 H), 1.20 - 1.29 (m, 27 H), 1.18 (br. s., 1 H), 1.15 (d, J=5.9 
Hz, 2 H), 1.06 (s, 2 H), 0.85 (t, J=7.3 Hz, 3 H), 0.33 ppm (br. s., 2 H). ESI MS calcd. for C82H125CoN15O15P 
+ H+ (M1+): m/z = 1650.8627, found 1650.7273; C82H125CoN15O15P + 2H+ (M2+): m/z = 825.9353, found 
825.9091. 
 
C18-Cbl-propylamine (2b). 2a (100 mg, 61 µmol) was dissolved in 10 mL of EtOH under N2. NH4Br (500 
mg, 5% w/v) and Zn powder (200 mg, 3 mmol) were added and the solution stirred for 20 min. To this slurry, 
3-chloropropylamine hydrochloride (40 mg, 305 µmol) was added. The resulting mixture was stirred for 3 h 
under continuous N2 flow. A color change from red to orange was observed.  Zn was removed by 
centrifugation, and the Cbl product recrystallized twice in 50 mL ether/chloroform (1:1). The resulting 
precipitate was collected by centrifugation and decantation. The pellet was dried under vacuum and 10 mL 
EtOH was added.  UV-Vis analysis revealed that alkylation had gone to completion. 2b was purified on a 
100 g Biotage KP-C18-HS flash column with a linear H2O:MeOH (0.1% TFA) gradient from 100% H2O – 
100% MeOH 8 column volumes. 2b eluted at 100% MeOH and, upon removal of MeOH furnished an orange 
solid in quantitative yield. 1H NMR (DMSO-d6, 400 MHz): δ= 7.76 (s, 1H), 7.67 (s, 1H), 7.55 - 7.63 (m, 2 H), 
7.51 (s, 1H), 7.37 – 7.44 (m, 3 H), 7.34 (s, 1H), 7.29 (s, 1H), 7.10 – 7.19 (m, 3 H), 7.00 (s, 1H), 6.93 (s, 1H), 
6.88 (s, 1H), 6.77 (s, 1H), 6.48 - 6.65 (br. m, 2 H), 6.25 (s, 1H), 6.12 (s, 1H), 4.71 (q, 2H, J = 7.04 Hz), 4.36 
(d, J = 8.61 Hz, 2H), 4.15 – 4.33 (br. m, 7H), 3.97 – 4.09 (m, 4H), 3.71 (t, J = 6.62 Hz, 2H), 3.51 (br. s, 2H), 
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3.12 (d, J = 8.61 Hz, 1H), 2.92 - 3.07 (br. m, 3H), 2.75 (br. m, 1H), 2.44 – 2.48 (br. m, 2H), 2.42 (s, 3H), 
2.37 (s, 3H), 2.15 – 2.24 (m, 7H), 1.98 – 2.08 (m, 2H), 1.69 – 1.95 (br. m, 8H), 1.64 (s, 3H), 1.37 (br. s, 3H), 
1.19 – 1.29 (m, 28 H), 1.15 (d, J = 6.26 Hz, 3H), 1.06 (s, 2H), 0.85 (t, J = 6.65 Hz, 3H), 0.47 (br. m, 3H), 
0.32 (br. m, 2H), 0.07 (br. m, 2H),-0.40 (br. m, 2H).  ESI MS calcd. for C84H133CoN15O15P + H+ (M1+): m/z = 
1682.9253, found 1682.9276; C84H133CoN15O15P + 2H+ (M2+): m/z = 841.9666, found 841.9669. 
 
C18-Cbl-butyrate (2c). 2a (100 mg, 61 µmol) was dissolved in 10 mL of EtOH under N2.  NH4Br (500 mg, 
5% w/v) and Zn powder (200 mg, 3 mmol) were added and the solution stirred for 20 min under N2. To this 
slurry, 4-chlorobutryic acid (30 µL, 305 µmol, mw = 122, d = 1.24) was added. The resulting mixture was 
stirred for 3 h under continuous N2 flow. A color change from red to orange was observed. Zn was removed 
by centrifugation, and the Cbl was recrystallized twice in ether/chloroform (50 mL). The resulting precipitate 
was collected by centrifugation and decantation. The pellet was dried under vacuum and 10 mL EtOH was 
added. 2c was purified on a 100 g Biotage KP-C18-HS flash column with a linear gradient from 100% H2O 
– 100% MeOH 8 column volumes. 2c eluted at 100% MeOH and, upon removal of MeOH furnished an 
orange solid in 82% yield. 1H NMR (DMSO-d6 ,400MHz): δ = 7.58 - 7.73 (m, 3 H), 7.47 - 7.57 (m, 2 H), 7.31 
- 7.40 (m, 2 H), 7.13 - 7.26 (m, 3 H), 7.04 - 7.12 (m, 2 H), 6.92 - 7.00 (m, 2 H), 6.74 - 6.88 (m, 3 H), 6.59 - 
6.69 (m, 2 H), 6.04 - 6.43 (m, 5 H), 4.50 - 4.75 (m, 3 H), 4.32 - 4.46 (m, 2 H), 4.14 - 4.33 (m, 4 H), 3.90 - 
4.09 (m, 3 H), 3.72 - 3.87 (m, 2 H), 2.91 - 3.01 (m, 3 H), 2.08 - 2.46 (m, 16 H), 1.75 - 2.00 (m, 8 H), 1.60 - 
1.73 (m, 5 H), 1.32 - 1.52 (m, 7 H), 1.15 - 1.32 (m, 26 H), 1.02 - 1.14 (m, 4 H), 0.93 - 1.02 (m, 2 H), 0.85 (t, 
J=7.1 Hz, 1 H), 0.50 - 0.76 (m, 4 H), 0.30 - 0.36 (m, 1 H), 0.01 - 0.24 (m, 3 H), -0.66 - -0.40 ppm (m, 3 H). 
ESI MS calcd. for C85H132CoN14O17P + H+ (M1+): m/z = 1711.9042, found 1711.9075; C85H132CoN14O17P + 
2H+ (M2+): m/z = 856.4560, found 856.4571. 
71 
 
  
Scheme 2.3. Synthesis and purification of C18-Cbl-MTX.  
C18-Cbl-MTX (Scheme 2.3). MTX (30 mg, 66 µmol), N,N,N′,N′-tetramethyl-O-(1H-benzotriazol-1-
yl)uronium hexafluorophosphate (HBTU, 25 mg, 66 µmol), and N,N-diisopropylethylamine (DIPEA, 58 µL, 
332 µmol) were dissolved in 5 mL of dimethylformamide (DMF) and stirred for 5 min.  2b (120 mg, 71 µmol) 
was added and the solution was stirred overnight. We were unable to separate 2b and C18-Cbl-MTX via 
HPLC and thus the mixture was exposed to 4,5,6,7,7-hexachloro-5-norbornene-2,3-dicarboxylic anhydride 
(37 mg, 185 µmol). The solution was stirred for 30 min and then frozen at -80 °C being careful not to thaw 
until just before purification.  C18-Cbl-MTX was purified on a 5 µm, 250 x 21.2 mm Viva C4 preparative 
column from Restek, using a H2O:CH3CN, 0.1% TFA gradient (elution time 46 min, Table 2.5). Orange 
solid, 37% yield. 1H NMR (DMSO-d6 ,400MHz): δ = 8.71 (s, 1 H), 8.19 - 8.26 (m, 1 H), 7.82 (d, J=12.9 Hz, 
2 H), 7.61 - 7.76 (m, 4 H), 7.58 (d, J=5.1 Hz, 3 H), 7.36 (d, J=9.8 Hz, 3 H), 7.05 - 7.21 (m, 3 H), 6.92 (br. s., 
2 H), 6.73 - 6.87 (m, 4 H), 6.61 (br. s., 2 H), 6.28 (d, J=16.4 Hz, 4 H), 4.87 (br. s., 2 H), 4.71 (d, J=4.7 Hz, 
2 H), 4.21 - 4.41 (m, 8 H), 4.04 (d, J=9.0 Hz, 3 H), 3.72 (br. s., 2 H), 3.30 - 3.42 (m, 2 H), 2.88 - 3.18 (m, 5 
H), 2.78 (br. s., 2 H), 1.38 (br. s., 4 H), 1.17 - 1.31 (m, 27 H), 1.14 (d, J=5.9 Hz, 3 H), 0.96 (d, J=7.4 Hz, 3 
H), 0.85 (t, J=6.7 Hz, 4 H), 0.56 (br. s., 2 H), 0.24 (br. s., 2 H), -0.02 (s, 2 H), -0.53 ppm (s, 2 H). ESI MS 
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calcd. for C104H153CoN23O19P + 2H+ (M2+): m/z = 1060.0469, found 1060.0476; C104H153CoN23O19P + 3H+ 
(M3+): m/z = 707.0339, found 707.0341. 
8
 
Scheme 2.4. Synthesis of C18-Cbl-COL. 
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C18-Cbl-COL (Scheme 2.4). 2d was synthesized as previously reported28.  2c (63 mg, 37 µmol, mw = 
1681), HBTU (10 mg, 26 µmol, mw = 379), and DIPEA (15 µL, 86 µmol) were dissolved in 2 mL of DMF 
and stirred for 5 min.  2d (10 mg, 28 µmol, mw = 1386) was added to the solution and the mixture stirred 
overnight. C18-Cbl-COL was purified on a 5 µm, 250 x 21.2 mm, Viva C4 preparative column using a 
H2O:CH3CN, 0.1% TFA, gradient (elution time 35 min, Table 2.5). Orange solid, 43% yield. 1H NMR (DMSO-
d6 ,400MHz): δ = 8.23 (d, J=7.4 Hz, 1 H), 7.78 (br. s., 1 H), 7.49 - 7.70 (m, 3 H), 7.42 (br. s., 1 H), 7.35 (br. 
s., 2 H), 7.13 - 7.26 (m, 2 H), 7.02 - 7.13 (m, 3 H), 6.93 - 7.02 (m, 2 H), 6.88 (d, J=7.4 Hz, 2 H), 6.77 (s, 2 
H), 6.59 (br. s., 1 H), 6.13 - 6.35 (m, 3 H), 4.71 (dd, J=11.2, 6.5 Hz, 2 H), 4.23 - 4.41 (m, 6 H), 4.14 (dd, 
J=17.8, 6.8 Hz, 3 H), 4.04 (d, J=7.0 Hz, 3 H), 3.88 (d, J=4.3 Hz, 3 H), 3.79 (s, 2 H), 3.61 (br. s., 1 H), 3.46 
- 3.53 (m, 7 H), 3.30 - 3.43 (m, 2 H), 3.14 - 3.21 (m, 1 H), 3.00 - 3.13 (m, 2 H), 2.96 (d, J=5.9 Hz, 2 H), 2.75 
(s, 1 H), 2.31 - 2.41 (m, 5 H), 2.20 - 2.29 (m, 6 H), 2.07 (s, 1 H), 1.73 - 1.95 (m, 6 H), 1.59 - 1.71 (m, 5 H), 
1.32 - 1.46 (m, 4 H), 1.17 - 1.31 (m, 25 H), 1.05 - 1.16 (m, 6 H), 0.81 - 0.90 (m, 3 H), 0.42 - 0.63 (m, 4 H), 
0.19 (br. s., 2 H), -0.34 ppm (s, 2 H). ESI MS calcd. for C105H153CoN15O21P + 2H+ (M2+): m/z = 1026.0295, 
found 1026.0299. 
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Scheme 2.5.  Synthesis of C18-Cbl-DEX. 
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C18-Cbl-DEX (Scheme 2.5). 2e was synthesized as previously reported29. 2e (6 mg, 12 µmol), HBTU (5 
mg, 12 µmol), and DIPEA (10 µL, 57 µmol) were dissolved in 1 mL of DMF and stirred for 5 min. 2b (30 
mg, 18 µmol) was added and the solution stirred overnight. C18-Cbl-DEX was purified on a 5 µm 250 x 21.2 
mm a Viva C4 preparative column using a H2O:CH3CN, 0.1% TFA gradient (elution time 62 min, Table 2.5). 
Orange solid, 70% yield. 1H NMR (DMSO-d6 ,400MHz): δ = 8.09 - 8.20 (m, 2 H), 8.02 - 8.07 (m, J=5.1 Hz, 
1 H), 7.92 (s, 1 H), 7.78 (s, 2 H), 7.60 - 7.69 (m, 2 H), 7.47 - 7.59 (m, 3 H), 7.21 - 7.37 (m, 4 H), 7.09 - 7.20 
(m, 3 H), 6.94 (br. s., 2 H), 6.77 (br. s., 3 H), 6.58 (br. s., 1 H), 6.22 (dd, J=10.2, 2.0 Hz, 2 H), 6.08 - 6.16 
(m, 2 H), 6.01 (s, 1 H), 5.38 (d, J=4.3 Hz, 1 H), 5.14 (s, 1 H), 5.04 (br. s., 1 H), 4.99 (s, 1 H), 4.76 (br. s., 1 
H), 4.66 - 4.74 (m, 2 H), 4.20 - 4.34 (m, 4 H), 4.07 - 4.19 (m, 3 H), 4.03 - 4.07 (m, 1 H), 3.96 - 4.02 (m, 2 
H), 3.80 - 3.89 (m, 2 H), 3.64 - 3.71 (m, 2 H), 3.54 - 3.60 (m, 3 H), 3.05 - 3.21 (m, 6 H), 2.92 - 3.04 (m, 4 
H), 2.40 - 2.47 (m, 5 H), 2.38 (br. s., 2 H), 2.16 - 2.24 (m, 5 H), 1.65 - 1.84 (m, 7 H), 1.48 (s, 5 H), 1.38 (br. 
s., 4 H), 1.23 (s, 27 H), 1.15 (d, J=6.3 Hz, 2 H), 0.97 - 1.11 (m, 4 H), 0.85 (t, J=7.3 Hz, 3 H), 0.78 (d, J=7.4 
Hz, 2 H), 0.46 (br. s., 3 H), 0.27 - 0.38 (m, 2 H), -0.02 - 0.12 (m, 3 H), -0.50 - -0.37 ppm (m, 2 H). ESI MS 
calcd. for C110H164CoFN15O22P + 2H+ (M2+): m/z = 1079.0693, found 1079.0707. 
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Figure 2.35.  LC-MS UV/Vis chromatograms 
of purified (a) C18-Cbl-MTX monitored at 300 
nm (b) C18-Cbl-COL monitored at 365 nm 
and (c) C18-Cbl-DEX monitored at 239 nm. 
The chromatogram of (c) is solvent 
background corrected. All peaks are 
normalized to C18-Cbl-COL. 
 
c) 
a) 
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Scheme 2.6.  Synthesis of C18-Cbl-TAM. 
 
C18-Cbl-TAM (Scheme 2.6). 5-Tetramethylrhodamine (TAM) (5 mg, 12 µmol), HBTU (4.5 mg, 12 µmol), 
and DIPEA (8.3 µL, 48 µmol) were dissolved in 5 mL of DMF and stirred for 5 min.  2b (20 mg, 12 µmol) 
was added and the solution stirred overnight.  C18-Cbl-TAM was purified on a 5 µm 250 x 21.2 mm a Viva 
C4 preparative column using a H2O:CH3CN, 0.1% TFA gradient (elution time 46 min, Table 2.5). Red solid, 
75% yield. 1H NMR (DMSO-d6 ,400MHz): δ = 8.56 - 8.63 (m, 1 H), 8.42 - 8.47 (m, 1 H), 8.01 - 8.06 (m, 1 
H), 7.95 - 8.00 (m, 1 H), 7.74 - 7.81 (m, 1 H), 7.65 - 7.70 (m, 1 H), 7.53 (br. s., 3 H), 7.32 - 7.36 (m, 1 H), 
7.24 - 7.29 (m, 1 H), 7.03 - 7.21 (m, 4 H), 6.96 (br. s., 4 H), 6.73 - 6.81 (m, 2 H), 6.54 - 6.60 (m, 1 H), 6.19 
- 6.26 (m, 1 H), 6.09 - 6.17 (m, 1 H), 4.66 - 4.74 (m, 1 H), 4.13 - 4.39 (m, 5 H), 3.96 - 4.08 (m, 2 H), 3.51 (s, 
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4 H), 3.27 (br. s., 5 H), 2.43 (br. s., 2 H), 2.30 - 2.36 (m, 2 H), 2.16 - 2.27 (m, 5 H), 2.05 - 2.09 (m, 2 H), 
1.70 (br. s., 3 H), 1.37 (br. s., 3 H), 1.18 - 1.31 (m, 28 H), 1.15 (d, J=6.3 Hz, 2 H), 1.03 (br. s., 1 H), 0.85 (t, 
J=6.8 Hz, 3 H), 0.47 (br. s., 3 H), 0.15 - 0.29 (m, 2 H), -0.27 - -0.10 ppm (m, 2 H). ESI MS calcd. for 
C109H154CoN17O19P+ + 1H+ (M2+): m/z = 1048.0377, found 1048.0386 
 
Scheme 2.7.  Synthesis of C18-Cbl-FAM. 
 
C18-Cbl-FAM (Scheme 2.7). 5-carboxyfluorecein (5-FAM, 5 mg, 12 µmol), O-(N-succinimidyl)-N,N,N′,N′-
tetramethyluronium tetrafluoroborate (TSTU, 3.6 mg, 12 µmol), and DIPEA (8.3 µL, 48 µmol) were dissolved 
in 5 mL of DMF and stirred for 5 min.  2a (20 mg, 12 µmol) was added and the solution stirred overnight.  
C18-Cbl-FAM was purified on a 5 µm 250 x 21.2 mm a Viva C4 preparative column using a H2O:CH3CN, 
0.1% TFA gradient (elution time 46 min, Table 2.5). Orange solid, 90% yield. 1H NMR (DMSO-d6 ,400MHz): 
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δ = 8.53 (br. s., 1 H), 8.18 (s, 1 H), 7.99 (d, J=7.8 Hz, 1 H), 7.79 (br. s., 1 H), 7.48 - 7.69 (m, 5 H), 7.28 - 
7.46 (m, 5 H), 7.08 - 7.21 (m, 3 H), 6.96 (br. s., 2 H), 6.87 (br. s., 2 H), 6.78 (br. s., 2 H), 6.67 - 6.71 (m, 2 
H), 6.50 - 6.63 (m, 5 H), 6.31 (br. s., 3 H), 4.71 (dd, J=11.2, 6.5 Hz, 3 H), 4.24 - 4.42 (m, 7 H), 4.00 - 4.16 
(m, 4 H), 3.73 (br. s., 2 H), 3.36 (d, J=7.0 Hz, 2 H), 3.17 (br. s., 2 H), 3.02 - 3.11 (m, 2 H), 2.91 - 3.01 (m, 3 
H), 2.69 - 2.85 (m, 4 H), 2.32 - 2.41 (m, 7 H), 2.21 - 2.29 (m, 6 H), 2.07 (s, 1 H), 1.72 - 1.97 (m, 9 H), 1.69 
(br. s., 3 H), 1.33 - 1.44 (m, 6 H), 1.26 (br. s., 5 H), 1.22 (s, 27 H), 1.14 (d, J=6.3 Hz, 2 H), 0.94 (s, 2 H), 
0.85 (t, J=6.7 Hz, 3 H), 0.57 (br. s., 3 H), 0.29 - 0.40 (m, 1 H), 0.13 - 0.28 (m, 2 H), -0.38 - -0.20 ppm (m, 2 
H). ESI MS calcd. for C105H143CoN15O21P + 2H+ (M2+): m/z = 1020.9905, found 1021.9900. 
 
 
Time  
(min) 
Flow 
(mL/min) 
H2O 
(%) 
CH3CN 
(%) 
0.01 10.00 90.0 10.0 
10.00 10.00 90.0 10.0 
30.00 10.00 45.0 55.0 
45.00 10.00 35.0 65.0 
60.00 10.00 25.0 75.0 
65.00 10.00 0.0 100.0 
75.00 10.00 0.0 100.0 
80.00 10.00 90.0 10.0 
90.00 10.00 90.0 10.0 
91.00 0.00 90.0 10.0 
 
Table 2.5.  Solvent gradient used for preparative HPLC to purify C18-Cbl-MTX, C18-Cbl-DEX, C18-Cbl-COL, 
C18-Cbl-TAM, and C18-Cbl-FAM. All solvents contained 0.1% v/v TFA. 
 
C18-AF700. Alexa Fluor 700 NHS ester (1 mg, 1 µmol), DIPEA (5 µL, 29 µmol), and octadecylamine (5 mg, 
19 µmol) were dissolved in 500 µL DMF and mixed by agitation overnight. The resulting mixture was added 
to 5 mL H2O:CH2Cl2 mixture (5:1). The CH2Cl2 layer was washed three times with 4 mL H2O, the CH2Cl2 
removed under reduced pressure and the product purified by flash chromatography silica column (30 g) 
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using a binary solvent system (A: CH2Cl2, B: MeOH) with an initial A:B ratio of 100:0, gradually increasing 
to 80:20. The purified lipidated fluorophore was concentrated by rotary evaporation. Note: the structure of 
AF700 has not been released. 
 
Cy5 and Cy7. Cy5 and Cy7 were synthesized as previously described.30,31  
 
Scheme 2.8.  Synthesis of C18-Cy5 and C18-Cy7. 
 
C18-Cy5 (Scheme 2.8). Cy5 (6.2 mg, 12.8 µmol) and diisopropylcarbodiimide (DIC, 2.5 mg, 19.2 µmol) were 
dissolved in CH2Cl2 (320 µL) and mixed for 5 min. A solution of ODA (6.9 mg) in chloroform (100 µL) was 
then added and the solution was allowed to react for 1 h. The solution was diluted with additional CH2Cl2 
(2 mL) and purified via silica gel elution using a binary solvent system (A: CH2Cl2, B: MeOH) with an initial 
A:B ratio of 90:10, gradually increasing to 1:4. Removal of solvent by rotary evaporation yielded a blue-
viscous oil (74%, calculated from absorption, λmax: 646 nm). 1H NMR (CD2Cl2, 400 MHz): δ = 7.85 - 7.95 
(m, 2 H), 7.37 - 7.46 (m, 4 H), 7.28 (q, J = 7.3 Hz, 2 H), 7.11 - 7.18 (m, 2 H), 6.63 (t, J = 12.5 Hz, 1 H), 6.12 
- 6.25 (m, 2 H), 4.01 (t, J = 7.6 Hz, 2 H), 3.57 (s, 3 H), 3.12 - 3.21 (m, 2 H), 2.20 (t, J = 7.0 Hz, 2 H), 1.84 
(br m, 6 H), 1.70 (s, 12 H), 1.42 - 1.55 (m, 4 H), 1.26 (m, 28 H), 0.88 (t, J = 7.5 Hz, 3 H). ESI MS calc. for 
C50H76N3O+ (M1+): m/z = 734.5988, found 734.5983.  
  
N+
HO
O
N
n
n= 1 C18-Cy5
2 C18-Cy7
DIC, CH2Cl2
ODA
N+
HN
O
N
n
n= 1 Cy5
2 Cy7
81 
 
 
 
Time (min)
0 2 4 6 8 10
In
te
n
si
ty
 
(m
AU
)
0
100
200
300
400
500
Time (min)
0 2 4 6 8 10
In
te
n
s
ity
 
(m
AU
)
0
20
40
60
80
100
120
140
160
 
 
Figure 2.36.  LC-MS UV/Vis chromatogram of purified C18-Cy5 collected using a C4 column and monitored 
at (a) 300 nm and (b) 600 nm. Pure DMSO was used as the loading solvent. 
 
C18-Cy7 (Scheme 2.8). Cy 7 (5.0 mg, 9.8 µmol) was coupled to ODA as described for C18-Cy5. Silica gel 
chromatography afforded a blue-green oil (95.2%, calculated from absorption, λmax: 760 nm). 1H NMR 
(CD2Cl2, 400 MHz): δ = 7.69 - 7.83 (m, 2 H), 7.35 - 7.45 (m, 4 H), 7.26 (m, 2 H), 7.14 (d, J = 7.8 Hz, 1H), 
7.09 (d, J = 7.8 Hz, 1H), 6.45 - 6.63 (m, 2 H), 6.19 (d, J = 13.7 Hz, 1 H), 6.08 (br m, 2 H), 3.95 - 4.03 (m, 2 
H), 3.52 (s, 2 H), 3.17 (d, J = 6.3 Hz, 2 H), 2.19 (t, J = 7.2 Hz, 2 H), 1.67 - 1.82 (br m, 21 H), 1.44 - 1.52 (br 
a) 
DMSO/solvent 
front 
 
DMSO/solvent 
front 
b) 
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m, 4 H), 1.22 - 1.34 (m, 26 H), 0.88 (t, J = 7.4 Hz, 3 H).  ESI MS calc. for C52H78N3O+ (M1+): m/z =760.6145, 
found 760.6324. 
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Figure 3.37.  LC-MS UV/Vis chromatogram of purified C18-Cy7 collected using a C4 column and monitored 
at (a) 300 nm and (b) 600 nm. Pure DMSO was used as the loading solvent 
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Scheme 2.9.  Synthesis of DY800 fluorophore. 
 
Cl-DY800 (Scheme 2.9). N-(5-carboxypentyl)-2,3,3-trimethyl indolium-5-sulfonate (300 mg, 850 µmol) and 
3-chloro-2,4-trimethyleneglutacondianil hydrochloride (305 mg, 850 µmol) were refluxed in a solution of 
acetic acid/acetic anhydride (4 mL, 1:1 ratio) for 2 h. The solvent was then removed under reduced pressure 
and the residue re-dissolved in a mixture of pyridine and acetic acid (4 mL, 1:1 ratio). N-(3-sulfopropyl)-
2,3,3-trimethyl indolium-5-sulfonate (325 mg, 850 µmol) was added and the solution was heated to 80 °C 
for 1 h. The product was then precipitated and washed 3x with ethyl acetate (100 mL). The blue precipitate 
was dissolved in water and eluted on a Biotage KP-C18-HS column using a binary solvent A:B solvent 
system (A: H2O .1 v/v% TFA, B: CH3CN .1 v/v% TFA). The A:B ratio was gradually increased from an initial 
ratio of 19:1 to 2:3. Removal of the solvent by lyophilization yielded a green solid (180 mg, 25% yield, λmax: 
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794 nm). 1H NMR (DMSO-d6, 400 MHz): δ = 8.25 (dd, J = 16.8 Hz, 14.5 Hz, 2 H), 7.79 (d, J = 9.0 Hz, 2 H), 
7.64 - 7.69 (m, 2 H), 7.47 (d, J = 8.6 Hz, 1 H), 7.36 (d, J = 8.2 Hz, 1 H), 6.59 (d, J = 14.1 Hz, 1 H), 6.30 (d, 
J = 14.1 Hz, 1 H), 4.39 (br s, 2 H), 4.18 (br s, 2H), 2.67 – 2.79 (m, 4 H), 2.64 (t, J = 6.6 Hz, 2 H), 2.20 (t, 
7.1 Hz, 2 H), 1.98 – 2.09 (br m, 2 H), 1.79 – 1.89 (br m, 2 H), 1.78 – 1.62 (m, 12 H), 1.61 – 1.48 (m, 3 H), 
1.31 – 1.44 (m, 3 H).  ESI MS calc. for C39H45ClN2O11S32- + 3H+ (M1+): m/z = 851.2109, found 851.2115.  
 
DY800 (Scheme 2.8). Chloro-DY800 (100 mg, 120 µmol) was dissolved in anhydrous DMF (18 mL) to 
which a solution of sodium phenoxide (139 mg, 1.2 mmol) in DMF (1mL) was added. The solution was 
stirred for 1 h, and then poured into a vigorously stirring solution of diethyl ether (250 mL). The precipitate 
was collected and then purified with a Biotage KP-C18-HS column using a binary solvent A:B solvent 
system (A: H2O .1 v/v% TFA, B: CH3CN .1 v/v% TFA). The A:B ratio was gradually increased from an initial 
ratio of 19:1 to 2:3. Lyophilization provided the product as a green solid (86 mg, 79% yield, λmax: 774 nm).  
1H NMR (DMSO-d6 ,400MHz): δ = 7.74 - 7.88 (m, 3 H), 7.56 - 7.65 (m, 3 H), 7.38 – 7.46 (m, 3 H), 7.25 (d, 
J = 8.2 Hz, 1 H), 7.16 (d, J = 8.2 Hz, 2 H), 7.05 (t, J = 7.2 Hz, 1 H), 6.49 (d, J = 14.5 Hz, 1 H), 6.13 (d, J = 
14.1 Hz, 1 H), 4.33 (br s, 2 H), 4.08 (br s, 2 H), 2.68 - 2.80 (m, 4 H), 2.56 (t, J = 6.5 Hz, 2 H), 2.19 (t, J = 
7.2 Hz, 2 H), 1.88 - 2.02 (m, 4 H), 1.61 - 1.73 (m, 3 H), 1.50 - 1.59 (m, 3 H), 1.21 - 1.40 (m, 12 H).  ESI MS 
calc. for C45H50N2O12S32- + 3H+ (M1+): m/z = 909.2761, found 909.2764. 
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Figure 2.38.  LC-MS UV/Vis chromatograms of purified chloro-DY800 collected with a reverse phase C18 
at (a) 300 nm and (b) 600 nm. DY800 is also shown with monitoring at (c) 300 nm and (d) 600 nm. Water 
was used as the loading solvent. 
 
a) b) 
d) c) 
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Scheme 2.10.  Synthesis of C18-DY800 
C18-DY800 (Scheme 2.10). DY800 (2.0 mg, 2.2 µmol) and HCTU (1.4 mg, 3.3 µmol) were dissolved in 
anhydrous DMF (500 µL) and allowed to react for 5 min. A 500 µL solution of ODA in chloroform (1 mg/mL) 
was added and the solution mixed for 1 h. The product was extracted into aqueous solution by washing of 
the organic solution with water (2 x 1 mL). The aqueous phase was then purified by HPLC using a stationary 
C4 phase with a A:B solvent system (A: H2O .1 v/v% TFA, B: CH3CN .1 v/v% TFA). The A:B ratio was 
gradually increased from 10:1 to 1:19. The solvent was removed by rotary evaporation to give a blue-green 
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oil (35% yield, λmax: 776 nm in ethanol).  1H NMR (DMSO-d6 ,400M Hz): δ = 7.72 – 7.87 (m, 3 H), 7.56 - 
7.65 (m, 3 H), 7.37 - 7.45 (m, 3 H), 7.19 - 7.26 (m, 1 H), 7.12 - 7.18 (m, 2 H), 7.02 - 7.09 (m, 1 H), 6.50 (d, 
J = 14.2 Hz, 1 H), 6.12 (d, J = 14.5 Hz, 1 H), 4.29 - 4.37 (m, 2 H), 4.02 - 4.11 (m, 2 H), 2.98 (dd, J = 12.7, 
6.8 Hz, 3 H), 2.74 - 2.80 (m, 2 H), 2.65 - 2.74 (m, 2 H), 2.31 - 2.35 (m, 2 H), 2.02 (t, J = 7.4 Hz, 3 H), 1.89 
- 1.99 (m, 4 H), 1.60 - 1.72 (m, 3 H), 1.47 - 1.58 (m, 3 H), 1.26 - 1.40 (m, 12 H), 1.22 (s, 30 H), 0.85 ppm (t, 
J = 6.8 Hz, 3 H).  ESI MS calc. for C63H87N3O11S32- + 3H+ (M1+): m/z = 1160.5737, found 1160.5738. 
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Figure 2.39.  LC-MS UV/Vis chromatogram of purified C18-DY800 collected using a reverse phase C18 
column and monitored at (a) 300 nm and (b) 600 nm. Water was used as the loading solvent.  
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Time 
(min) 
Flow 
 (mL/min) 
Water  
(%) 
CH3CN 
(%) 
0 1 90 10 
1 1 90 10 
7 1 5 95 
8 1 0 100 
10 1 0 100 
11 1 90 10 
16 1 90 10 
 
Table 2.6.  Gradient used for LC-MS analysis of C18-Cy5 and C18-Cy7 using a Viva C4 column (5 µm, 50 
mm x 2.1 mm). Product elution was detected using absorption at 600 nm.  All solvents contained 0.1% v/v 
FA. 
 
 
 
 
 
 
 
 
Table 2.7.  Gradient used for LC-MS analysis of C18-DY800 and intermediates using an Agilent Eclipse 
Plus C18 column (3.5 µm, 4.6 mm x 150 mm). All solvents contained 0.1% v/v FA. Product elution was 
detected using absorbance at 600 nm.  
 
  
Time 
(min) 
Flow 
 (mL/min) 
Water  
(%) 
CH3CN  
(%) 
0 1 97 3 
5 1 97 3 
18 1 3 97 
20 1 3 97 
24 1 97 3 
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MTX LC-MS Assay. The following experiments were analyzed using the MTX LC-MS Assay: 
Octanol/Water Partition MTX, RBC Drug Loading Capacity, and MTX Photolysis from Erythrocyte 
Membranes. Samples of 75 µL were injected onto an 1200 series Agilent HPLC with a UV-Vis detector, 
1260 infinity fluorescent detector, and 6110 quadrapole mass spectrometer from a 384 well plate.  The 
mobile phase consisted of H2O:CH3CN 0.1% FA (Formic Acid) (gradient provided in Table 2.8). The column 
used was a Viva C4 analytical column 5 µm, 50 x 21.2 mm from Restek. Concentrations were determined 
by taking the area under UV absorbance trace at 300 nm from 3.1 - 3.7 min where the C18-Cbl-MTX 
cleavage products were shown to elute and this integration was compared to known standards (Figure 
2.10). Spectrofluorimetry (ʎex: 365 nm ʎem: 470 nm) was used to detect the possible presence of MTX by-
products due to light degradation32 (none were observed), undamaged MTX is non-fluorescent. 
 
COL LC-MS Assay. The following experiments were analyzed using the COL LC-MS Assay: RBC Drug 
Loading Capacity Samples and Photo-release of COL and DEX from C18-Cbl-COL- and C18-Cbl-DEX-
embedded Erythrocytes. Samples of 75 µL were injected onto an 1200 series Agilent HPLC with a UV-Vis 
detector, 1260 infinity fluorescent detector, and 6110 quadrapole mass spectrometer from a 384 well plate.  
The mobile phase consisted of H2O:CH3CN (0.1% FA) (gradient provided in Table 2.8).  The column used 
was a Viva C4 analytical column 5 µm, 50 x 21.2 mm. Concentrations were determined by taking the area 
under UV absorbance trace at 365 nm from 4.3 - 4.8 min where the C18-Cbl-COL cleavage products were 
shown to elute and this integration was compared to known standards (Figure 2.10).  LC gradient is given 
in the MTX LC-MS Assay. 
 
DEX LC-MS Assay. The following experiments were analyzed using the DEX LC-MS Assay: RBC Drug 
Loading Capacity Samples and Photo-release of COL and DEX from C18-Cbl-COL- and C18-Cbl-DEX-
embedded Erythrocytes.  Samples of no less than 120 µL were boiled for 10 min to denature and precipitate 
any protein and lipids present in the erythrocytes samples.  Protein was then pelleted by centrifugation at 
21,000 g.  Samples of 75 µL were injected onto an 1200 series Agilent HPLC with a UV-Vis detector, 1260 
infinity fluorescent detector, and 6110 quadrapole mass spectrometer from a 384 well plate.  The mobile 
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phase consisted of H2O:CH3CN (0.1% FA) (gradient provided in Table 2.8). The column used was a Viva 
C4 analytical column 5 µm, 50 x 21.2 mm. Concentrations were determined by taking the area under UV 
absorbance trace at 239 nm from 4.5 - 4.9 min (if erythrocytes were present in the experiment) where DEX 
was shown to elute. If no RBCs were present, integration occurred from 5.3 - 5.7 min. Integrations were 
compared to known standards of DEX (Figure 2.10).   
 
 
Time 
(min) 
Flow 
(mL/min) 
Water 
(%) 
CH3CN 
(%) 
0 1 97 3 
1 1 97 3 
8 1 20 80 
10 1 20 80 
11 1 97 3 
15 1 97 3 
 
Table 2.8.  The solvent gradient used for analytical MTX, COL, and DEX LC-MS assays.  All solvents 
contained 0.1% v/v FA. 
 
Octanol/Water Partition MTX. Octanol (100 µL) containing C18-Cbl-MTX (5 µM) was thoroughly mixed 
with phosphate buffered saline (PBS, 500 µL) in a 1.5 mL clear centrifuge tube and allowed to equilibrate 
for 30 min in the dark before undergoing centrifugation for 10 min at 21,000 g.  Samples were photolyzed 
with a 525 nm LED for 0 min, 1 min, 2 min, 5 min, 10 min, and 20 min before being mixed by shaking and 
allowed to equilibrate for 15 min. This was followed by a 10 min centrifugation at 21,000 g. The octanol 
layer was removed and 100 µL aliquots were taken from the remaining aqueous layer and loaded onto a 
384 well plate. The concentration of MTX was determined by the MTX LC-MS assay. 
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Octanol/Water Partition TAM. Octanol (100 µL) containing the C18-Cbl-TAM (10 µM) was thoroughly 
mixed with PBS (300 µL) in a 1.5 mL clear centrifuge tube and allowed to equilibrate for 30 min in the dark 
before undergoing centrifugation for 10 min at 21,000 g in a quartz fluorescence cuvette with a 200 µL 
viewing window. The fluorescence of the aqueous layer was measured using a PTI Model 710 LPS-220 
(ʎex: 555 nm ʎem: 570 - 600 nm). The solution was transferred to a clear 1.5 mL centrifuge tube and 
photolyzed using a 525 nm centered LED array for 0 min, 1 min, 2 min, 3 min, and 10 min. The solutions 
were transferred back to the cuvette for 10 min centrifugation at 21,000 g and the fluorescence was 
measured again.  All samples were measured in triplicate. 
 
Erythrocyte Storage. Erythrocytes were washed 3x with RBC buffer (PBS, 1 mM MgCl2) and diluted to 
10% hematocrit. Erythrocytes were stored for no more than one month at 4 °C.    
 
Erythrocyte Loading Procedure. Lipidated compounds were added at various loading concentrations to 
erythrocytes (10% hematocrit). The erythrocytes were then incubated at RT for 20 min and subsequently 
washed 3x and stored at 10% hematocrit in RBC buffer. RBCs were allowed to sit for up to 48 h before use. 
 
Widefield Microscopy with Cbl-TAM Loaded Erythrocytes. 10% hematocrit erythrocytes were loaded 
with 10 µM C18-Cbl-TAM using the Erythrocyte Loading Procedure. 2 µL of loaded erythrocytes were then 
added to 200 µL RBC buffer and imaged using widefield microscopy. Images were taken using 20 µs 
exposure times and a Cy3 filter cube 333 ms apart.   
 
Hemolysis Assay. To a 1.5 mL Eppendorf tube containing 100 µL of a Cbl drug conjugate (C18-Cbl-MTX, 
C18-Cbl-COL, or C18-Cbl-DEX) in PBS at various concentrations (5 µM, 10 µM, 20 µM, and 40 µM) was 
added 100 µL RBCs in RBC buffer (10% hematocrit). Two controls were performed: 100 µL of RBCs treated 
with PBS buffer and RBCs treated with SDS (100% hemolysis). Final concentrations were 0.05% SDS; 0 
µM, 2.5 µM, 5 µM, 10 µM, and 20 µM lipidated complex. Cells were mixed by flicking before centrifugation 
at 300 g for 30 min. Samples were re-homogenized and allowed to incubate at 4 °C overnight. Samples 
were pelleted at 1000 g for 5 min. 150 µL of the supernatant was plated in a 96 well plate and analyzed at 
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550 nm by UV Vis. SDS samples were diluted 10 fold in order to accurately measure heme concentration. 
SDS absorbance multiplied by 10 was considered to be complete hemolysis and PBS treated blood was 
considered to be completely intact and the absorbance from those samples was subtracted from the 
background of the rest.   
 
 
 
RBC Drug Loading Capacity. 10% hematocrit RBCs were loaded with varying concentrations of C18-Cbl-
MTX, C18-Cbl-COL, and C18-Cbl-DEX using the Erythrocyte Loading Procedure.  C18-Cbl-MTX was 
loaded at 6 µM, 4 µM, 2 µM, and 1 µM. C18-Cbl-COL was loaded at 10 µM, 8 µM, 6 µM, 4 µM, and 2 µM.  
The cells were diluted to 5% hematocrit and photolyzed for 2 h using a board containing 525 nm centered 
LEDs. The cells were then spun down at 1000 g. Concentration was determined by the respective LC-MS 
assays. 
 
Dihydrofolate Reductase (DHFR) Inhibition Assay. DHFR activity was monitored using the Sigma 
Dihydrofolate Reductase Assay Kit. This kit was used to monitor conversion of NADPH to NADP+. Briefly, 
assay buffer was prepared containing 1.5 mU DHFR, 100 µM NADPH, and 1x assay buffer (provided with 
kit). Inhibition of DHFR activity at various MTX concentrations or various photolyzed C18-Cbl-MTX 
concentrations (100 nM - 5 µM) was monitored using a fluorescent plate reader (ʎex: 340 nm ʎem: 450 nm).  
 
Treatment of HeLa Cells with COL. HeLa cells were plated in a 6-well glass bottom plate (Mattek) at a 
density of 1.5 x 105 cells per well and maintained at 37 ºC in a humidity-controlled incubator with a 5% CO2 
atmosphere in DMEM (10% FBS, 1% Pen-Strep). The following day, cells were treated with COL (Sigma 
C9754; 1 mM stock in DMSO) or DMSO for either 30 min or 1 h at 37 ºC in a humidity-controlled incubator. 
At the conclusion of the incubation period, cells were fixed with 1 mL of methanol at room temperature for 
10 min. Cells were washed 2 x 1 mL with PBS and blocked for 1 h in 5% donkey serum. Blocking was 
followed by overnight incubation at 4 ºC with mouse anti-tubulin antibody (Cell Signaling 3873S) at 1:100 
% 	
	 =
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dilution in antibody dilution buffer (1% BSA; 0.3% Triton-X-100; PBS). Cells were then washed with PBS (3 
x 5 min) before incubation with anti-mouse AlexaFluor 488 secondary antibody (Life Technologies A21202) 
at 1:500 dilution in antibody dilution buffer. After washing cells with PBS (3 x 5 min), images were acquired 
with an inverted Olympus IX81 microscope equipped with a Hamamatsu C8484 camera, 40X phase 
contrast objective and a FITC filter cube (Semrock). Metamorph software was employed for image analysis. 
 
Treatment of HeLa Cells with C18-Cbl-COL-Loaded RBCs. HeLa cells were plated in 24-well glass 
bottom plates (Mattek) at a density of 3.3 x 104 cells per well and maintained at 37 ºC in a humidity-
controlled incubator with a 5% CO2 atmosphere in DMEM (10% FBS, 1% Pen-Strep). The following day, 
cells were washed 2x with PBS, followed by the addition of 100 µL of L-15 media. Cells were then treated 
with 250 µL of a suspension of C18-Cbl-COL loaded erythrocytes in PBS (6 µM loading concentration at 
5% hematocrit) or 250 µL PBS (control cells). Cells were then either kept in the dark at 37 ºC in a humidity-
controlled incubator, or exposed to 530 nm LED flood light (PAR38; 500 – 570 nm emission; 5 mW power) 
for 5, 10, or 20 min at room temperature. All cells incubated for 1 h in a 37 ºC in a humidity-controlled 
incubator post-photolysis.  At the conclusion of the incubation period, cells were washed 3 x 1 mL with PBS 
and then fixed with 1 mL of methanol at room temperature for 10 min. Cells were washed 2 x 1 mL with 
PBS and blocked for 1 h in 5% Donkey Serum. Blocking was followed by overnight incubation at 4 ºC with 
mouse anti-tubulin antibody (Cell Signaling 3873S) at 1:100 dilution in antibody dilution buffer (1% BSA; 
0.3% Triton-X-100; PBS). Cells were then washed with PBS (3 x 5 min) before incubation with anti-mouse 
AlexaFluor 488 secondary antibody (Life Technologies A21202) at 1:500 dilution in antibody dilution buffer. 
After washing cells with PBS (3 x 5 min), images were acquired with an inverted Olympus IX81 microscope 
equipped with a Hamamatsu C8484 camera, 40X phase contrast objective and a FITC filter cube 
(Semrock). Metamorph software was employed for image analysis. 
 
Treatment of HeLa Cells with DEX. HeLa cells were plated in a 6-well glass bottom plate (Mattek) at a 
density of 7.5 x 104 cells per well and maintained at 37 ºC in a humidity-controlled incubator with a 5% CO2 
atmosphere in DMEM (10% FBS, 1% Pen-Strep). The following day, cells were treated with varying 
concentrations of DEX (1 mM stock in DMSO) or DMSO for 1 h at 37 ºC in a humidity-controlled incubator. 
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At the conclusion of the incubation period, cells were fixed with 4% PFA in PBS for 10 min at room 
temperature, then washed 1x with PBS, and then treated with 1 mL of methanol at room temperature for 5 
min. Cells were washed 2 x 1 mL with PBS and subsequently incubated overnight at 4 ºC with rabbit anti-
GRα antibody (abcam 3580) at 1:100 dilution in antibody dilution buffer (1% BSA; 0.3% Triton-X-100; PBS). 
Cells were then washed with PBS (3 x 5 min) before incubation with anti-rabbit AlexaFluor 488 secondary 
antibody (Life Technologies A21206) at 1:500 dilution in antibody dilution buffer for 1 h at room temperature. 
Cells were washed with PBS (3 x 5 min) and Hoescht 33342 (100 µg/mL in PBS) applied for 30 min before 
an additional wash with PBS.  Images were subsequently acquired with an inverted Olympus IX81 
microscope equipped with a Hamamatsu C8484 camera, 40X phase contrast objective and a FITC filter 
cube (Semrock). Metamorph software was employed for image analysis. 
 
Treatment of HeLa Cells with C18-Cbl-DEX Loaded RBCs. HeLa cells were plated in 12-well glass bottom 
plates (Mattek) at a density of 2.5 x 104 cells per well and maintained at 37 ºC in a humidity-controlled 
incubator with a 5% CO2 atmosphere in DMEM (10% FBS, 1% Pen-Strep). The following day, cells were 
washed 2x with PBS, then treated with 500 µL of a suspension of C18-Cbl-DEX loaded red blood cells in L-
15 media (1 µM loading concentration at 5% hematocrit) or 500 µL L-15 (control cells). Cells were then 
either kept in the dark at 37 ºC in a humidity-controlled incubator, or exposed to 530 nm LED flood light 
(PAR38; 500 – 570 nm emission; 5 mW power) for 10, 20, or 30 min at room temperature. All cells incubated 
for 1 h in a 37 ºC in a humidity-controlled incubator post-photolysis. At the conclusion of the incubation 
period, cells were washed 3 x 1 mL with PBS and then fixed with 4% PFA in PBS for 10 min at room 
temperature, then washed 1x with PBS and treated with 1 mL of methanol at room temperature for 5 min. 
Cells were subsequently washed 2 x 1 mL with PBS and then incubated overnight at 4 ºC with rabbit anti-
GRα antibody (abcam 3580) at 1:100 dilution in antibody dilution buffer (1% BSA; 0.3% Triton-X-100; PBS). 
Next, cells were washed with PBS (3 x 5 min) before incubation with anti-rabbit AlexaFluor 488 secondary 
antibody (Life Technologies A21206) at 1:500 dilution in antibody dilution buffer for 1 h at room temperature. 
Cells were finally washed with PBS (3 x 5 min). Images were subsequently acquired with an inverted 
Olympus IX81 microscope equipped with a Hamamatsu C8484 camera, 40X phase contrast objective and 
a FITC filter cube (Semrock). Metamorph software was employed for image analysis. 
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Photolytic Release of TAM and FAM from C18-Cbl-TAM- and C18-Cbl-FAM-Embedded Erythrocytes. 
Erythrocytes were taken from 10% hematocrit stock solutions.  RBCs were loaded with 1 µM C18-Cbl-TAM 
or C18-Cbl-FAM as described in the Erythrocyte Loading Procedure. For those experiments requiring 
lipidated fluorophores, 5 µM were also loaded from stock solutions in DMSO. Erythrocytes were 
resuspended to 10% hematocrit and exposed to LEDs centered at varying wavelengths for set time points. 
After photolysis, the erythrocyte solution was centrifuged at 1,000 g and the supernatant was analyzed for 
TAM (ʎex: 550 nm ʎem: 580 nm) or FAM (ʎex: 492 nm ʎem: 519 nm) release using a fluorescent plate reader.  
 
Cbl-DEX Light Independent Translocation Test. HeLa cells were plated in 6 well glass bottom plates 
(Mattek) at a density of 8.8 x 104 cells per well and maintained at 37 ºC in a humidity-controlled incubator 
with a 5% CO2 atmosphere in DMEM (10% FBS, 1% Pen-Strep). The following day, cells were washed 2x 
with PBS, then treated with 250 µL of a suspension of C18-Cbl-DEX loaded erythrocytes in L-15 media (1 
µM loading concentration at 5% hematocrit) or 250 µL L-15 (control cells). HeLa cells were then incubated 
in the dark for 1 h at 37 ºC in a humidity-controlled incubator. After the 1 h pre-incubation, HeLa cells were 
washed 3 x 1 mL with PBS (dark room; red safe light) to remove the erythrocytes and 2 mL of L-15 added 
to each well. The washed HeLa cells were then exposed to a green LED light source (PAR38; 500 – 570 
nm emission; 5 mW power) or kept in the dark for 15 min at room temperature. All cells were incubated for 
1 h in a 37 ºC in a humidity-controlled incubator post-photolysis. At the conclusion of the second incubation 
period, cells were washed 3 x 1 mL with PBS and then fixed with 4% PFA in PBS for 10 min at room 
temperature, then washed 1x with PBS and treated with 1 mL of methanol at room temperature for 5 min. 
Cells were subsequently washed 2 x 1 mL with PBS and then incubated overnight at 4 ºC with rabbit anti-
GRα antibody (abcam 3580) at 1:100 dilution in antibody dilution buffer (1% BSA; 0.3% Triton-X-100; PBS). 
Next, cells were washed with PBS (3 x 5 min) before incubation with anti-rabbit AlexaFluor 488 secondary 
antibody (Life Technologies A21206) at 1:500 dilution in antibody dilution buffer for 1 h at room temperature. 
Cells were finally washed with PBS (3 x 5 min). Images were subsequently acquired with an inverted 
Olympus IX81 microscope equipped with a Hamamatsu C8484 camera, 40X phase contrast objective and 
a FITC filter cube (Semrock). Metamorph software was employed for image analysis. 
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Assessment of the C18-Cbl-TAM:C18-Cy5 Ratio for Optimal TAM Release. To 10% hematocrit 
erythrocytes, various concentrations of C18-Cbl-TAM (0 to 10 µM) and various concentrations of C18-C18-
Cy5 were added (0 to 20 µM). Erythrocytes were photolyzed using the 660 nm LED board for 30 min. After 
photolysis, erythrocytes were spun down at 1,000 g for 3 min and the supernatant was analyzed for TAM 
(ʎex: 550 nm ʎem: 580 nm) release using a fluorescent plate reader. 
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Light Power Measurements. All light measurements were recorded with a Coherent Field Max II detector. 
Each measurement is reported as the average of 13 readings and the error is reported as the standard 
deviation. The light was measured in a fashion consistent with photolytic release of drugs erythrocytes. 
 
Confocal Images of Erythrocytes Loaded with C18-Cy5. C18-Cy5 was loaded onto erythrocytes (10% 
hematocrit) at a concentration of 5 µM using the Erythrocyte Loading Procedure. 2 µL of loaded erythrocytes 
were then added to 200 µL RBC buffer and imaged using confocal microscopy. Images were taken using 
4% laser power, and 10 µs/pixel in line scan mode with a 635 nm laser. 
 
MTX Photolysis from Erythrocyte Membranes. C18-Cbl-MTX and either C18-Cy5, C18-AF700, C18-Cy7, 
C18-DY800 were loaded onto erythrocytes (Erythrocyte Loading Procedure) using a concentration of 1 µM 
(C18-Cbl-MTX) and 5 µM (C18-fluorophore), respectively. After loading, erythrocytes were resuspended to 
5% hematocrit and exposed to 660 nm, 725 nm, or 780 nm centered LEDs for 30 min. Other loaded 
erythrocytes were photolyzed for 2 h using 525 nm LEDs to free all bound MTX to assess the total amount 
of drug loaded.  After photolysis, the erythrocyte solution was centrifuged at 1,000 g and the supernatant 
analyzed for MTX using the MTX LC-MS assay. 
98 
 
Photo-release of COL and DEX from C18-Cbl-COL- and C18-Cbl-DEX-loaded Erythrocytes. C18-Cbl-
COL (5 µM) or C18-Cbl-DEX (0.5 µM) were loaded with either C18-DY800 or C18-Cy5 fluorophore according 
to the Erythrocyte Loading Procedure. C18-DY800 was added to a final concentration of 5 and 2.5 µM for 
C18-Cbl-COL and C18-Cbl-DEX erythrocytes, respectively. C18-Cy5 was added to a final concentration of 
25 and 2.5 µM for C18-Cbl-COL and C18-Cbl-DEX erythrocytes, respectively. Erythrocytes were 
resuspended to 5% hematocrit. The C18-DY800 samples were exposed to 525 nm for 2 h or 780 nm for 0 
and 30 min and the C18-Cy5-containing samples were exposed to 525 nm and 660 nm in similar fashion. 
After photolysis, the erythrocyte solution was centrifuged at 1,000 g and the supernatant analyzed for COL 
or DEX release by LC/MS. Baseline was determined by analyzing erythrocyte samples lacking the Cbl 
bound drugs. 
Treatment of HeLa Cells with C18-Cbl-DEX/C18-Cy5-loaded Erythrocytes. HeLa cells were plated in 35 
mm glass bottom dishes (Mattek) at a density of 1.0 x 105 cells per well and maintained at 37 ºC in a 
humidity-controlled incubator with a 5% CO2 atmosphere in DMEM (10% FBS, 1% Pen-Strep). The 
following day, the HeLa cells were washed 3x with PBS, then treated with 200 µL of a suspension of C18-
Cbl-DEX/C18-Cy5 (0.5 µM/2.5 µM) loaded erythrocytes in L-15 media (5% hematocrit) or 200 µL L-15 
(control cells). Samples were either kept in the dark or exposed to a 660 nm LED array for 10, 20, or 30 
min using the appropriate filter sets. All samples were placed in a 37 ºC in a humidity-controlled incubator 
post-photolysis until harvest 1 h after the end of the last photolysis interval.  HeLa cells were washed 3 x 1 
mL with PBS and then fixed with 4% PFA in PBS for 10 min at room temperature, then washed 1x with PBS 
and treated with 1 mL of methanol at room temperature for 5 min. Cells were subsequently washed 2 x 1 
mL with PBS and then incubated overnight at 4 ºC with rabbit anti-GRα antibody (abcam 3580) at 1:100 
dilution in antibody dilution buffer (1% BSA; 0.3% Triton-X-100; PBS). Next, cells were washed with PBS 
(3 x 5 min) before incubation with anti-rabbit AlexaFluor 488 secondary antibody (Life Technologies 
A21206) at 1:500 dilution in antibody dilution buffer for 1 h at room temperature. Cells were finally washed 
with PBS (3 x 5 min). Images were subsequently acquired with an inverted Olympus IX81 microscope 
equipped with a Hamamatsu C8484 camera, 60X oil objective and a FITC filter cube (Semrock). Metamorph 
software was employed for image analysis. 
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Treatment of HeLa Cells with Cbl-COL/C18-Cy5-loaded Erythrocytes. HeLa cells were plated in 35 mm 
glass bottom dishes (Mattek) at a density of 1.0 x 105 cells per well and maintained at 37 ºC in a humidity-
controlled incubator with a 5% CO2 atmosphere in DMEM (10% FBS, 1% Pen-Strep). The following day, 
HeLa cells were washed 3x with PBS, then treated with 200 µL of a suspension of C18-Cbl-COL/C18-Cy5 
(5 µM/25 µM) loaded erythrocytes in L-15  (5% hematocrit) or 200 µL L-15 (control cells). Samples were 
then either kept in the dark at 37 ºC in a humidity-controlled incubator, or exposed to a 660 nm LED array 
for 10, 20, or 30 min using the appropriate filter sets. All samples were incubated for 1 h in a 37 ºC in a 
humidity-controlled incubator post-photolysis.  At the conclusion of the incubation period, HeLa cells were 
washed 3 x 1 mL with PBS and then fixed with 1 mL of methanol at room temperature for 10 min. Cells 
were washed 2 x 1 mL with PBS and blocked for 1 h in 5% Donkey Serum. Blocking was followed by 
overnight incubation at 4 ºC with mouse anti-tubulin antibody (Cell Signaling 3873S) at 1:100 dilution in 
antibody dilution buffer (1% BSA; 0.3% Triton-X-100; PBS). Cells were then washed with PBS (3 x 5 min) 
before incubation with anti-mouse AlexaFluor 488 secondary antibody (Life Technologies A21202) at 1:500 
dilution in antibody dilution buffer. After washing cells with PBS (3 x 5 min), images were acquired with an 
inverted Olympus IX81 microscope equipped with a Hamamatsu C8484 camera, 60X oil objective and a 
FITC filter cube (Semrock). Metamorph software was employed for image analysis. 
Treatment of HeLa Cells with C18-Cbl-COL/C18-DY800-loaded Erythrocytes. HeLa cells were plated in 
35 mm glass bottom dishes (Mattek) at a density of 1.0 x 105 cells per well and maintained at 37 ºC in a 
humidity-controlled incubator with a 5% CO2 atmosphere in DMEM (10% FBS, 1% Pen-Strep). The 
following day, cells were washed 3x with PBS, then treated with 200 µL of a suspension of C18-Cbl-
COL/C18-DY800 (5 µM/5 µM) loaded erythrocytes in L-15 (5% hematocrit) or 200 µL L-15 (control cells). 
Samples were then either kept in the dark at 37 ºC in a humidity-controlled incubator, or exposed to a 780 
nm LED array for 10, 20, or 30 min using the appropriate filter sets. All samples were incubated for 1 h in a 
37 ºC in a humidity-controlled incubator post-photolysis.  At the conclusion of the incubation period, HeLa 
cells were washed 3 x 1 mL with PBS and then fixed with 1 mL of methanol at room temperature for 10 
min. Cells were washed 2 x 1 mL with PBS and blocked for 1 h in 5% Donkey Serum. Blocking was followed 
by overnight incubation at 4 ºC with mouse anti-tubulin antibody (Cell Signaling 3873S) at 1:100 dilution in 
antibody dilution buffer (1% BSA; 0.3% Triton-X-100; PBS). Cells were then washed with PBS (3 x 5 min) 
100 
 
before incubation with anti-mouse AlexaFluor 488 secondary antibody (Life Technologies A21202) at 1:500 
dilution in antibody dilution buffer. After washing cells with PBS (3 x 5 min), images were acquired with an 
inverted Olympus IX81 microscope equipped with a Hamamatsu C8484 camera, 60X oil objective and a 
FITC filter cube (Semrock). Metamorph software was employed for image analysis. 
CETSA Assay of HeLa Cells Treated with C18-Cbl-MTX-loaded RBCs. HeLa cells were plated in 12-well 
tissue culture plates at a density of 9.4 x 104 cells per well and maintained at 37 ºC in a humidity-controlled 
incubator with a 5% CO2 atmosphere in DMEM (10% FBS, 1% Pen-Strep). The following day, cells were 
washed 3x with PBS, then treated with 300 µL of a suspension of C18-Cbl-MTX-loaded erythrocytes in L-
15 (5 µM MTX loading concentration at 5% hematocrit), 300 µL L-15 (control cells), or 300 µL L-15 with 10 
µM MTX (positive control). Samples were then either kept in the dark at 37 ºC in a humidity-controlled 
incubator, or exposed to a green LED light source (PAR38; 500 – 570 nm emission; 5 mW power) for 10, 
20, or 30 min. At the end of the photolysis interval, all samples were incubated for 1 h in a 37 ºC in a 
humidity-controlled incubator.  The cells were then washed with 3 x 1 mL with PBS and trypsinized with 
300 µL 0.05% Trypsin (Gibco) for 5 min at 37 ºC. Trypsinized cells were then pelleted (5 min, 2000 rpm, 4 
ºC), washed 1 x 300 µL PBS, and then pelleted again. After removal of the supernatant, cell pellets were 
heated at 52 ºC in a temperature controlled heat block for 3 min, and then cooled for 3 min at room 
temperature. 30 µL of lysis buffer (25 mM Tris HCl/2 mM DTT/1X Pierce HALT protease and phosphatase 
inhibitor) was added to each pellet, which were then subjected to 2 freeze-thaw cycles in liquid N2. The 
resulting solutions were then spun at 17000 g for 20 min at 4 ºC. The resulting supernatants were removed 
and combined with 6X LSB-BME and boiled for 4 min at 95 ºC, then analyzed by western blot (overnight 
incubation at 4 ºC with Santa Cruz anti-DHFR E18 primary antibody (1:1000 in TBST/5%BSA) and Cell 
Signaling anti- Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) antibody (1:2000), followed by 
incubation with the appropriate secondary antibodies.  
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Chapter 3:  Erythrocyte Loaded Near IR Activated Phototherapeutics 
(This work was performed with assistance from Robert Hughes and Christina Marvin) 
3.1.  Background 
 In the previous chapter, cobalamin-drug complexes were loaded onto red blood cell membrane to 
utilize erythrocytes as drug delivery vehicles.  While the plasma membrane provides a buffer zone that 
prevents enzymes from processing light activatable prodrugs prior to illumination, the vast majority of the 
work pertaining to erythrocyte mediated drug delivery has utilized internally loaded blood cells.  Red blood 
cells have been loaded with a surprising diversity of cargo resulting in an exciting array of potential therapies 
for human disease. 
 Erythrocytes possess a unique ability to form a stable pore when exposed to hypotonic solution.  
Upon exposure to isotonic medium, pores reseal and no lasting damage is done to the cell1.  This leads to 
an exchange of cellular contents with molecules in the surrounding medium, which can then be sealed 
inside by increasing the ionic strength of the buffer2.  A major class of encapsulated cargo comprises 
exogenous enzymes with therapeutic applications.  Sufferers of severe combined immunodeficiency 
disease have a mutation that prevents adenosine deaminase expression (an enzyme that metabolizes 
adenosine in cells and in blood plasma)3.  Adenosine builds up in the blood of these patients and leads to 
severe immune system depression3.  Simply injecting adenosine deaminase into the blood stream leads to 
rapid clearance by the kidneys and PEGylation (the most common means of preventing protein clearance) 
provokes immune reactions in many people.  The problems of rapid clearance and immunogenicity common 
difficulties with enzyme replacement therapies4,5.  However, loading a patient’s own red blood cells with this 
enzyme once every 2 – 3 weeks overcomes these problems by transforming their own erythrocytes into 
persistent blood borne bioreactors that remain functional for the life of the modified cells6,7.  Adenosine is 
actively imported into red blood cells and converted into inosine.  A number of clinical trials, including one 
that lasted for 9 years, have been able to lower the patient blood plasma adenosine levels by an order of 
magnitude7. 
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 Erythrocyte bioreactor therapy can also involve imparting a biological function that that the patient 
has not necessarily lost.  It has been recognized for decades that acute lymphoblastic leukemia (ALL) cells 
are incapable of producing asparagine and must import it from the blood serum.  By loading human 
erythrocytes with L-asparaginase from E. coli, researchers demonstrated that erythrocytes actively import 
asparagine from blood plasma in mice, allowing the exogenous enzyme cargo to convert it into aspartic 
acid, which is then exported back into the blood stream8,9,10.  The depletion of asparagine was effective 
enough to be used as a therapy for childhood ALL in phase II and III clinical trials11.     
 Erythrocytes can also be used as internal reservoirs of drugs for slow release into the blood stream.  
Small molecule pro-drugs modified with a charged or otherwise hydrophilic moiety that renders them 
membrane impermeable until endogenous enzymes can slowly convert them into the active cell permeable 
form.  This design maintains a low, clinically relevant level of drug in the blood stream without exposing the 
patient to unnecessary levels of the therapeutic agent, leaving them vulnerable to deleterious side 
effects12,11,13.  Multiple clinical trials have been performed that demonstrate this principle as a viable mode 
of drug delivery in humans14,15,16.  
The most advanced of these technologies is the EryDex loading system, a fully automated device 
capable of loading dexamethasone sodium phosphate into erythrocytes11.  The phosphorylated prodrug is 
biologically inert until phosphatases within the erythrocyte slowly convert it to dexamethasone, a powerful 
anti-inflammatory agent.  This maintains a reservoir of cell impermeable dexamethasone hidden inside the 
corpuscles of the blood, which is slowly released into the plasma, maintaining a low therapeutic dose of 
dexamethasone12 (Figure 3.1).   Phosphorylated dexamethasone has proven to be an effective prodrug for 
erythrocyte mediated delivery and continues to show clinical promise (including a phase II clinical trial in 
2014)17.  A similar strategy has been tried with 5-fluoro-2’-deoxyuridine, a chemotherapeutic for liver 
metastases from colorectal carcinomas18,19.  An entire list of drugs that have been delivered in this way 
would be beyond the scope of this introduction but there are many other examples of erythrocyte delivery 
of therapeutic agents such as chemotherapeutics20,21, anti-parasidics22,22, and cardiovascular drugs23,24.  
The fact that these loading procedures have advanced to the point of full automation, coupled with the 
steadily increasing number of clinical trials that demonstrate the therapeutic advantages of this method of  
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Figure 3.1.  (a) Hypotonic pore formation and loading of dexamethasone phosphate into red blood cells.  
(b)  After restoration of buffer isotonicity, the phosphate moiety renders the prodrug unable to exit the interior 
of the erythrocyte.  Slow enzymatic action by intracellular phosphatases gradually processes the prodrug 
into its active, cell permeable form.  Thus blood plasma levels of dexamethasone can be maintained at low 
levels to avoid side effects3. 
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drug delivery seem to indicate that the average medical consumer will have access to these treatments 
within the next decade25.   
For many years people have promised that nanoparticles and liposomes would be the carriers of 
choice for light activated drug release26,27.  However these suffer rapid clearance from the blood stream or 
are composed of materials that have no means of physiological degradation and remain trapped in organ 
tissues for life, making them non-ideal for clinical purposes28.  Erythrocytes do not suffer these problems 
but they require a technology capable of converting loaded prodrugs from cell impermeable to permeable 
with light in the optical window of tissue.  Cobalamin is large, hydrophilic, and incapable of penetrating 
membranes on its own.  We have demonstrated in numerous publications, it can be cleaved from 
compounds using light within the optical window29,30,31.  Just as cell permeable dexamethasone has been 
made impermeable by the addition of a phosphate group until exposed to phosphatases, cell-permeable 
drugs attached to cobalamin via a photolabile Co-C bond would be prevented from traversing the RBC 
membrane until exposure to light.  In this case, release from the erythrocyte would be mediated by a specific 
and controllable light signal.  (Figure 3.2).   
In this chapter, we will show promising progress towards a light activatable drug delivery system 
capable of maintaining an intracellular supply of three prodrugs (cobalamin modified with methotrexate, 
colchicine, and doxorubicin).  We aim to show the synthesis and light dependent action of these constructs 
after being loaded inside human erythrocytes via hypotonic pore formation.  We present these results as 
the second generation of our light mediated RBC drug delivery vehicle. 
3.2.  Design and Synthesis 
The following three cobalamin-drug constructs were synthesized for this work.  We appended  
photolabile methotrexate and colchicine to cobalamin (Cbl-MTX and Cbl-Col) and we attached a 
photolabile doxorubicin to cobalamin with a cy5 antenna (Cy5-Cbl-Dox) (Figure 3.3).  Methotrexate and 
colchicine were discussed in the previous chapter.  The addition of doxorubicin to our repertoire of light 
controlled drugs reflects the cardiotoxicity of this highly effective chemotherapeutic. Cancer patients 
responding well to doxorubicin treatment face a life time limit of doxorubicin after which the risk of cardiac 
damage forces them to consider other options that may not be as effective.  By selectively delivering  
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Figure 3.2. Cobalamin gated RBC drug delivery.  (a) Hypotonic medium induces increased osmotic 
pressure on the interior of the human erythrocyte, causing it to swell until a stable pore is formed.  Light 
activated prodrugs in the buffer can freely diffuse into and out of the interior of the red blood cell.  (b)  
Transfer of erythrocytes to isotonic medium (such as PBS or buffer of similar ionic strength) causes the 
pore to reseal.  Cobalamin is membrane impermeable and prevents the drugs from escaping.  (c)  
Illumination at the excitation wavelength of an appended fluorophore causes release of membrane 
permeable drugs into the surrounding medium.  Choosing a fluorophore that is excited by wavelengths 
within the optical window of tissue allows for maximal photolysis depth in living tissue. 
 
 
 
 
 
 
 
 
 
a) b) c) 
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doxorubicin to tumor sites, one might avoid this scenario altogether and free the clinician to prescribe this 
chemotherapeutic for an extended period of time32. 
Small molecules such as colchicine and doxorubicin are known to be cell permeable and have 
been photo-released from cobalamin in bioactive forms in the past, making them ideal candidates for this 
work.  In contrast methotrexate has been shown to be actively taken up by red blood cells and sequestered 
into intracellular polygultamate bodies that are trapped inside.  Our construct conveniently places a propyl-
amide at the γ-carboxyl position of the glutamate moiety of MTX, which is required for the formation of such 
bodies33.  Furthermore, conversion of this site to a relatively hydrophobic moiety should aid the translocation 
of MTX across the RBC membrane unaided. 
 Cbl-MTX was synthesized by an amide coupling of 2a and methotrexate as shown in Scheme 3.1.  
In a similar fashion, the carboxylic acid of 2b was activated by HBTU and coupled to deacetylcolchicine to 
form Cbl-COL, as shown in Scheme 3.2.  Finally Cy5-Cbl-DEX was synthesized by appending a Cy5 
fluorophore to the photostable underside of cobalamin to create 2e, followed by amide coupling of 2e to the 
free amine of doxorubicin (Schemes 3.3 and 3.4).  This amine is not essential for the activity of DOX and 
can freely modified without significant loss of activity34. 
3.3.  Photolysis Products of Cbl-MTX and Cbl-COL. 
 To confirm that photocleavage of Cbl-MTX and Cbl-COL renders the same products as their C18 
bound counterparts, both drug complexes were photolyzed for 20 min in PBS at 525 nm light and their 
products were determined by mass spectrometry.  The clean hydrogen abstraction product is not observed 
after photolysis of Cbl-MTX.  Only Cbl-COL yields both the alkyl chain and photo-oxidation products.  In 
Chapter 2, photocleavage of our constructs on the erythrocyte membrane (as opposed to PBS solvation) 
resulted in a greater percentage of clean H-abstraction for photoreleased drugs over radical degradation 
byproducts (Tables 2.2 and 2.4).  A further 40 – 50% decrease in radical mediated oxidation was observed 
when employing fluorophore assisted photolysis from erythrocytes (Table 2.4).   Further study is required 
to determine whether photolysis within the red blood cell yields a similar improvement for Cbl-MTX and 
Cbl-COL. 
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Scheme 3.1.  Structure and synthesis of Cbl-MTX. 
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Scheme 3.2.  Design and synthesis of Cbl-COL. 
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Scheme 3.4.  Design and synthesis of Cy5-Cbl-DOX. 
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Figure 3.4.  On the left, the structure of the photocleaved drugs is marked with an X where variation due 
to photoxodiation is expected.  On the right, the observed products are shown. 
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Species Observed By Mass Spectometry 
Cbl-MTX Cbl-COL 
No Photolysis M2+ 912.5 M2+ 878.5 
 
Parent Compound Parent Compound 
M3+ 608.8 M3+ 586.2 
Parent Compound Parent Compound 
 
20 min Photolysis M2+ 665.0 M2+ 665.0 
 
B12a B12a 
M+ 510.2 M+ 442.2 
X=OH X=OH 
 
M+ 426.2 
X=H 
 
Table. 3.1 Observed masses before and after photocleavage.  X refers to the position of variation illustrated 
in Figure 3.4.  B12a refers to hydroxocobalamin.     
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3.4.  Light Induced Dosage of Erythrocyte Delivered Drugs to HeLa Cells 
 Both Cbl-MTX and Cbl-COL were loaded by hypotonic swelling into human red blood cells.  The 
goal of this design stipulates that the encapsulated drug should not release prematurely or cause a 
biological effect until exposed to light.   Using the Cellular Thermal Shift Assay (CETSA)35, it was possible 
to detect the presence of MTX bound to nuclear dihydrofolate reductase in HeLa cells when cells were 
treated with Cbl-MTX loaded blood and photolyzed with 525 nm light (Figures 3.5 and 3.6).  Photolysis 
showed no change in DHFR thermal stability in the absence of loaded blood, just as the loaded blood 
caused no effect on DHFR in the absence of light.  Taken together these figures indicate that Cbl-MTX is 
impermeable until the active drug is cleaved away from cobalamin with light. 
Next, we demonstrated that erythrocytes loaded with Cbl-COL were capable of disrupting the 
microtubule networks of HeLa cells.  Again, with an ideal delivery system, HeLa cell microtubule networks 
should only appear to be disrupted in the presence of loaded red blood cells and 525 nm light.  In the 
absence of colchicine, antibody tubulin staining shows the microtubule networks to be well defined and 
branching.  In the presence of photolyzed Cbl-COL, they become twisted, cloudy, and disorganized.  Only 
in the presence of red blood cells loaded with Cbl-COL do we see a disruption of microtubule networks 
upon exposure to 525 nm light (Figure 3.7).  This clearly demonstrates the effectiveness of red blood cells 
to shield their external environment from highly toxic chemicals until they are released by photolysis. 
3.5.  Conclusion 
We have developed a system for internally loading human erythrocytes with cytotoxic agents that 
are fully controlled by light.  These prodrugs change from membrane impermeable to membrane permeable 
species upon photolysis.  This unique system is able to precisely control when and where toxic drugs are 
released.  We have shown the chemical species formed upon photolysis and demonstrated their effects on 
living cells. 
3.6.  Future work 
We have yet to report the toxic effects of photolysis (650 nm) of erythrocytes loaded with Cy5-Cbl-
DOX.  A simple live dead assay will be used to determine whether the highly damaging effects of 
doxorubicin can be focused in a targeted area using hypotonically loaded erythrocytes and red light.   
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Figure 3.5.  Assessment of MTX photo-release using 525 nm light from Cbl-MTX-loaded erythrocytes via 
the CETSA. In the absence of MTX (“Dark” or “No RBCs”) no DHFR is detected from HeLa cells.  This lack 
of MTX can be seen upon incubation of HeLa cell lysates at 52 oC. which caused most unbound DHFR to 
denature.  By contrast, exposure of HeLa cells to Cbl-MTX loaded erythrocytes with light leads to increasing 
amounts of DHFR stable to 52 °C incubation. Loading control: GAPDH. 
  
Dark Dark 525 nm 525 nm 
No RBCs Cbl-MTX RBCs 
GAPDH 
DHFR 
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Figure 3.6.  Quantification of optical densities shown in figure 5 for the CESTA.  These data clearly 
demonstrate that the translocation of MTX from the interior of the red blood cell to the interior of a living 
HeLa cell  only occurs in the presence of light and Cbl-MTX-loaded erythrocytes  
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Figure 3.7.  The effect of 525 nm photolysis on HeLa cells coincubated with Cbl-COL loaded erythrocytes. 
COL transferred from inside erythrocyte bound to the tubulin of microtubules in HeLa cells. Human 
erythrocytes were loaded with Cbl-COL (10% hematocrit, 10 µM).  (a) dark, (b) 45 min photolysis at 525 
nm, (c) dark with Cbl-COL loaded erythrocytes, (d) 45 min photolysis at 525 nm with Cbl-COL loaded 
erythrocytes. Disruption of microtubule networks from photolyzed Cbl-COL is shown in panel d. 
  
a) b) 
c) d) 
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However, based on these early results and previous work done by Shell et al.29, we feel confident that we 
can achieve spatial and temporal control of this cytotoxin as well. 
 
3.7.  Materials and Methods 
 
Scheme 3.5.  Structure and synthesis of 3a and 3b. 
 
3-aminopropylcobalamin (3a):  Was synthesized as previously described Shell, T. et al.29  Briefly, 
cyanocobalamin was dissolved in MeOH under inert atmosphere.  Zn powder was added and stirred for 30 
min before adding 3-chloropropylamine hydrochloride.   After 3 h the reaction reached completion and 3a 
was purified as previously described.  Product confirmed by mass spectrometry. 
Cobalaminbutyrate (3b):  Was synthesized as reported by Bagnato et al.36  Briefly cyanocobalamin was 
dissolved in MeOH and degassed under N2.  Zn powder was added and the solution was stirred for 20 min 
in inert atmosphere.  3-chlorobutyric acid was added and the resulting mixture was stirred for 3 h under 
continuous N2 flow.  A color change from red to orange was observed.  Zinc was removed by centrifugation, 
and the cobalamin was recrystallized twice in either/chloroform.  UV-Vis analysis revealed the alkylation 
went to completion.  3b was purified on a 100g C18 flash column with a linear gradient an H2O:MeOH (0.1% 
TFA) gradient from 0 – 100% in 8 column volumes.   3b eluted at 60% MeOH. 
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Methotrexate cobalamin (Cbl-MTX):  Methotrexate (30 mg, 66 µmol), N,N,N′,N′-Tetramethyl-O-(1H-
benzotriazol-1-yl)uronium hexafluorophosphate (HBTU, 25 mg, 66 µmol, mw=379), and N,N-
Diisopropylethylamine (DIPEA, 58 µL, 332 µmol) were dissolved in 5 mL of DMF and stirred for five min.  
3a (98 mg, 71 µmol, mw=1386) was added and the solution was stirred overnight. Cbl-MTX was purified 
on a C18 flash column with a linear gradient in H2O:MeOH (0.1% TFA) gradient from 0 – 100% in 8 column 
volumes.  Methotrexate cobalamin (Cbl-MTX): orange solid, 65%, ESI MS calcd. for C85H116CoN22O18P 
(M2+) = 912.3954, found 912.9064; (M3+) = 608.5969, found 608.9274. 
Colchicine cobalamin (Cbl-Col):  3b (58 mg, 41 µmol, mw=1416), HBTU (10 mg, 26 µmol, mw=379), and 
DIPEA (15 µL, 86 µmol, mw=129, d=0.74) were dissolved in 2 mL of DMF and stirred for five min.  
Deacetylcolchicine (10 mg, 28 µmol) was added and the solution was stirred overnight. Cbl-Col was purified 
on a 100g C18 flash column with a linear gradient an H2O:MeOH (0.1% TFA) gradient from 0 – 100% in 8 
column volumes.  Colchicine cobalamin (Cbl-Col): orange solid, ESI MS calcd. for C86H116CoN14O20P (M2+) 
= 878.9, found 878.6; (M3+) = 586.3, found 586.1. 
Scheme 3.6.  Structure and synthesis of 3c. 
Ethylamine-Cbl-CN (3c):  3c was synthesized as previously described by Shell et al.7  Briefly, 
cyanocobalamin was reacted with CDT in DMSO.  Ethylene diamine was added to the activated cobalamin 
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and allowed to react for 1 h.  3c was purified by ether/chloroform recrystallization and C18 flash 
chromatography and confirmed by mass spectrometry. 
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Scheme 3.7.  Structure and synthesis of 3d. 
Ethylamine-Cbl-Butyrate (3d):  2c (100 mg, 69 µmol) was dissolved in 10 mL of MeOH under N2.  NH4Br 
(500 mg, 5% w/v) and Zn powder (100 mg, 1.5 mmol) were added and the solution stirred for 20 min under 
N2. To this slurry, 4-chlorobutryic acid (30 µL, 305 µmol) was added. The resulting mixture was stirred for 
3 h under continuous N2 flow. A color change from red to orange was observed.  Zn was removed by 
centrifugation, and the Cbl was recrystallized twice in ether/chloroform (50 mL). The resulting precipitate 
was collected by centrifugation and decantation. The pellet was dried under vacuum and 10 mL EtOH was 
added. 3d was purified on a 100 g Biotage KP-C18-HS flash column with a linear gradient from 100% H2O 
– 100% MeOH 8 column volumes. 3d eluted at 55% MeOH and, upon removal of MeOH furnished an 
orange solid in 82% yield. 
Cy5-Cbl-butyrate (3e): Sulfo-Cy5 (8 mg, 13 µmol) was dissolved in 2 mL DMF with 15 µL DIPEA and 
HBTU (1 eq to Cy5).  After 5 min. 3d (30 mg, 20 µmol) was added and the amide coupling was allowed to 
proceed in the dark for 3 h at room temperature.  3e was purified on a 30 g Biotage KP-C18-HS flash 
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column with a linear gradient from 100% H2O – 100% MeOH 8 column volumes.  3e eluted at 55% MeOH.  
Cy5-Cbl-butyrate (3e): Blue solid, 45% yield, ESI MS calcd. for C101H135CoN17O24PS23- (M2+) = 1062.9188, 
found 1063.3782; (M3+) = 708.9459, found 708.8134. 
Cy5-Cbl-Dox: 3e (10 mg, 4 µmol) was dissolved in 1 mL DMF with 10 µL DIPEA and HBTU (1 eq to Cbl).  
After 5 min. doxorubicin (4 mg, 10 µmol) was added and allowed to react in dark for 3 h at room temperature.  
3e was purified on a C18 HPLC (Apollo C18, 5 µm, 250 x 22 mm column).  Elution time 40 min.  Cy5-Cbl-
Dox:  Green solid, 30% yield.  ESI MS calcd for C129H165CoN18O33PS21- (M2+) = 1324.0149, found 
1324.2640; (M3+) = 883.0099, found 883.5066. 
Time  
(min) 
Flow 
(mL/min) 
H2O 
(%) 
CH3CN 
(%) 
0.01 10.00 90.0 3.0 
10.00 10.00 90.0 3.0 
30.00 10.00 45.0 55.0 
45.00 10.00 35.0 65.0 
60.00 10.00 25.0 75.0 
65.00 10.00 0.0 100.0 
75.00 10.00 0.0 100.0 
80.00 10.00 90.0 3.0 
90.00 10.00 90.0 3.0 
91.00 0.00 90.0 3.0 
 
Table 3.2.  Solvent gradient used for preparative HPLC to purify Cy5-Cbl-DOX. 
Determination of Products of Photolysis 
Cbl-MTX and Cbl-COL were dissolved in PBS at a concentration of 10 µM.  After photolysis at 525 nm for 
20 min the solutions were injected on the LC-MS (20 µL).  Samples of 75 µL were injected onto a 1200 
series Agilent HPLC with a UV-Vis detector, 1260 infinity fluorescent detector, and 6110 quadrapole mass 
spectrometer from a 384 well plate.  Methotrexate was detected by absorbance at 300 nm.  Colchicine was 
detected by absorbance at 365 nm.  The mobile phase consisted of H2O:CH3CN 0.1% FA (Formic Acid) 
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(gradient provided in Table 2). The column used was a Viva C4 analytical column 5 µm, 50 x 21.2 mm from 
Restek.  Species were identified by mass. 
Time 
(min) 
Flow 
(mL/min) 
Water 
(%) 
CH3CN 
(%) 
0 1 97 3 
1 1 97 3 
8 1 20 80 
10 1 20 80 
11 1 97 3 
15 1 97 3 
 
Table 3.3.  Solvent gradient used for the detection of photolyzed species of Cbl-MTX and Cbl-COL. 
Hypotonic Loading Procedure 
Erythrocytes (1 mL, 10% hematocrit) were pelleted via centrifugation and the supernatant was removed. 
Lysis was induced by mixing the pelleted erythrocytes with 900 µL of a hypotonic solution of a cobalamin 
conjugated drug and incubating on ice for 5 min.  The erythrocytes were resealed by addition of 100 µL of 
10x PBS/10 mM MgCl2. Loaded erythrocytes were incubated at room temperature for 30 min. before being 
washed 3x with isotonic PBS buffer (1000 g, 3 min.).  
CETSA assay of HeLa cells treated with Cbl-MTX internally loaded RBCs 
HeLa cells were plated in 12-well tissue culture plates at a density of 1.0 x 105 cells per well and maintained 
at 37 ºC in a humidity-controlled incubator with a 5% CO2 atmosphere in DMEM (10% FBS, 1% Pen-Strep). 
The following day, cells were washed 3x with PBS, then treated with 200 µL of a suspension of Cbl-MTX  
internally loaded red blood cells in L-15 (10 µM methotrexate loading volume at 10% hematocrit) with 10% 
FBS or 200 µL L-15 with 10% FBS (control cells). Cells were then either kept in the dark at room 
temperature, or exposed to a 525 nm LED array for 45 min. At the end of the photolysis interval, all cells 
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were incubated for 45 min in a 37 ºC in a humidity-controlled incubator.  Next, cells were washed 3 x 1 mL 
with PBS and trypsinized with 300 µL 0.05% Trypsin (Gibco) for 5 min at 37 ºC. Trypsinized cells were then 
pelleted (5 min, 2000 rpm, 4 ºC), washed 1 x 300 µL PBS, and then pelleted again. After removal of the 
supernatant, cell pellets were heated at 52 ºC in a temperature controlled heat block for 3 min, and then 
cooled for 3 min at room temperature. 30 µL of lysis buffer (25 mM Tris HCl, 2 mM DTT, 1X Pierce HALT 
protease and phosphatase inhibitor) was added to each pellet, which were then subjected to 2 freeze-thaw 
cycles in liquid N2. The resulting solutions were then spun at 17000 x g from 20 min at 4 ºC. The resulting 
supernatants were removed and combined with 6X LSB-BME and boiled for 4 min at 95 ºC, then analyzed 
by western blot (Overnight incubation at 4 ºC  with Santa Cruz anti-DHFR E18 primary antibody( 1:1000 in 
TBST, 5%BSA) and Cell Signaling anti-GAPDH antibody (1:2000), followed by incubation with the 
appropriate secondary antibodies.  
Treatment of HeLa cells with Cbl-COL  internally loaded RBCs 
HeLa cells were plated in 35 mm glass bottom dishes (Mattek) at a density of 1.0 x 105 cells per well and 
maintained at 37 ºC in a humidity-controlled incubator with a 5% CO2 atmosphere in DMEM (10% FBS, 1% 
Pen-Strep). The following day, cells were washed 3x with PBS, then treated with 200 µL of a suspension 
of Cbl-COL internally loaded red blood cells in L-15 with 10% FBS  (10 µM colchicine loading volume at 
10% hematocrit) or 200 µL L-15 with 10% FBS (control cells). Cells were then either kept in the dark or 
exposed to a 525 nm LED array for 45 min. at room temperature using the appropriate filter sets. All cells 
were incubated for 45 min in a 37 ºC in a humidity-controlled incubator post-photolysis.  At the conclusion 
of the incubation period, cells were washed 3 x 1 mL with PBS and then fixed with 1 mL of methanol at 
room temperature for 10 min. Cells were washed 2 x 1 mL with PBS and blocked and permeablized for 20 
min in antibody dilution buffer (1% BSA; 0.3% Triton-X-100; PBS) at 4 ºC. Blocking was followed by 
overnight incubation at 4 ºC with mouse anti-tubulin antibody (Cell Signaling 3873S) at 1:100 dilution in 
antibody dilution buffer (1% BSA; 0.3% Triton-X-100; PBS). Cells were then washed with PBS (3 x 5 min) 
before incubation with anti-mouse AlexaFluor 488 secondary antibody (Life Technologies A21202) at 1:500 
dilution in antibody dilution buffer. After washing cells with PBS (3 x 5 min), images were acquired with an 
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inverted Olympus IX81 microscope equipped with a Hamamatsu C8484 camera, 60X oil objective and a 
FITC filter cube (Semrock). Metamorph software was employed for imaging analysis. 
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Chapter 4.  Development of a Src Kinase Sensor that is Sequestered in Cellular Membranes 
Until Exposed to Green Light 
 
(This work was performed with assistance from Melanie Priestman) 
4.1.  Background 
 As discussed in Chapter 1, the field of photochemical biology was born out of a desire to study the 
activity of endogenous enzymes in their native cellular environments.  The concept, synthesis, and resulting 
experiments involving the first caged compound, nitrobenzyl modified ATP, were all focused around the 
idea that a substrate should be delivered inside a living system and not interact with the complex 
intracellular environment until signaled to do so with light1.  In order to function properly, an enzyme’s activity 
must be subject to the mechanisms of cellular regulation, which dictates that in order to study them in a 
meaningful way, one must be able sample their activity in a temporally controlled manner.  Caged substrate 
reporters have allowed researchers to do this for a wide variety of enzymes.   
 An early example of this, by Swezey et al,. employed a caged glucose-6-phosphate to study a 
metabolic pathway in sea urchin eggs (a model species for the study of gastrulation) at various time points 
after fertilization.  By caging a radiolabeled glucose-6-phosphate (G6P) with a nitrobenzyl derivative, these 
researchers were able to measure the rate at which radioactive metabolites appeared after photolysis2.  It 
was discovered that the fertilized egg undergoes an elevated consumption of G6P at 2 min. after fertilization 
that levels off after 20 min. at a rate that was over 100 times faster than pre-fusion levels3.  A non-caged 
substrate only provides an average reaction rate over the course of an experiment because the substrate 
is acted upon immediately after loading, and information about initial rates or activity transients is lost.   
 Photogenerated substrates are important for studying the dips and spikes of intracellular enzymatic 
activity where the timing, duration, and even the location of catalysis can have a profound impact on 
physiological processes.  No group of enzymes seems to have a clearer need of light activatable substrates 
than the protein kinases.  Protein kinases are an important class of enzymes that make up the largest class 
of proteins responsible for signal transduction in mammalian cells4.  Their catalytic action is involved in the 
132 
 
regulation of such processes as cell growth and proliferation5,6,7,8,9, cellular necrosis and 
apoptosis10,11,12,13,14, migration15,16,17,18, differentiation19,20,21,22,23, and metabolism24,25 to name a few.  Given 
their ubiquitous nature in cellular function, the dysfunction of these enzymes is implicated in many illnesses 
such as autoimmune disorders (rheumatoid arthritis26,
 
Crohn’s disease27,
 
and multiple sclorosis28),  
neurological disorders (Parkinson’s disease29, migraines30, ALS31, etc.), and cancer32,33,34.  Cancer, in 
particular, can be thought of almost entirely as a collection of cellular signaling disorders leading to 
unregulated growth and invasion35.  Therefore, understanding the roles of, and developing an activity profile 
for protein kinases in a particular type of malignancy should prove profoundly useful in the development of 
treatment strategies36, diagnoses37, and patient prognoses38. 
 Given their remarkably diverse role in cellular biology, biochemical repertoire of kinases is limited 
to three very similar reactions.  Most protein kinases transfer the γ-phosphoryl moiety of ATP to the hydroxyl 
group of either a serine, threonine, or tyrosine residue of a peptide or protein4.  Despite this chemical 
simplicity, this class of enzymes are challenging to study.  Each kinase has a variety of factors it uses to 
“decide” to phosphorylate one residue over another; such as the amino acid sequence surrounding the 
target residue39, recognition motifs that can reside near the target or on entirely different protein subunits39, 
interactions with the cellular environment40, and even the location within the cell41.  To add to this difficulty, 
the vast majority of cellular kinases occur within the bounds of the lipid bilayer membrane which almost 
universally rejects the influx of peptide or protein substrates that they target42,43.  Therefore, the ability to 
activate kinase substrates for phosphorylation at precisely timed intervals with subcellular spatial precision 
is invaluable in the study of signal transduction in eukaryotes. 
 Echoing the work of Hoffman1, Oien et al. loaded a fluorescent sensor for protein kinase A activity 
into human erythrocytes.  By appending a o-nitrobenzyl on the phosphorylated serine of the reporter 
peptide, they were able to load all assay components, re-seal the erythrocytes, and sample the activity at 
a time when they were ready to monitor it44.  Had they simply used a peptide with no light cleavable 
protecting group, the endogenous PKA would have begun acting on the substrate the moment it was loaded 
in the erythrocytes.  As the majority of the activity occurred within the first 60 s after photolysis, it is unlikely 
there would have been sufficient time to prepare the cells for microscopy before the completion of the 
kinase reaction without the use of a caged substrate44.  In an earlier work, a caged fluorescent reporter of 
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phosphorylation by protein kinase C was used in a similar way to determine the role of PKC in mitosis in 
living cells45.  By uncaging the sensor at various time points prior to and following the breakdown of the 
nuclear envelope, the researchers were able to sample the kinase activity as a function of time relative to 
this event.   Without the precise temporal control over the start time of the assay, they would never have 
been able to resolve a sharp increase in PKC β (an isoform of PKC) minutes prior to the breakup of the 
nuclear envelope or determine that this activity is required for the nucleus to degrade during mitosis45.  It 
should also be noted that tyrosine kinase substrates can also be caged in this fashion for these types of 
studies46 (Figure 4.1).   
 In this chapter, we put forward a fundamentally new approach for the control of enzymatic activity 
on exogenous peptide sensors.  Our goal was to create a kinase substrate that is sequestered to the plasma 
membrane, rendering it inaccessible to endogenous enzymes until release into the cytoplasm is triggered 
by a ≤ 577 nm light signal (Figure 4.2).  We surmised that proteins and glycans bound to the membrane 
would create a crowded environment inaccessible to action by kinases.  This goal consists of the following 
three parts: (1) The substrate needs to bind tightly to the cell membrane; (2) The substrate needs to be 
inaccessible to its target kinase until illuminated with light; and (3) The substrate is required to flip onto the 
inner leaflet of the plasma membrane.   
 Our efforts were focused on the proto-oncogene tyrosine-protein kinase Src, or c-Src, to assess its 
role in prostate cancer metastasis47.  Prostate cancers can be divided into groups of relatively benign 
neoplasms that are unlikely to be life threatening and aggressive tumors that are highly prone to metastasis 
and associated with poor patient prognosis48,49.  Reliable, quantitative tests  need to be developed that can 
differentiate between patients who face more harm than benefit from conventional cancer treatment and 
patients who face a life threatening condition requiring aggressive therapy50.  c-Src has been implicated in 
migration and proliferation of aggressive prostate cancer cell lines47.  If our strategy proved successful for 
the detection of kinase activity, it would potentially move diagnosis forward by allowing clinicians to sample 
Src activity from patient biopsies, and develop a “fingerprint” for aggressive prostate cancers. 
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Figure 4.1.  A small snippet of a tyrosine kinase peptide substrate is shown with a nitrobenzyl moiety 
appended to the crucial p-hydroxyl group of the tyrosine residue.  The site of phosphorylation is “blocked” 
and can only be accessed after photolysis with 365 nm light.  As implied by the lack of surrounding residues, 
this strategy is sequence independent and only relies on modification of the amino acid modified by the 
enzyme.  Analogous strategies are used for serine and threonine kinases13. 
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Figure 4.2.  A kinase substrate bound close to the membrane surface could be “hidden” among membrane 
bound proteins and polysaccharides and be protected from the catalysis of a cytosolic enzyme.  Once 
liberated from the membrane surface, the substrate is free to be acted upon by freely diffusive enzymes.  
However, the enzyme might not always need to be freely diffusive for this strategy to be effective.  A 
membrane bound enzyme could still be blocked from acting on a membrane bound substrate provided that 
the lipid anchor prevented the substrate from obtaining the necessary orientation within the enzymatic 
active site for catalysis to occur. 
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4.2.  Selection of a Src Substrate 
 The first step in the design of a membrane sequestered Src substrate was the selection of an 
appropriate peptide sequence.  We chose a sequence that had been previously validated in an earlier work 
by Xu et al.51 (Figure 4.3).  Apart from some terminal modifications, the basic amino acid sequence was left 
unaltered.  A change of fluorophore from fluorescein to the more photostable tetramethylrhodamine was 
required to improve the ability to analyze cellular localization of the substrate by microscopic techniques.  
The fluorophore would not only allow the location of the peptide to be visualized in living cells but would 
also make it easier to detect the substrate by means of LC-MS to determine the degree of peptide 
phosphorylation.  C and N terminal ornithine residues are not part of the recognition sequence for Src family 
kinases and were removed39.   An N-terminal lysine or cysteine was alternatively added for the purpose of 
conjoining a photolabile membrane anchor (Figure 4.3).  
4.3.  Hydrophobic Membrane Anchors 
 Our stated aims required the peptide substrate to bind to the phospholipid bilayer as closely as 
possible in order to use membrane bound structures as a shield against Src activity.  Chemical ligation of 
the substrate to the cell would permanently bind the peptide to the membrane but it would do nothing to 
pull the substrate as near as possible lipid bilayer surface.  Therefore, a hydrophobic tether, to serve as an 
anchor with the lipid bilayer, was needed.  At the outset of this work, it was the prevailing view in the field 
that peptides merely needed myristoylation in order to traverse the cell membrane52.  Thus the lipophilic 
moiety first selected to bind the peptide to cellular membranes was dodecyl amine because of the simplicity 
in attaching it to the 5’ hydroxyl of the cobalamin ribose to make C12-Cbl (4c, Scheme 4.1).  A variety of 
linkages between the cobalt and peptide were available.  Shorter tethers were desirable to constrain the 
movement of the substrate against the surface of the plasma membrane.  However, the β – axial position 
proved to be a crowded environment and useful yields were only possible with an extended tether.  This 
was accomplished by alkylation of the cobalt with a propyl amine to form C12-B12-propylamine (4d) and a 
subsequent reaction involving succinic anhydride to extend the peptide coupling site away from the corrin 
ring, creating C12-B12-succinate (4e), our first generation membrane anchor  (Scheme 4.1).  Activation of 
the carboxylic acid of 4e facilitated the coupling of C12-B12-succinate the peptide substrate. 
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Figure 4.3.  The peptide substrate for this project closely matches a previously validated substrate for c-
Src (top, 5-FAM-Orn(Ac)EEEIYGEF-Orn(Ac)-NH2) used by Xu et al.51  The tyrosine served as the site of 
phosphorylation.  The acetylated ornithine residues were determined to be non-essential for recognition or 
selectivity and were removed.  The 5-FAM, used by Dr. Xu for detection by CE-LIF51, was replaced with a 
5-TAMRA fluorophore, as it is less prone to photobleaching.  This is essential for microscopic imaging.  
Either an N-terminal lysine (4a) or cysteine (4b) was added as an attachment site for the membrane anchor 
(middle, 5-TAM-KEEEIYGEF-NH2; bottom, 5-TAM-CEEEIYGEF-NH2). 
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Scheme 4.1.  The synthesis of C12-B12-succinate (4c) 
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 A wide variety of lipophilic membrane anchors were attempted.  Obvious choices to anchor a 
molecule to a biological membrane are glycerophospholipids.  Three phospholipid cobalamin adducts were 
attempted by reacting CDT activated cobalamin with DMPE, DSPE, and DOPE (Figure 4).  Of these three, 
only the dioleoyl-glycerophospholipid-cobalamin was obtained in a detectable yield, (10%).  A 10% yield 
was not viewed as an efficient process so the phospholipids were abandoned.  The remaining two 
membrane anchors candidates were octadecylamine (ODA) and cholesterol, which were both easily 
appended to the cobalamin ribose to form chol-B12 (4f) and C18-B12 (4g) as shown in Schemes 4.7 & 4.2.   
 The hydrophobic properties of 4e and 4f were compared by octanol/water partition experiments.  
Surprisingly, when 4e was dissolved in octanol and then mixed with an equal volume of water, 10% of the 
molecule resided in the aqueous phase.  In contrast, 4f showed no observable migration from octanol into 
water.  While an equilibrium must exist, the aqueous concentration of 4f was not detectable by UV-Vis.  
Therefore it was determined that only 4f would be alkylated.  4f was converted to C18-Cbl-propylamine (2a) 
as described in Chapter 2. 
 Our experience has shown that the chemistry of coupling large peptides to the β-axial side of the 
Cbl corrin ring tended to occur at relatively slow rates.  Such coupling reactions often took hours to near 
completion.  Therefore, it was decided that activated ester chemistry would be replaced with a maleimide 
click reaction to avoid hydrolysis of our activated membrane anchor.  6-maleimidohexanoic acid NHS ester 
and C18-Cbl-propylamine were reacted in the presence of DIPEA to form C18-Cbl-maleimide (4g, Scheme 
4.2).  4g could then be reacted with thiol containing peptides for an extended period of time. 
 With the synthesis of two membrane anchors complete (4e and 4g) it was possible to combine 
them with peptide substrates 4a and 4b to create a Src substrate capable of membrane binding and light 
triggered efflux.  Two substrates were synthesized and denoted as C12-Cbl-Src and C18-Cbl-Mal-Src.  C12-
Cbl-Src was synthesized via NHS ester activation of C12-Cbl-succinate with TSTU and a subsequent 
reaction with peptide 4a
 
 (Scheme 4.3).  C18-Cbl-Mal-Src was synthesized by treating the Src substrate, 
peptide 4b, with lipid anchor 4g in EtOH (scheme 4.4).  Once synthesized, the physical and biological 
properties of these compounds were determined. 
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Figure 4.4.  Proposed cobalamin based cellular membrane anchors using DMPE, DSPE, and DOPE using 
a CDT coupling.  Only the reaction involving DOPE yielded any product (only 10%). 
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Figure 4.5.   The structures of Chol-Cbl (4e) and C18-Cbl (4f). 
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Scheme 4.2.  The synthesis and structure of C18-B12-maleimide 4g.  
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Scheme 4.3.  The synthesis and structure of C12-Cbl-Src.  The structure of C12-Cbl-Src can be divided into 
the following three parts: (1) the fluorescent Src peptide substrate with N-terminal Lys for anchor 
attachment,(2) the photolabile cobalt carbon linkage, and (3) lipophilic C12 tail designed to anchor the 
complex into a cellular membrane. 
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Scheme 4.4.  The synthesis and structure of C18-Cbl-Mal-Src.  The structure of C18-Cbl-Mal-Src can be 
divided into the following three parts: (1) the fluorescent Src peptide substrate with N-terminal Cys for 
anchor attachment, (2) the photolabile cobalt carbon linkage, and (3) lipophilic C18 tail designed to anchor 
the complex into a cellular membrane. 
 
 
 
 
 
145 
 
 
4.4.  Products of C12-Cbl-Src and C18-Cbl-Mal-Src Photolysis 
 In order to perform their desired function, these lipophilic substrates needed to transition from 
hydrophobic molecules to hydrophilic peptides upon photolysis.  C12-Cbl-Src  and C18-Cbl-Mal-Src were 
photolyzed with 525 nm light and the products of photolysis were determined by mass spectrometry.  Partial 
photolysis of C12-Cbl-Src afforded the intact parent molecule, a photocleaved peptide (Src-Pep), and the 
C12-Cbl-OH anchor.   Further illumination yielded only cleavage products (C12-Cbl-OH and Src-Pep) 
(Scheme 4.5 and Table 4.1).  Interestingly, the carbon centered radical known to form upon alkyl cobalamin 
photolysis appears to have abstracted a hydrogen from an unknown donor.  There were no masses to 
suggest products of radical degradation or oxidation of the peptide substrate for C12-Cbl-Src  cleaved in 
PBS.   
 The photolysis buffer for C18-Cbl-Mal-Src contained thiol reducing agents to match the enzyme 
buffer conditions in which it was needed to perform.  This led to some undesired by products but photolysis 
mainly afforded a saturated alkyl chain as shown in Scheme 4.6 and Table 4.1.  In order to be able to 
photolyze the substrate in the presence of active Src kinase, C18-Cbl-Mal-Src needed to be stable in the 
Src reaction buffer until exposed to light.  The standard reducing agents used in Src reactions in the 
literature (DTT or β-mercaptoethanol), were incompatible with cobalamin photochemistry because once the 
alkyl ligand is photolyzed away, cobalamin is capable of catalytically oxidizing thiols in solution that do not 
form stable Co-S bonds53.  In the presence of oxygen the resulting Co(II) that forms from the homolytic 
cleavage of Co-S can react with molecular oxygen to form radical species.  We found that in the presence 
of 1 mM DTT, cleaved C18-B12-propylamine, was able to completely inactivate Src activity.  This effect was 
abrogated by switching to 1 mM GSH, which forms one of the most stable Co-S bonds with cobalamin of 
any known sulfhydryl containing molecule54.  Figure 4.6 demonstrates that the oxidative damage caused to 
Mal-Src-Pep (Scheme 4.6) by photolysis in 1 mM GSH was minimal. 
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 Species Observed By Mass Spectrometry 
 C12-Cbl-Src  C18-Cbl-Mal-Src 
No Photolysis M3+ 1084 M3+ 1136.2 
 
Parent Compound Parent Compound 
M3+ 1127.2 M4+ 850.3 
C12-Cbl-Src + DIPEA Salt Parent Compound 
 
1 min Photolysis M3+ 1127.1 M4+ 850.2 
 
C12-Cbl-Src + DIPEA Salt Parent Compound 
M2+ 770.7 M2+ 812.6 
C12-Cbl-OH C18-Cbl-OH 
M2+ 778.7 M2+ 821.2 
C12-Cbl-OH* C18-Cbl-OH* 
M2+ 854.5 M2+ 890.3 
Cleaved Src Peptide Cleaved Src Peptide1 
M2+ 919.5 M2+ 901.8 
Peptide + DIPEA Salt Cleaved Src Peptide2 
 
M2+ 906.0 
Cleaved Src Peptide3 
 
20 min Photolysis M2+ 855.1 M2+ 891.6 
 
Src-Pep Mal-Src-Pep1 
M2+ 778 M2+ 901.5 
C12-Cbl-OH* Mal-Src-Pep2 
 
M2+ 906.0 
Mal-Src-Pep3 
M2+ 812.7 
C18-Cbl-OH 
M2+ 821.0 
C18-Cbl-OH* 
 
Table 4.1. The masses represent the species found by mass spectrometry after various periods of 
photolysis of C12-Cbl-Src  and C18-Cbl-Mal-Src.  C12-Cbl-Src  had a strong affinity for the protonated salt 
of DIPEA such that they co-eluted during HPLC purification.  C18-Cbl-OH* indicates that the mass is either 
due the to retention of the β hydroxyl cobalt ligand during the ionization process (unusual for 
hydroxocobalamins) or oxidative damage to the corrin ring.  1Photolysis afforded an alkyl chain by hydrogen 
abstraction.  2Photolysis afforded a primary alcohol through radical mediated oxidation.  3Photolysis 
afforded an aldehyde through a radical mediated oxidation.  The aldehyde is hydrated under these 
conditions.  Schemes 4.5 and 4.6 contain the structures found in this table. 
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Scheme 4.5.  Photolysis products for C12-Cbl-Src.  The masses observed after photolysis (Table 4.1) 
correlated to each of the species presented in this scheme.  The peptide appeared to have “cleanly” 
separated from the cobalamin anchor upon photolysis with 525 nm light.  We assume that a hydrogen 
abstraction from an unknown donor in solution was able to prevent the peptide from undergoing damage 
from radical propagation.   
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Scheme 4.6.  Photolysis products for C18-Cbl-Mal-Src.  The masses observed after photolysis (Table 4.1) 
correlated to each of the species presented in this scheme.  It was shown that thiol reducing agents 
(required for kinase assays) increased the number of byproducts from photolysis.  By optimizing for the 
correct type and concentration of reducing agent most of the peptide was able to “cleanly” separate from 
the cobalamin anchor upon photolysis with 525 nm light.   
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Figure 4.6.  Photolysis of C18-Cbl-Mal-Src by HPLC.  C18-Cbl-Mal-Src (20 µM) was dissolved in Src 
reaction buffer, 1 mM GSH, 1 mM ATP, 5 mM MgCl2, and 50 mM phosphate buffer pH 7.5.  After 5 h of 
incubation (30 oC) in the dark the solution was analyzed by LC-MS (absorbance measured at 555 nm) and 
then exposed to 525 nm light for 20 min.  In the absence of light, C18-Cbl-Mal-Src (top) eluted at 12.7 min.  
After photolysis, the cleaved, hydrophilic substrate eluted earlier (bottom).  Comparing with scheme 4.6, 
the species eluting at 8.4 min was the hydroxyl derivative, at 9 min the aldehyde eluted, at 9.4 min species 
where X=H eluted, and finally at 12.6 min C18-Cbl-OH eluted.  Species were confirmed by mass 
spectrometry.  
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 Finally, it was important to ensure that photolysis led to a de-quenching of the fluorescent dye 
bound to our enzyme substrates.  Cobalamin acts as a non-fluorescent dye and covalent linkage of TAM 
to cobalamin complexes is reported to produce a quenching effect55.  The photolytic release of TAMRA 
from cobalamin should result in a fluorescent increase, and in fact, we saw exactly that (shown in Figure 
4.7).  Even though this profluorescent property was not essential to the function of our molecule, it indicated 
that we were not damaging our fluorophore during photolysis and that our system was functioning as it 
should. 
 To summarize, we have shown 1) photolysis under experimental conditions affords the desired 
peptide cleavage products.  2)  Radical damage to the peptide substrates was minimal for conditions used.  
3)  Once cleaved the peptide no longer associates strongly with the cobalamin as seen by the increase in 
fluorescence.  Next, we would need to examine the change in hydrophobicity of our molecules. 
4.5.  Photolysis Induced a Change in Hydrophobicity of Peptide Substrates 
 By designing a system that exploits the hydrophobic effect to bind water soluble, peptide substrates 
to cellular membranes, one would expect that a change in hydrophobicity would occur with the peptides 
upon photolysis.  The simplest way to measure a change in hydrophobicity was found to be the octanol / 
water partition coefficient.  In this regard, C18-Cbl-Mal-Src proved to be a unique chemical species in that 
the phase transition depended on the initial phase that the molecule was dissolved in.  If diluted in water, 
the species remained primarily partitioned in the water and would not appreciably transfer to the octanol in 
an observable time frame.  If dissolved in octanol, the species remained partitioned primarily in octanol and 
would not transition into the water in an appreciable amount.  No amount of mixing or homogenization of 
the phases appeared to affect the equilibrium of either transition (data not shown).  We postulate that this 
was due to micellular structures formed when C18-Cbl-Mal-Src was dissolved in solvent (inverted micelles 
in hydrophobic solvent).  The peptides made for a sizable hydrophilic head group that could almost 
completely shield the hydrophobic C18 core of such micelles, requiring them to break apart before a 
transition to the organic phase was possible. 
 In order to demonstrate light dependent migration of the Mal-Src-Pep substrate from the organic 
layer to the water, C18-Cbl-Mal-Src was dissolved in octanol (20 µM) and photolyzed for various time points.   
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Figure 4.7.  Fluorescent increase of C18-Cbl-Mal-Src upon photolysis.  C18-Cbl-Mal-Src (10 µM) was 
dissolved in Src reaction buffer and placed in a PTI spectrofluorometer (ʎex: 555 nm, ʎem: 585 nm) with the 
excitation gate closed.  T0 indicates the time when the gate was opened and recording began.  The act of 
measuring the fluorescence of TAMRA was sufficient excitation to cleave the Co-C bond and causes a 
fluorescent increase, as we expected see.  Photolysis led to a maximal fold increase of 2.1.  
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 As shown in Figure 4.8, the transfer of peptide from octanol into the water occurred in a light 
dependent manner.  Photolysis by 525 nm LEDs moved the equilibrium of peptide into the aqueous phase 
by homolytic cleavage of the lipophilic anchor.  This process can be seen visually in Figure 4.9.  Taken 
together, these data clearly indicate that our strategy produced a peptide with light dependent hydrophilicity. 
4.6.  Erythrocyte Ghosts as Model Membranes 
 Much thought was given to the choice of the membrane to use in testing the effectiveness and 
biological properties of our tethered substrates.  Living cells would have been difficult to maintain intact and 
study.  Isolated mitochondria were suggested because of previous membrane binding experiments 
performed with them.  However, even out of their cellular environment they showed activity that seemed to 
considerably confuse results obtained from them.  Their double membrane structure, one of which was 
partially permeable, seemed to offer unnecessary complexity to our results.  Variability in purchased 
mitochondria was also problematic and their biological and structural properties could vary wildly from one 
batch to the next.  Liposomes with consistent properties are widely available but the lack of proteins and 
glycans on their surface precludes the basis for the strategy: namely, peptides can be hidden underneath 
the glycoprotein forest.  What was needed was a largely inactive biological membrane that was easy to 
obtain with as little variability between batches as possible.   
 Conveniently, Dr. Nathan Oien was experimenting with human red blood cell ghosts as model cells.  
Erythrocytes have remarkable membrane integrity such that one can place them in hypotonic buffer swell 
the corpuscles to the point where a pore forms allowing the contents inside to be released by passive 
diffusion56.  Once devoid of their contents they are essentially an inert membranous structure and an 
obvious choice as a model in this work.  Of the many modes of preparation of erythrocyte ghosts, we chose 
a method of repeated pelleting by centrifugation, supernatant removal, and suspension in hypotonic 20 mM 
Tris buffer, pH 7.  The ghosts were maintained on ice to provide structural rigidity to their membranes 
throughout this process.  By this method, virtually all hemoglobin could be removed and resulting solutions 
of 50% hematocrit transitioned from deep red (blood) to white or pale orange (ghosts). 
 During the course of these experiments, a bacterial contaminant was introduced to the ghosts and 
was subsequently transferred to new batches.  This led to the introduction of unknown proteases that 
digested Src substrates.  Addition of 0.1% sodium azide was able to prevent this from occurring but once 
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Figure 4.8. Light induced migration of TAMRA from octanol to 50 mM phosphate buffer, pH 7.5, as 
quantified by UV-Vis spectroscopy.  C18-Cbl-Mal-Src (20 µM) was dissolved in the octanol layer and 
photolyzed using 525 nm LEDs.  Migration is represented as the concentration of TAMRA in the aqueous 
layer by monitoring absorbance at 555 nm.  Data are represented as averages with standard errors from 
three independent experiments. 
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Figure 4.9.  Visualization of light dependent migration from octanol to water Mal-Src-Pep.  C18-Cbl-Mal-
Src (10 µM) was dissolved in 0.8 mL octanol and mixed with 0.2 µL dH2O.  Fluorescent peptide was 
visualized by excitation with invisible 365 nm light, allowing for TAMRA to fluoresce without background 
interference from the light source.  (From left to right)  Each image was taken of the same sample after 
different periods of photolysis (2, 5, 10, and 20 min respectively).  The layers were homogenized and 
underwent centrifugation until the layers were fully separated again at the beginning of the experiment and 
after each image was taken.  Photocleavage of the peptide-cobalamin complex resulted in the migration 
and subsequent concentration of Mal-Src-Pep into the more confined aqueous layer.  
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present, azide was not sufficient to halt proteolysis.  The onset of this proteolytic activity could happen 
within several hours of azide free conditions (such as those used to prepare the ghosts), making it 
necessary to find a treatment to block this protease activity.  As the identity of the contaminant proteases 
were unknown, a broad-spectrum treatment cocktail was devised.   Contaminated ghosts could be salvaged 
by treatment with 5 mM PMSF, 5 mM NEM, and 30 mM EDTA.  PMSF is known to irreversibly inhibit serine 
proteases, NEM is a thiol specific alkylating agent capable of deactivating cysteine proteases, and EDTA 
chelates zinc to make it unavailable for metalloproteases.  Treatment of ghosts with this cocktail at 4 oC for 
several hours was sufficient to eliminate contaminated proteases after which they could be maintained by 
storage in 20 mM Tris pH 7.5 with 0.1% sodium azide. 
4.7.  Membrane Affinity of Anchored Peptides 
 In order to determine the affinity of the cobalamin anchored peptides to the plasma membrane, a 
simple assay was developed.  Lipophilic constructs were allowed to incubate with red blood cell ghosts for 
30 min, after which time the ghosts were pelleted (10,000 xg, 10 min), the supernatant was removed and 
collected, and the membranes resuspended.  This is referred to as a wash. By washing three times and 
collecting the supernatant, we were able to measure the concentration of peptide in the supernatant by the 
absorbance of TAMRA at 550 nm for comparison with known standards, providing an accurate measure of 
peptide concentration.  After the washes, the amount of peptide remaining on the membrane could be 
photolyzed  from the surface of the ghosts and the concentration of peptide in the supernatant could again 
be measured by absorbance.  This is more reliable than a fluorescence assay as small changes in peptide 
localization or interactions with proteins in solution could affect the fluorescence of the fluorophore. 
 Erythrocyte ghosts were treated with C12-Cbl-Src and C18-Cbl-Mal-Src (20 µM) and washed three 
times.  By the end of three washes, there was very little C12-Cbl-Src left on the membrane.  The C12 anchor 
was not hydrophobic enough to hold the negatively charged peptide fixed to the membrane.  In contrast 
C18-Cbl-Mal-Src, with its C18 anchor remained bound to the membrane until exposed to 525 nm as shown 
in Figures 4.10, 4.11, and 4.12.   
 The C18 lipid anchor was able to release peptide from the membrane in a light dependent manner.  
The longer the photolysis time, the more peptide that was released (Figure 4.11).  Careful accounting of 
peptide concentrations (in solution and membrane adsorbed) revealed that the substrate was released into 
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the buffer solution at the expense of peptide bound to ghost membranes and the total peptide in the system 
was conserved (Figure 4.12).   
 We went on to establish that the peptide photolyzed from RBC membranes was the same substrate 
formed during photolysis in solution by HPLC.  Ghosts were loaded with C18-Cbl-Mal-Src, washed, and 
then incubated for 1 h in the dark at 30 oC.  The ghosts were pelleted and their supernatants were collected 
before being resuspended and photolyzed and the supernatant was analyzed for the presence of Mal-Src-
Pep by HPLC before and after photolysis.  Analysis by HPLC demonstrated that intact peptide could be 
recovered by photolysis from erythrocyte membranes.  It also provided compelling evidence that the 
substrate did not leak from the membrane into solution before photolysis occurred (Figure 4.13).   
 In order to show that C18-Cbl-Mal-Src was capable of binding to more than one membrane, it was 
loaded onto trypsonized HepG2 cells.  Using a lower centrifugal force (500 xg), we were able to treat these 
cells as ghosts.  They were not as robust as red blood cell membranes. For example, they only had a shelf 
life of one day, as opposed to three weeks for RBC ghosts, and experiments involving many pelleting steps 
were not recommended.  HepG2 cells were loaded with 6 µM C18-Cbl-Mal-Src and washed three times 
before being resuspended in Src reaction buffer.  Half were photolyzed for 20 min and half remained in the 
dark.  Both were pelleted and the supernatants were analyzed by LC-MS (Figure 4.14).  Mal-Src-Pep is 
only detected in the supernatant after exposure to 525 nm light. Taken together these photolysis 
experiments involving erythrocyte ghost membranes and HepG2 cells offer conclusive evidence that our 
peptide-cobalamin conjugate bound to biological membranes until photolysis caused the Src substrate to 
be released. 
4.8.  Determination of Enzyme Kinetics of a Src Substrate on and off the Membrane 
 The key question to answer in this chapter is whether or not the activity of Src kinase on a peptide 
substrate can be allayed by membrane sequestration.  To answer that question one needs to know the 
following:  1)  Is C18-Cbl-Mal-Src a Src kinase substrate before or after photolysis? 2)  Is our membrane 
model system conducive to Src activity and function?  3)  What is the rate of phosphorylation of membrane 
bound Src substrate vs. photolyzed, freely diffusible peptide?  
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Figure 4.10.  Assessment of Src peptide loaded onto red blood cell ghosts.   Erythrocyte ghosts were 
treated with 20 µM of C18-Cbl-Mal-Src and washed three times.  The supernatant of each wash was 
photolyzed and measured for the concentration of TAMRA.  After the third wash the peptide was allowed 
to incubate in the dark for 2 h at 30 oC after which the ghosts were pelleted and the concentration of peptide 
that had leaked into the supernatant was determined.  The ghosts were then resuspended and the peptide 
remaining on the membrane was photolyzed for 20 min before the ghosts were pelleted once more and the 
amount of photolyzed peptide in the supernatant was determined.  Concentrations were determined by 
comparing absorbance at 550 nm to a known standard. Data are represented as averages with standard 
errors of five independent experiments. 
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Figure 4.11.  Demonstration of light proportional release from erythrocyte membranes.  Ghosts were loaded 
with C18-Cbl-Mal-Src (20 µM) in 50 mM phosphate buffer.   After loading, the ghosts were washed 3x 
(collecting the supernatants to measure the concentration of peptide that did not adhere to the membranes) 
and resuspended in Src reaction buffer.  Loaded ghosts were aliquoted and photolyzed for various time 
points (0, 1, 2, 5, and 10 min). After photolysis the membranes were pelleted by centrifugation and the 
concentrations of peptide in the supernatant determined by absorbance at 550 nm (compared to known 
standards).  Data are represented as averages with standard errors of three independent experiments. 
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Figure 4.12.  Membrane bound peptide is inversely proportional to peptide in solution.  Erythrocyte ghosts 
were allowed to load in 50 mM phosphate buffer containing 10 µM C18-Cbl-Mal-Src.  After washing three 
times the ghosts were divided into aliquots, some of which were photolyzed for 0, 2, and 10 min.  After 10 
min the ghosts were pelleted and the supernatant was removed.  The membranes were dissolved in 20% 
DMSO and all samples were photolyzed for 20 min to ensure complete photolysis.  The concentration of 
peptide in each sample was determined by absorbance at 555 nm and comparing it to known standards.  
The concentration of peptide in the membranes was found to decrease with photolysis time (black dots) 
while concentration of TAMRA labeled peptide in the supernatant (white triangles) showed an increase.  If 
concentrations of the pellet and the supernatant are added together the sums work out to be 0.85 µM ± 
0.11 µM (0 min), 0.78 µM ± 0.02 µM (2 min), and 0.94 µM ± 0.06 µM (10 min), which are roughly in error of 
one another.  This means that the total concentration of peptide remained relatively constant, none was 
destroyed by photolysis, it simply translocated from one medium to another.  Data are represented as 
averages with standard errors of three independent experiments. 
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Figure 4.13.  Light dependent release of Src peptide from erythrocyte ghosts as measured by LC-MS.  
Erythrocyte ghosts (20% hematocrit) were treated with 25 µM 4i for 30 min at 30 oC.  The loaded ghosts 
were washed three times with phosphate buffer (50 mM, pH 7.5) and resuspended in Src reaction buffer.  
The loaded ghosts were allowed to incubate for 1 h at 30 oC in the dark.  Half the ghosts were photolyzed 
at 525 nm for 10 min and the other half remained in the dark at the same temperature.  Ghosts were pelleted 
and their supernatants were analyzed by LC-MS observing the absorbance of Tamra at 555 nm.  The 
ghosts that remained in the dark contained no detectable peptide in their supernatants (top).  The ghost 
supernatants that were photolyzed contained the dye conjugated peptide (bottom). 
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Figure 4.14.  Light dependent release of Src peptide from HepG2 cells as measured by LC-MS.  
Trypsinized HepG2 cells were diluted to 20% (v/v) in PBS with 6 µM C18-Cbl-Mal-Src for 30 min.  Cells 
were washed three times, resuspended in Src reaction buffer.  Half were photolyzed for 10 min at 525 nm.  
Half were left in the dark.  Cells were pelleted at 500 xg and the supernatant was analyzed by LC-MS using 
a C4 analytical column.  The supernatant of the non-photolyzed cells (top) showed no absorbance at 555 
nm, indicating no peptide species was present in solution.  The photolyzed supernatant (bottom) contained 
two species.  The species eluting at 3.9 min was a proteolyzed mass that corresponded to TAM-
Cys(Mal)EEE-OH.  The peak eluting at 4.3 min corresponded to the mass of TAM-Cys(Mal)EEEIYGEF-
NH2, or the intact peptide with a “clean” hydrogen abstraction. 
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 Enzyme assays involving the photolabile C18-Cbl-Mal-Src substrate were performed in tandem 
with a previously verified Src substrate provided by Dr. Qunzhao Wang, Ac-EEK(Cascade Yellow)IYGEIEA-
NH2 (4h, shown in Figure 4.15).  Dr. Wang’s peptide served as a positive control for Src activity in all kinetic 
studies.  In order to rigorously test the premise of this work (and to make results easier to interpret), we 
employed the oncogenic and constitutively active v-Src, rather than the wild type c-Src.  The v-Src enzyme 
is nearly identical to the human c-Src isoform but it lacks a c-terminal self inhibitory region contained by 
endogenous c-Src21.  While this region is useful for intracellular control of the kinase, it was important to 
use an isoform that was always active to be able to give the enzyme every possible chance to phosphorylate 
the substrate to ensure that it was the membrane and nothing else that offered protection from photolysis.  
 Incubation of Src in the presence of both C18-Cbl-Mal-Src and 4h in Src reaction buffer (with and 
without photolysis) provided an assessment of the relative efficiency of the two molecules as substrates. 
The percent conversion of the two substrates were compared against each other.  It was not surprising that 
Mal-Src-Pep was the superior substrate because 4h was not designed for speed.  Rather 4h was designed 
to facilitate an interaction between Tyr-5 and cascade yellow to provide a fluorescent quench until 
phosphorylation caused the two to move apart and provide a fluorescent increase46.  This interaction would 
have to be disrupted before phosphorylation could occur, thus slowing the kinetics of the overall reaction 
when compared to Mal-Src-Pep which contained no such encumbrance (Figure 4.16).   
 It was more surprising that the enzymatic reaction appeared to be even faster with the non-
photolyzed peptide (Figure 4.16).  This is not immediately obvious from the data because all peptide was 
consumed with and without photolysis.  However, when one looks at the completeness of the reactions of 
both C18-Cbl-Mal-Src and 4h, one finds that the enzyme is not able to process as much total substrate in 
the time allotted.  Since 4h did not change when exposed to light, one must assume then that the turnover 
rate of Mal-Src-Pep is the factor slowing the enzyme as opposed to more quickly processed C18-Cbl-Mal-
Src.  One could argue that providing the enzyme with a micelle decorated with substrate would be much 
more efficient than freely diffusing peptide because the local concentration of peptide is very high on the 
surface of each micelle.  Potentially the enzyme merely needed to collide with one of these micelles to be 
exposed to many different peptides to phosphorylate in rapid succession.  At this point, such theories  
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Figure 4.15.  The structure of Src substrate 4h.  4h was detected by our instruments by the fluorescence 
of the cascade yellow dye appended to Lys-3 (ʎex: 400 nm, ʎex: 550 nm).  Ac-EEK(Cascade 
Yellow)IYGEIEA-NH2 
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Figure 4.16.  Dual substrate Src kinase assay between 4h and (photolyzed/intact) C18-Cbl-Mal-Src. 
C18-Cbl-Mal-Src (5 µM) and 4h (5 µM) were diluted into Src Reaction buffer (1 mM GSH, 5 mM MgCl2, 1 
mM ATP, 50 mM phosphate buffer, pH 7.5).  Half of this solution was photolyzed for 20 min and half 
remained in the dark.  After this time 25 nM v-Src was added and the enzyme was allowed to react for 20 
min before being quenched with desatinib (100 µM) and analyzed via LC-MS and products were determined 
by mass.  4j phosphorylation was monitored by the fluorescence of cascade yellow.  The parent peptide 
eluted at 6.1 min while the phospho peptide eluted at 7.7 min.  All of the maleimide bound Src peptide, 
monitored by the absorbance of the TAMRA, was consumed, leaving only phospho peptide (eluting at 7.6 
min).  The minor peaks that are visible in the UV-Vis chromatogram were degradation peaks.  Figures a) 
and c) depict 4h and Mal-Src-Pep phosphorylation (respectively) after photolysis.  Figures b) and d) depict 
4h and C18-Cbl-Mal-Src phosphorylation before exposure to light. 
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are speculative but these data convincingly demonstrate that C18-Cbl-Mal-Src is indeed a Src substrate 
with and without photolysis in the absence of a membrane.  Therefore, any light dependent boost in 
phosphorylation in the presence of RBC ghosts would be due to membrane interactions, not the change in 
the structure of the substrate itself. 
 The second question that needed to be addressed was whether v-Src was active in the presence 
of red blood cell ghosts.  If the model system had not been conducive to Src activity, all subsequent 
experiments would have been moot.  To answer this question we treated red blood cell ghosts with C18-
Cbl-Mal-Src and 4h, washed three times, resuspended them in Src reaction buffer, and then photolyzed.  
Figure 4.17 demonstrates that upon addition of Src, there was indeed phosphorylation of the photolyzed 
substrate and the control peptide, 4h.  When Src was added to ghosts containing substrates and dasatinib 
(DS), a powerful Src family kinase inhibitor57, activity was extinguished. 
 Third, does membrane sequestration of kinase substrates prevent phosphorylation in a light 
reversible manner?  We first tested the robustness of our phosphorylation suppression strategy using an 
endpoint assay in which C18-Cbl-Mal-Src was loaded onto the membrane of RBC ghosts.  After washing 
the ghosts and resuspending them in Src reaction buffer, the kinase reaction was initiated by the addition 
of 25 nM v-Src and allowed to run unperturbed at 30 oC for 90 min in the dark.  Previous experiments had 
proven this to be over 4x the time needed to fully phosphorylate Mal-Src-Pep under similar conditions.  
After 90 min, the kinase was quenched with 100 µM DS and the peptide was cleaved from the membrane 
with light for analysis by LC-MS.  We found the results of these assays to be highly dependent on the batch 
of the red blood cells that were used to create our ghosts.  In some cases we observed that membrane 
sequestration offered complete protection from phosphorylation and in others we saw no difference (Figure 
4.18).  In all cases we found that photolyzed peptide and positive control 4h to be completely 
phosphorylated.  As the variation was only seen in membrane bound substrate, one must assume that 
different blood samples provided Src with varying levels of access to the membrane sequestered substrate. 
 After our initial trials, two conclusions could be drawn.  Variations in the membranous environment 
drastically altered its ability to offer protection of our substrate from phosphorylation and there was some 
background phosphorylation that took place without the addition of Src enzyme.  This was perplexing to us 
as we did not observe phosphorylation from RBC lysates without the addition of Src (data not shown).  
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Figure 4.17.  Confirmation of Src kinase activity in the presence of red blood cell ghosts.  To a solution of 
10% hematocrit ghosts were added 10 µM of C18-Cbl-Mal-Src and 4h.  C18-Cbl-Mal-Src was photolyzed 
for 20 min at 525 nm to release the membrane bound substrate into solution.  The ghosts were then divided 
into three batches.  To one batch 25 nM v-Src was added (black), to another batch 25 nM v-Src + 100 µM 
DS (red), and the remaining ghosts were treated with neither enzyme or DS (blue).  After 1 h incubation at 
30 oC the ghosts were pelleted supernatant was analyzed by LC-MS.  The eluents were simultaneously 
monitored by the absorbance of TAMRA at 555 nm (left) and by fluorescence of the appended cascade 
yellow (ʎex: 400 nm, ʎem: 550 nm, right).  The increased retention time due to phosphorylation is observed 
in the presence of Src but not observed in the absences or inhibition of Src.  Species identification was 
aided by mass detection. 
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Figure 4.18.  The maximum extent of phosphorylation of C18-Cbl-Mal-Src in the presence of erythrocyte 
ghosts.  Ghosts were loaded with 20 µM C18-Cbl-Mal-Src, washed three times, and resuspended in Src 
reaction buffer.  Ghosts were either photolyzed for 10 min with 525 nm light or left in the dark.  The enzyme 
reaction was initiated with the addition of 98 nM v-Src and allowed to continue for 1 h.  The reaction was 
quenched with dasatinib and the remaining samples were photolyzed.  The ghosts were then pelleted by 
centrifugation (10,000 xg, 10 min) and the supernatants were analyzed by LC-MS.  (a) Black and white 
bars represent data from red blood cells of two separate individuals.  Dasatinib (100 µM) was added to 
some Src reactions as a negative control.  Oddly, some phospho peptide (~20%) was generated in the 
absence of Src (confirmed to be phospho peptide by mass).  (b)  The average and standard deviation of 
four different experiments using ghosts derived from blood taken from four different individuals.  Membrane 
sequestration afforded nearly complete protection in some instances and allowed up to 86% 
phosphorylation in others. 
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 However, it was interesting to note that those ghosts that did offer protection from enzymatic action also 
prevented the background phosphorylation in the absence of light (Figure 4.18).     
 In order to ascertain more clearly what was needed to improve the membrane sequestration system 
we switched to a time point kinase assay in order to collect rate data.  The enzyme reactions were prepared 
just as before with C18-Cbl-Mal-Src loaded ghosts.  Half the loaded ghosts were photolyzed prior to the 
addition of Src while half remained in the dark.  The enzyme reaction was quenched at select time points 
with DS in order to compare the kinetics of phosphorylation for substrates on and off the membrane.  After 
the reaction had been sampled and quenched for all time points, the non-photolyzed samples were exposed 
to light for 10 min to liberate the peptide from the membrane for analysis. 
 We began by studying ghosts that had allowed for complete phosphorylation of both membrane 
sequestered substrate and photolyzed peptide.  Figure 4.18 (a, white bars) indicates that this batch of 
ghosts shows no difference in phosphorylation levels between illuminated and dark samples after 90 min.  
Surprisingly, when the kinase assay was repeated with the same ghosts using the time point assay, it can 
be seen that while nearly all peptide was phosphorylated after 1 h, the actual rate of phosphorylation was 
very different between photolyzed and non-photolyzed ghosts (Figure 4.19). Importantly, it also appears 
that a significant amount of phosphorylation had the appearance of occurring before the experiment began.    
 The high levels of phospho peptide that were observed in less than a minute could imply two things.  
The peptide could be acted on before the Src was added, which would disagree with previous results that 
found only low levels of activity without added enzyme (<20% phosphorylation without Src).  Alternatively, 
there may have been a delay in the ability of the inhibitor to stop the active Src.  We see in Fig. 4.18 that 
addition of DS prior to the addition of Src appeared to be sufficient to prevent activity.  However, if the 
ghosts were creating sinks for the relatively hydrophobic DS or compartments that took time to fully saturate 
it could mean that the reaction was allowed to proceed after the intended stopping point, making the 
observed reaction rate appear much faster than it was. 
 In order to alleviate this artifact, the quenching medium was modified by the addion of 40 mM EDTA 
to the DS to bind Mg2+ from solution and prevent the enzyme from utilizing ATP.   Figure 4.20 demonstrates 
the dramatic difference created by this change.  EDTA and DS are most likely synergistic as DS must bind  
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Figure 4.19.  Src kinase time point assay with ghosts interference with enzyme quench.  Ghosts were 
loaded with 20 µM C18-Cbl-Mal-Src, washed three times, and resuspended in Src reaction buffer.  Ghosts 
were either photolyzed for 15 min with 525 nm light or left in the dark.  The enzyme reaction was initiated 
with the addition of 25 nM v-Src and allowed to continue for various time points before aliquots were taken 
and quenched with dasatinib (final concentration 100 µM).  The photolyzed ghosts (circles) were sampled 
at 30 s, 1 min, 2 min, 5 min, and 10 min.  The non-photolyzed ghosts (triangles) were sampled at 1 min, 5 
min, 10 min, 20 min, 30 min, and 60 min.  After 1 h the dark samples were photolyzed.  The ghosts were 
then pelleted by centrifugation (10,000 xg, 10 min) and the supernatants were analyzed by LC-MS.  The 
photolyzed curve clearly illustrates a reaction that rapidly went to near completion in 10 min while the dark 
sample took the entire hour to reach the same level.  We also observed a high initial level of phospho 
peptide.  
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Figure 4.20.  Src kinase time point assay with enzyme quenching cocktail.  Ghosts were loaded with 5 µM 
C18-Cbl-Mal-Src, washed three times, and resuspended in Src reaction buffer.  Ghosts were either 
photolyzed for 15 min with 525 nm light or left in the dark.  The enzyme reaction was initiated with the 
addition of 25 nM v-Src and allowed to continue for various time points before aliquots were taken and 
quenched with dasatinib (final concentration 100 µM) and EDTA (30 mM).  The photolyzed ghosts (circles) 
were sampled at 30 s, 1 min, 2 min, and 5 min.  The non-photolyzed ghosts (triangles) were sampled at 1 
min, 2 min, 5 min, 10 min, and 20 min.  After 1 h the dark samples were photolyzed.  The ghosts were then 
pelleted by centrifugation (10,000 xg, 10 min) and the supernatants were analyzed by LC-MS.  Initial rate 
analysis indicated a 20 fold increase in activity upon photolysis.  Phosphorylation reached a maximum of 
30% in the absence of light. 
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to the ATP binding pocket of tyrosine kinases and without magnesium ATP cannot bind there, drastically 
reducing the concentration of ATP with which the inhibitor effectively had to compete.   
 According to Figure 4.20, by improving the quenching conditions designed to halt phosphorylation 
more efficiently, ghosts that had allowed for 100% dark phosphorylation leveled off at around 30% 
completion.  The combination of kinase quenchers in the kinetic assay provided substantial evidence that 
the variation in phosphorylation observed by the endpoint assay was most likely due to variations in the 
ability of DS to permeate the solution and properly quench the enzyme.  This could have been due to 
structural reasons or variations in protein expressions between different individuals.  Further strategies of 
Src inactivation were tried such as 0.1 M HCl and 0.1% SDS but these caused drastic changes in the 
solubility and appearance of erythrocyte ghosts, making the peptide difficult to isolate for LC-MS analysis.
 Interpolating the slope of the reaction to time 0, the moment of Src addition, it would appear that at 
least 16% of the  substrate was converted before the addition of Src.  We can infer that the activity happened 
before the addition of Src because there was no difference in levels of initial phospho peptide between 
illuminated and dark ghosts even though photolysis provided a 20 fold rate increase in the rate of 
phosphorylation.  Hence, the unknown enzymatic culprit must have acted on the two species before 
photolysis occurred, perhaps even during the loading process.  This was also consistent with our findings 
with the Src kinase end point assay, which showed up to 20% phosphorylation in the absence of added 
Src. 
 Finally, the data appears to indicate the existence of multiple populations of loaded kinase.  There 
seemed to be a certain amount of sequestered peptide that was accessible by freely diffusing enzymes, 
the consumption of which lead to the termination of the phosphorylation at arbitrary yields (often around 
20-30%) independent of the concentration of added enzyme.  This seemed to suggest that certain binding 
sites on the erythrocyte membrane were more accessible or prone to equilibrium than others.  Thus, a 
protein scavenger capable of removing cobalamin complexes not tightly bound to the membrane was 
needed.  Bovine serum albumin (BSA) and the human ortholog (HSA) are known fatty acid transporters 
with several lipid binding pockets58.  Therefore, 0.1% BSA was added to the wash buffer in the ghost loading 
procedure.  This simple change in the washing procedure dramatically altered the change in  
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Figure 4.21.  Src kinase time point assay with enzyme quenching cocktail and 0.1% BSA washes.  Ghosts 
were loaded with 5 µM C18-Cbl-Mal-Src, washed three times in 50 mM phosphate buffer with 0.1% BSA 
(w/v), and resuspended in Src reaction buffer.  Ghosts were either photolyzed for 15 min with 525 nm light 
or left in the dark.  The enzyme reaction was initiated with the addition of 25 nM v-Src and allowed to 
continue for various time points before aliquots were taken and quenched with dasatinib (final concentration 
100 µM) and EDTA (30 mM).  The photolyzed ghosts (circles) were sampled at 20 s, 30 s, 1 min, 2 min, 
and 5 min, and 10 min.  The non-photolyzed ghosts (triangles) were sampled at 10 s, 30 s, 1 min, 5 min, 
10 min, and 20 min.  After 1 h the dark samples were photolyzed.  The ghosts were then pelleted by 
centrifugation (10,000 xg, 10 min) and the supernatants were analyzed by LC-MS.  Initial rate analysis 
indicated a 61 fold increase in activity upon photolysis.   
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phosphorylation rates between photolyzed and non-photolyzed red blood cell ghosts, resulting in a 60 fold 
rate enhancement upon photolysis (Figure 4.21). 
 Figure 4.21 clearly indicates a substantial depression in phosphorylation rates of the Src substrate 
when the peptide was sequestered at the surface of red blood cell ghosts.  While complete protection from 
enzymatic catalysis was seldom seen, we have shown that the RBC ghosts are capable of offering a 
substantial shielding effect against phosphorylation.  It is worth mentioning that the erythrocytes have a net 
negative membrane potential due to their sialic acid content59.  This negative charge acted as a repulsive 
force between the erythrocyte and the negatively charged peptide.  Therefore, it is not unreasonable to 
assume a 60 fold rate enhancement in Src phosphorylation upon photolysis using erythrocyte membranes 
could potentially translate into much greater fold changes in another cell type and a more favorable 
membrane potential.  Given the initial results showing a substantial rate increase upon photolysis, it was 
decided that this system should be tested on living cells containing endogenous Src. 
4.9.  Treatment of HeLa Cells with C18-Cbl-Mal-Src 
 Before we could detect intracellular kinase activity, we needed to ensure that the peptide was able 
to translocate into the plasma membrane of a living cell.  Treating HeLa cells with varying doses of C18-
Cbl-Mal-Src for 30 min before washing with PBS, cells were imaged on a widefield microscope by TAMRA 
fluorescence.  Upon imaging, the peptide appeared to be internalized in a punctate pattern which suggested 
endosomal uptake (Figures 4.22, 4.23).  Since visualization of the TAMRA peptide necessitates cleavage 
of the membrane tethered substrate, the lack of a change in localization upon photolysis further enforced 
the idea of endosomal compartmentalization.   
 In order to better understand cellular transport of C18-Cbl-Mal-Src, peptide localization was 
observed after varying time points of incubation (Figure 4.23).  Before 5 min of incubation, membrane 
binding was insignificant.  From 5 min onward, we saw significant membrane localization.  However, the 
act of imaging was sufficient to photolyze the cobalamin.  After one 250 ms exposure, all peptide bound to 
the outer membrane of HeLa cells had been cleaved into the medium.  This highlights the extremely 
photosensitive nature of the of the Co-C bond.  After 40 min of incubation time, we began to see the 
characteristic signs of endosomal uptake (punctate loading that did not dissipate upon photolysis).   
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Figure 4.22.  Non-cytosolic distribution of C18-Cbl-Mal-Src.  Adherent HeLa cells were incubated at 37 oC 
with different concentrations of C18-Cbl-Mal-Src: a) 1 µM b) 500 nM c) 250 nM d) 50 nM in 500 µL PBS for 
30 min.  Loading media was removed and cells were washed with PBS three times and covered in L15 
medium with 1% FBS and then imaged with a widefield microscope.   
 
 
Figure 4.23.  Adherent HeLa cells were incubated at 30 oC with 1 µM C18-Cbl-Mal-Src.  Transmitted 
image overlayed with TAMRA fluorescence revealing endosomal trapping of Mal-Src-Pep. 
a) b) 
c) d) 
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Figure 4.24. C18-Cbl-Mal-Src loading 
and photolysis from HeLa cell 
membranes.  HeLa cells were 
incubated at 37 oC with 250 nM C18-
Cbl-Mal-Src: a) 2 min b) 5 min c) 10 
min d) 20 min and e) 40 min in 500 µL 
PBS before washing.  PBS was 
replaced with L15 Medium and 1% 
FBS.  Cells were focused by 650 nm, 
transmitted light and imaged at 550 
nm.  Images were taken on a 
widefield microscope with a 250 ms 
exposure time.  One image was 
sufficient to completely photolyze the 
fluorescent peptide from the 
membrane.  By 40 min of incubation 
time the peptide had been taken up 
into endosomes. 
a) 
b) 
c) 
d) 
e) 
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4.10.  Attempts to Penetrate the Cellular Membrane 
 Peptides capable of passively translocating the plasma membrane have been known for decades.  
Most proposed mechanisms involve some form of bilayer invagination and some authors even maintain 
clusters of peptide trigger dynamic pore formation60.  Therefore, we surmised that electrostatic interactions 
between positive cell penetrating peptides (CPPs) and C18-Cbl-Mal-Src would cause the two to become 
associated with one another and that the cobalamin-complex could accompany the CPP as it journeyed to 
the inner leaflet.  Hoping to sample more than one mode of membrane translocation to give the construct 
the best chance of entrance into the cytoplasm, three cell penetrating peptides were synthesized: (SOK-
Cy5)61, Cy5-R12 (poly arginine)60, and Pep162 (commercially sold as chariot TM). (Figure 4.25). 
 HeLa cells were treated with varying amounts of SOK-Cy5, Cy5-R12, and Cy5-Pep1.  Cells showed 
non-punctate loading of CPPs, even though they appeared to gravitate to different organelles (Figure 4.26).  
HeLa cells appeared to tolerate CPPs without morphological changes indicative of damage or stress.  After 
confirming that these peptide sequences were entering the cytosol of living HeLa cell, the fluorophores 
were removed to avoid cross-talk photolysis.  The non-fluorescent CPPs and C18-Cbl-Mal-Src were 
coincubated for 5 min to allow them time to oligomerize, and the mixtures were loaded onto HeLa cells for 
30 min at 37 oC.  After washing three times with PBS, fluorescent imaging revealed that the Src substrate 
loading was still punctate.  Photolysis did not release Mal-Src-Pep fluorescence into the cytosol. 
4.11.  Conclusion 
 Without ready access to the cytoplasm we could not measure kinase activity in living cells.  We 
acknowledge this difficulty in our caging system.  Many different strategies are currently being employed in 
the field of biological chemistry to address the problem of endosomal trapping of diagnostic or therapeutic 
peptides.  We hope to revisit this strategy when a solution emerges.   However, we did show that membrane 
sequestration offers a high degree of protection for our Src kinase substrate from phosphorylation by active 
enzyme on erythrocyte ghosts.  Concurrent work involving serine kinase substrate shielding by membrane 
sequestration was done by Nguyen et al.  The positively charged peptides used in those studies showed a 
greater degree of protection, presumably due to a higher binding strength with the negatively charged 
erythrocyte membranes63.  These constructs also suffered from endosomal entrapment, preventing them 
from detecting endogenous enzyme activity in adherent cell lines.   
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 There is a distinct possibility that peptide from both studies were released into the cytoplasm of 
living cells but even if a large percentage were able to diffuse into the cytosol, the volume of the endosomal 
compartments within a cell is miniscule compared with the overall volume of the cell.  This means that one 
could deliver half of the fluorescent peptide into the cytoplasm and the fluorescence of the endosome would 
still be orders of magnitude greater than the fluorescence of the cytoplasm, obscuring the signal from the 
delivered peptide.  Preliminary work to quench the fluorescence of peptide trapped in the endosome 
appears to show that the localized brightness of these subcellular compartments can obscure the dimmer 
fluorescence of substrate delivered to the cytoplasm (data not shown).  As of yet there is no way to quantify 
the degree to which peptide is released, so until a more robust delivery system is developed these works 
remain a proof of concept. 
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Figure 4.25.  CPPs synthesized to ferry C18-Cbl-Mal-Src into the cytoplasm of HeLa cells. Peptide SOK-
Cy5, is a peptide of the sequence Ac-Cha-r-Cha-k-Cha-r-Cha-K(Cy5)-NH2, where Cha is 
cyclohexylalanine61.  Peptide Cy5-R12 is a repeat of 12 arginine residues with an N-terminal cy5 that was 
found to enter the cytoplasm by macropinocytosis60.  The hydrophobic fluorophore is required for it to 
function.   Finally, Cy5-Pep1 was a sequence engineered to carry negatively charged cargo into the cell62. 
  
Cy5-Pep1 
Cy5-R12 
SOK-Cy5 
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Figure 4.26.  Demonstration of CPP cellular distribution by fluorescent microscopy.  HeLa cells were 
incubated at 37 oC with a) 1 µM Cy5-R12  b) 10 µM SOK-Cy5 in 500 µL PBS for 30 min before washing 
three times.  PBS was replaced with L15 Medium and 1% FBS.  Cells were imaged on a widefield 
microscope with a 40x dry objective using a cy5.5 filter cube.  Cytosolic loading of peptides was seen with 
each CPP interacting with subcellular organelles. 
 
 
  
a) 
b) 
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Figure 4.27.  SOK peptide fails to assist in 
cytoplasmic distribution of our fluorescent 
Src substrate.  Loading buffers were 
prepared by incubating C18-Cbl-Mal-Src 
(500 nM) with SOK at varying concentration 
(a) 0 µM b) 1 µM and c) 10 µM) in 500 µL 
PBS for 5 min at 37 oC.  HeLa cell medium 
was removed and replaced and replaced with 
loading buffer and allowed to incubate at 37 
oC for 30 min before washing three times with 
PBS.  Cells were then covered with L15 
Medium and 1% FBS and imaged.  Cells 
were brought into focus with transmitted light 
(> 600 nm) and imaged using TAMRA 
fluorescence.  Images were taken on a 
widefield microscope with a 250 ms exposure 
time and a 40x objective.  Increased SOK 
concentration appears to increase the 
amount of TAMRA inside each of the cells 
but the punctate pattern suggests that Mal-
Src-Pep was trapped in endosomal bodies.  
Photolysis did not release peptide into the 
cytosol. 
a) 
b) 
c) 
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Figure 4.28.  Pep1 fails to assist in cytoplasmic distribution of our fluorescent Src substrate.  Loading buffer 
was prepared by incubating C18-Cbl-Mal-Src (500 nM) with Pep1 (a) 0 µM b) 10 µM) in 500 µL PBS for 5 
min at 37 oC.  HeLa cell medium was removed and replaced and replaced with loading buffer and allowed 
to incubate at 37 oC for 30 min before washing three times with PBS.  Cells were then covered with L15 
Medium and 1% FBS and imaged.  Cells were brought into focused by transmitted light (> 600 nm) and 
imaged using TAMRA fluorescence.  Images were taken on a widefield microscope with a 250 ms exposure 
time and a 40x objective.  Punctate pattern suggests that Mal-Src-Pep was trapped in endosomal bodies.  
Photolysis did not release peptide into the cytosol. 
 
  
a) b) 
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4.12.  Materials and Methods 
 
C12-Cbl (4c). Hydroxocobalamin hydrochloride (100 mg, 72 µmol) was dissolved in 5 mL anhydrous DMSO 
and CDT (121  mg, 740 µmol)  was  added along with 20 µL DIPEA.  The solution was stirred for 45 min 
before being added and precipitated in 45 mL ether/chloroform.  The precipitate was collected by 
centrifugation and the pellet was dried under vacuum before being dissolved in 2 mL dry DMSO and 
recrystallized 2 more times by the same method.  Dried product was added to a solution of DDA in 5 mL 
DMSO (200 µL, 864 µmol) with excess amine acting as base. The resulting mixture  was stirred for 1 h 
before being added to 45 mL ether/chloroform.  The resulting precipitate was dissolved and recrystallized 
twice more in this fashion.  The  pellet  was dissolved  in  EtOH  and  purified  on  a  100 g Biotage  KP-
C18-HS flash  column  with  a linear gradient of H2O:MeOH from 100% H2O to 100% MeOH in 8 column 
volumes. 4c eluted at 100% MeOH and, upon removal of MeOH furnished a red solid in 75% yield. ESI MS 
calcd. for C75H114CoN14O15P- (M2+): m/z = 770.36 found 770.7.  
 
C12-Cbl-propylamine (4d):  4c (50 mg, 32 µmol) was dissolved in 10 mL of EtOH and degassed under N2.  
NH4Br (500 mg, 5% w/v) and Zn powder (200 mg, 3 mmol) were added and the solution was stirred for 20 
min under N2.  To this slurry 3-chloropropylamine hydrochloride (40 mg, 305 µmol) was added.  The 
resulting mixture was stirred for 3 h under continuous N2 flow.  A color change from red to orange was 
observed.  Zinc was removed by centrifugation, and the cobalamin was recrystallized twice in 
ether:chloroform (50 mL).  The resulting precipitate was collected by centrifugation and decantation.  The 
pellet was dried under vacuum and 10 mL EtOH was added.  UV-Vis analysis revealed the alkylation went 
to completion.  4d was purified on a 100 g C18 flash column with a linear gradient an H2O:MeOH (0.1% 
TFA) gradient from 0 – 100% in 8 column volumes.   4d eluted at 100% MeOH.  C12-Cbl-propylamine (4b): 
orange solid, ESI MS calcd. for C78H121CoN15O15P- (M2+): m/z = 799.4, found 800.0. (M3+): m/z = 533.9 
found 533.8. 
 
C12-Cbl-Succinate (4e):  4d (40 mg, 23 µmol) was added to a 5 mL solution of succinic anhydride (26 mg, 
230 µmol) in DMF and 20 µL DIPEA.  The solution was allowed to shake at 37 oC for 2 h.  Reaction went 
to completion by LC-MS.  4e was purified on a 100 g C18 flash column with a linear gradient an H2O:MeOH 
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(0.1% TFA) gradient from 0 – 100% in 8 column volumes.   4e eluted at 100% MeOH.  C12-Cbl-Succinate 
(4e): orange solid, ESI MS calcd. for C83H127CoN15O18P- (M2+): m/z = 856.46, found 857.0. (M3+): m/z = 
572.0, found 571.7. 
 
DOPE-Cbl. Hydroxocobalamin hydrochloride (100 mg, 72 µmol) was dissolved in 5 mL anhydrous DMSO 
and CDT (121  mg, 740 µmol) was  added.  The solution was stirred for 45 min before being added and 
precipitated in 45 mL ether/chloroform.  The precipitate was collected by centrifugation and the pellet was 
dried under vacuum before being dissolved in 2 mL dry DMSO and recrystallized 2 more times by the same 
method.  Dried product was added to a solution of DOPE in 5 mL DMSO (200 mg, 269 µmol). The resulting  
mixture  was stirred for over night before being added to 45 mL ether/chloroform.  The resulting precipitate 
was dissolved and recrystallized twice more in this fashion.  The  pellet  was dissolved  in  EtOH  and  
purified  on  a  100 g Biotage  KP-C18-HS flash  column  with  a linear gradient of H2O:MeOH from 100% 
H2O to 100% MeOH in 8 column volumes. DOPE-Cbl eluted at 100% MeOH and, upon removal of MeOH 
furnished a red solid in 10% yield. ESI MS calcd. for C104H164CoN14O24P2-(M2+): m/z = 1057.7 found 1058.1. 
 
 
Scheme 4.6.  The structure and synthesis of 4i 
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Scheme 4.7.  The structure and synthesis of 4e. 
 
Chol-Cbl (4e):  Cholesteryl chloroformate (500 mg, 1.1 mmol) was dissolved in 20 mL dry dichloromethane 
containing ethylene diamine (EDA) (400 µL, 5.8 mmol) and allowed to stir for 3 h at r.t.  After this, excess 
ethylene diamine was washed four times with 50 mM HCl (100 mL) to remove excess EDA.  The organic 
layer was collected and dried by rotary evaporation and ethylaminocholesterol (4i) was considered pure 
enough to proceed to the next step without further purification.  Hydroxocobalamin hydrochloride (100 mg, 
72 µmol) was dissolved in 5 mL of anhydrous DMSO and CDT (121 mg, 740 µmol) was added. The solution 
was stirred for 45 min before being added and precipitated in 45 mL ether/chloroform.  The precipitate was 
collected by centrifugation and the pellet was dried under vacuum before being dissolved in 2 mL dry DMSO 
and recrystallized 2 more times by the same method.  The dissolved product was added to a solution of 3a 
in DMSO (68 mg, 144 µmol, 3 mL) and shaken for 2 h before being recrystallized three times in 
ether/chloroform.  The resulting precipitate was collected by centrifugation and decantation.  The pellet was 
dried under vacuum and 10 mL EtOH was added. The pellet was dissolved in EtOH and purified on a 100g 
C18 flash column with a linear gradient an H2O:MeOH gradient from 0 – 100% in 8 column volumes.   C18 
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modified cobalamin eluted at 100% MeOH with a yield of 50% with respect to cobalamin.  Chol-Cbl (4e): 
red solid.  ESI MS calcd. For C93H139CoN15O18P- (M1+): m/z = 1826.95, found 1826.9544. (M2+): m/z = 
913.975, found 913.9787.   
 
 
Scheme 4.8.  Structure and Synthesis of 4f. 
 
C18-B12a (4f) Hydroxocobalamin hydrochloride (200 mg, 144 µmol) was dissolved in 10 mL anhydrous 
dimethylsulfoxide (DMSO) and carbonylditriazole (CDT, 121 mg, 740 µmol) was added. The solution was 
stirred for 45 min.  To this solution octadecylamine (ODA, 398 mg, 1.48 mmol) was added to the rapidly 
stirring solution.  The resulting mixture was stirred for 1 h before being added to 90 mL either/chloroform.  
The resulting precipitate was collected by centrifugation and decantation.  The pellet was dried under 
vacuum and 10 mL EtOH was added.  Dimerized ODA formed a white precipitate which was removed by 
centrifugation and the cobalamin was precipitated in 40 mL either/chloroform and collected by centrifugation 
and decantation.  The pellet was dissolved in EtOH and purified on a 100 g Biotage KP-C18-HS flash 
column with a linear gradient an H2O:MeOH gradient from 0 – 100% in 8 column volumes.   4f eluted at 
100% MeOH.  Red solid, 60%, ESI MS calcd. for C81H126CoN14O16P- (M2+- OH): m/z = 811.93 found 812.6. 
 
C18-Cbl-maleimide (4g):  2b (40 mg, 21 µmol) was added to a 5 mL solution of 3 eq N-succinimidyl 6-
maleimidohexanoate (19 mg, 61 µmol, mw=308) and 20 µL DIPEA in DMF.  Solution was allowed to shake 
in the dark at room temperature for 3 h.  Reaction went to completion by LC-MS.  4g was purified on a 100g 
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C18 flash column with a linear gradient an H2O:MeOH (0.1% TFA) gradient from 0 – 100% in 8 column 
volumes.   4g eluted at 100% MeOH.  C18-Cbl-maleimide (4g): orange solid, quantitative yield.  ESI MS 
calcd. for C94H144CoN16O18P (M2+): m/z = 939.1, found 939.0 (M3+): m/z = 626.40, found 626.46. 
 
C12-Cbl-Src:  4e (22 mg, 12 µmol) was added to a 500 µL solution of 24 mM TSTU (DMF) and 10 µL 
DIPEA.  The solution was allowed to react at r.t. for 5 min after which time 5-TAM-KEEEIYGEF-NH2 (9 mg, 
9 µmol, mw = 1555) was added and allowed to react for 6 h. C12-Cbl-Src was purified on a Viva C4 
preparative column 5 µm,250 x 21.2 mm) from Restek, H2O:CH2Cl2, 0.1% TFA, elution time 45 min.  C12-
Cbl-Src: red solid, 20% yield, ESI MS calcd. for C160H223CoN28O39P- (M3+) = 1084.2, found 1084.2. (M4+) = 
813.15 found 813.3.  
 
C18-Cbl-Mal-Src:  4g (10 mg, 5 µmol) was added to a 500 µL solution of EtOH with 5-TAM-CEEEIYGEF-
NH2 (5 mg, 3 µmol, mw = 1529) with 2 µL DIPEA and allowed to react for 6 h. C18-Cbl-Mal-Src was purified 
on a Viva C4 preparative column 5 µm,250 x 21.2 mm) from Restek, H2O:ACN, 0.1% TFA, elution time 55 
min.  C18-Cbl-Mal-Src: red solid, 50% yield, ESI MS calcd. for C168H234CoN28O40PS (M3+) = 1135.95, found 
1136.2. 
 
Peptide Synthesis (4a, 4b, 4h, Cy5-SOK, SOK, Cy5-R12, Cy5-Pep1, Pep1) Standard solid phase peptide 
synthesis on a Prelude peptide synthesizer from Protein Technology with Fmoc protected amino acids.  A 
0.21 mmol/g a NovaSyn TGR resin was employed with 5 eq amino acids, 4.9 eq HCTU, 10 eq DIPEA, 
double coupling (20 min each). 3 eq Fmoc-NH-PEG3-CH2CH2COOH.  Fmoc deprotection was performed 
in 20% piperidine (5 times for 3 min each).  The N-terminus was acetylated with acetic anhydride with 20% 
DIPEA.  Ac-GRAGRRNAIHD-PEG3-K-NH2.  Peptide cleavage took place in 95% TFA, 2.5% H2O, and 2.5% 
TIS.  If a cysteine were present in the sequence then cleavage cocktail was changed to 94% TFA, 2% H2O, 
2% TIS, and 2% EDT.  Crude peptide was purified by HPLC using a C18 column.  5-TAM was coupled 
twice (2 eq TAMRA, 1.9 eq HCTU, 5 eq DIPEA).  Cy5 was coupled once (1.5 eq Cy5, 1.4 eq HCTU, 5 eq 
DIPEA).  
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4a, 5-TAM-KEEEIYGEF-NH2, red solid.  ESI MS calcd. for C77H96N13O22+ (M2+) m/z = 777.34, found 778.0.  
(M3+) m/z = 518.23, found 519.0. 
 
4b, 5-TAM-CEEEIYGEF-NH2, red solid.  ESI MS calcd. for C77H96N13O22+ (M2+) m/z = 765.30, found 765.5. 
 
4h, Ac-EEK(Cascade Yellow)IYGEIEA-NH2, red solid.  ESI MS calcd. for C77H101N14O26S+ (M2+-2H) m/z = 
833.395, found 833.4. 
 
Cy5-SOK, Ac-Cha-r-Cha-k-Cha-r-Cha-K(Cy5)-NH2, blue solid.  ESI MS calcd. for C94H150N19O10+ (M2+) m/z 
= 853.18, found 853.1.  (M3+) m/z = 568.79, found 568.3. 
 
SOK, Ac-Cha-r-Cha-k-Cha-r-Cha-K(Cy5)-NH2, white solid.  ESI MS calcd. for C62H113N17O9+ (M1++H) m/z 
= 1241.8, found 1241.0.  (M2++H) m/z =  621.85, found 621.2.  
 
Cy5-R12, Cy5-RRRRRRRRRRRR-NH2, blue solid.  ESI MS calcd. for C104H184N51O13+ (M2+) m/z = 1178.48, 
found 1178.7.  (M3+) m/z = 785.65, found 785.7. 
 
Cy5-Pep1, Cy5-KETWWETWWTEWSQPKKKRKV-NH2, blue solid. ESI MS calcd. for C168H234N39O33+ 
(M3+) m/z = 1109.32, found 1109.8 (M4+) m/z = 831.99, found 831.5. 
 
Pep1, Ac-KETWWETWWTEWSQPKKKRKV-NH2, white solid.  ESI MS calcd. for C138H199N37O33+ (M2++4H) 
m/z = 1454.17, found 1454.9 (M3++4H) m/z = 969.45, found 969.6.  (M4+) m/z = 727.09, found, 727.8. 
 
Comparison of Cholesterol and C18 hydrophobicity by Octanol / Water partition  re 
The partition coefficient for Chol-Cbl and C18-Cbl were determined by dissolution of 100 µM of each 
compound in 1 mL octanol.  This solution was then combined with 1 mL dH20 and mixed vigorously.  The 
two species were allowed to equilibrate between octanol and water for 24 h after which the samples 
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underwent centrifugation (24,000 g for 30 min).  The concentration of cobalamin was determined in the 
aqueous layer by UV-Vis spectroscopy.   The partition coefficient was described as: 
/	
 = 
 

 
 
Photolysis of Cobalamin Compounds 
The light source employed for visible wavelength photolysis was a two dimensional 525 nm centered LED 
array.  LEDs were powered with a 12 V DC power supply with 4 LEDs in series with a 100 Ω resistor.  The 
light source was positioned above the plane of photolysis at a distance that insured 25 mW / cm2 light 
intensity in a manner illustrated by Figure 4.29. 
 
 
Figure 4.29.  An image of the 525 nm photolysis chamber.  Centrifuge tubes indicate the position of 
photolyzed samples. 
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Determination of the Products of Photolysis  
Photolyzed samples of 20 µL were injected onto an 1200 series Agilent HPLC with a UV-Vis detector, 1260 
infinity fluorescent detector, and 6110 quadrapole mass spectrometer from a 394 well plate.  The mobile 
phase consisted of H2O:CH2Cl2 (0.1% FA) (gradient provided in the following table).  The column used was 
a Viva C18 analytical column 5 µm, 50 x 21.2 mm from Restek.  UV-Vis absorbance detection was set to 
555 nm to coincide with the ʎmax of TAMRA.  Mass spectrometry was used to determine the product of 
photolysis. 
 
Measuring Fluorescent Increase Upon Photolysis 
C18-Cbl-Mal-Src was dissolved in 1x PBS (1 µM, 200 µL) in a quartz cuvette and the fluorescence was 
measured on a PTI spectrofluorometer (ʎex = 555 nm and ʎem = 585 nm), being careful not to expose the 
compound to any light before the measurement began by closing the excitation gate on the device.  After 
temperature equilibration the gate was opened and the excitation light cleaved the cobalamin from the 
substrate and the resulting fluorescent increase was measured until the increase plateaued.   
 
Migration of C18-Cbl-Mal-Src from Octanol to Water Upon Photolysis By UV-Vis Spectrometry 
C18-Cbl-Mal-Src was dissolved in 200 µL octanol (20 µM) and then mixed with 1000 µL phosphate buffer 
pH 7 (50 mM).  The presence of peptide in the aqueous layer was determined by UV-Vis spectroscopy.  
TAMRA concentration measured with spectroscopic absorbance at 555 nm, the ʎmax of the dye (ε555nm: 
94,000 M-1cm-1).  This heterogeneous mixture was photolyzed for various times at 525 nm before the two 
layers were homogenized and allowed to reach equilibrium for 10 min before the layers were fully separated 
by centrifugation (24,000 g, 30 min).  After photolysis the concentration in the aqueous layer was measured 
again. 
 
Migration of C18-Cbl-Mal-Src from Octanol to Water Upon Photolysis (Photographic Method) 
C18-Cbl-Mal-Src was dissolved in 800 µL octanol (10 µM) and then mixed with 200 µL phosphate buffer 
pH 7 (50 nM).  TAMRA was visualized by 365 nm excitation which caused the fluorophore to fluoresce 
orange against a UV background (unseen) making fluorescence easy to see.  This heterogeneous mixture 
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was photolyzed for 0, 5, 10, and 20 min at 525 nm before the two layers were homogenized and allowed 
to reach equilibrium for 10 min before the immiscible solvents were fully separated by centrifugation (24,000 
xg, 30 min).  The rate of diffusion of the cleaved peptide was such that no detectable diffusion from organic 
to aqueous solvent occurred without mixing, making it possible to visualize the location of the compound 
before migration occurred.   
 
Determination of Peptide Concentration by UV-Vis Spectroscopy 
Peptide concentration was analyzed on a 96 well Perkin Elmer UV-Vis plate reader at 550 nm with 100 µL 
volume (50 mM phosphate buffer pH 7).  Peptide samples that were not photolyzed during the course of 
an experiment were photolyzed for 30 min with 525 nm LEDs before being read by the instrument in order 
to make all results comparable.  Absorbance values were compared to a standard curve obtained by 
dilutions of Mal-Src-Pep (0, 1, 5, 10, 20, and 30 µM) that underwent photolysis with 525 nm light for 30 
min.   
 
Figure 4.30.  Beers law plot of Mal-Src-Pep. Concentrations of TAMRA labeled Src substrates could be 
determined by comparing their absorbances at 550 nm to this standard curve up to 20 µM, beyond which 
a point is reached where the peptide no longer obeys beers law.  Peptide concentration below 20 µM can 
be assessed with the following equation. 
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Preparation of Erythrocyte Ghosts 
Erythrocyte ghosts were prepared by suspending human erythrocytes in “hypotonic buffer” (50 mM Tris pH 
7.5).  Blood was allowed to incubate on ice for 5 min and then underwent centrifugation (10,000 g, 5 min).  
The heme was removed with the supernatant and the process was repeated until the pellets were light 
orange to white in color.  0.1% sodium azide was added to prevent bacterial growth.  Inoculated ghosts 
were reclaimed adding 5 mM PMSF, 5 mM NEM, and 30 mM EDTA in 20 mM Tris pH 7.5 and incubating 
at 4 oC for 5 h. 
 
 
Measuring Erythrocyte Loading and Release from Membranes. 
To 10% hematocrit erythrocytes ghosts, C18-Cbl-Mal-Src was added to a final concentration of 20 µM. The 
erythrocytes were then incubated at RT for 30 min. and subsequently washed 3x in 1x 50 mM phosphate 
buffer, pH 7.  Washes were collected so that the amount of peptide that did not adhere to cell membrane 
could be quantified by absorbance.  After the final wash erythrocytes were resuspended to 10% hematocrit 
and exposed to 525 nm light for various time points. After photolysis, the erythrocyte solution was 
centrifuged at 10,000 xg and the supernanent was analyzed for TAMRA (ʎ: 550 nm).   
 
Kinase Endpoint Assay 
Src Reaction buffer consisted of 5 mM MgCl2, 0.01 mg/mL BSA, 1 mM GSH, 1 mM ATP, in 50 mM Tris pH 
7.5.  It was important to use glutathione instead of other common reducing reagents such as DTT because 
thiols react with hydroxocobalamin (a byproduct of B12 photocleavage).  Glutathione-cobalamin complexes 
are more stable and less likely to lead to a catalytic depletion of the reducing agent.  The enzyme was 
constitutively active v-Src purchased from Invitrogen in a 9.6 µM stock. One of two known peptide 
substrates (20 µM) for Src kinase were used  Ac-EK(R)EIYGEIEA (where R was either Atto 655 or Cascade 
Yellow) were used as a positive control for Src activity.  Desatinib (100 µM) was added to the Src reaction 
buffer for a negative control. Reactions were all performed at 30 oC in either an incubator or water bath, 
with a 15 min temperature equilibration time prior to initiation.  Reactions took place in the presence or 
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absence of red blood cell ghosts and were initiated by the addition of enzyme and allowed to proceed in 
the dark for 90 min.  Any remaining enzyme was quenched with 100 µM DS.  If a cobalamin sequestered 
substrate was used, it was photolyzed at this time (525 nm 30 min).  Samples underwent centrifugation at 
24,000 xg for 15 min to remove solid materials.  Supernatants were analyzed via LC-MS. The column used 
was a Viva C18 analytical column 5 µm, 50 x 21.2 mm from Restek.  CMal-Src parent peptide eluted at 8.7 
min. and the phosphor peptide eluted at 10 min c-EK(Atto 655)EIYGEIEA parent peptide eluted at 5.7 min 
and the phospho peptide eluted at 7.8 min.   
 
Kinase Timepoint Assay 
Src Reaction buffer consisted of 5 mM MgCl2, 0.01 mg/mL BSA, 1 mM GSH, 1 mM ATP, in 50 mM Tris pH 
7.5.  The enzyme used was constitutively active vSrc purchased from Invitrogen in a 9.6 µM stock. One of 
two known peptide substrates (20 µM) for Src kinase were used  Ac-EK(R)EIYGEIEA (where R was either 
Atto 655 or Cascade Yellow) were used as a positive control for Src activity.  DS (100 µM) was added to 
the Src reaction buffer for a negative control. Reactions were all performed at 30 oC in either an incubator 
or water bath, with a 15 min temperature equilibration time prior to initiation.  Reactions took place in the 
presence of red blood cell ghosts and were initiated by the addition of enzyme and allowed to proceed in 
the dark for 1 h during which time aliquots were taken and quenched in a solution of 100 µM DS and 40 
mM EDTA (final concentration).  If a cobalamin sequestered substrate was used, it was photolyzed from 
the membrane at this time (525 nm 30 min).  Samples underwent centrifugation at 24,000 xg for 15 min to 
remove solid materials.  Supernatants were analyzed via LC-MS. CMal-Src parent peptide eluted at 8.7 
min. and the phospho peptide eluted at 10 min c-EK(Atto 655)EIYGEIEA parent peptide eluted at 5.7 min 
and the phospho peptide eluted at 7.8 min.   
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Chapter 5.  Engineering Green Light Regulated Protein Kinase A Activity 
 
5.1.  Background 
Thus far, I have focused on the development of “caged” or sequestered bioactive small molecules 
or peptides designed to interact with biological environments after excitation with light.  However, Hoffman’s 
principles of caging can be applied to macromolecules as well.  The history of engineered light responsive 
enzymes began earlier than any other class of caged molecule, predating the concept of caging as outlined 
by Hoffman by nearly a decade1.  No other class of biomolecule has been controlled so precisely or with a 
greater diversity of chemical and biological tools and techniques as the photoactivated enzyme.  
The first caged enzyme was created following a series of proof of principle papers from the late 
1960’s that sought to address possible mechanisms by which sunlight could modulate enzymatic activity in 
living organisms.  In 1968, Kaufman et al. showed that they could slow the rate of protease inactivation by 
an azobenzene based irreversible inhibitor depending on the light switchable, cis/trans configuration of the 
inhibitor2.  They then demonstrated that they could oscillate between active and inactive enzymes with 
reversible azobenzene inhibitors using UV and visible light3,4.  In 1971 this work culminated in the first caged 
enzyme when Berezein and colleagues went one step further by covalent modification of the α-
chymotrypsin active site with a cis-cinnamoyl moiety that modified the protease active site, attenuating 
activity 2000 fold.5  This enzyme-cinnamate ester had a half-life of greater than 24 h at physiological pH.  
Upon irradiation with 313 nm light, the light sensitive adduct underwent a cis to trans isomerization that 
rendered it susceptible to hydrolysis, decreasing the half-life of the ester to ~1 min, and restoring the native 
state of the protease and wild type activity1 (Scheme 5.1).  This first caged enzyme was thought of as a 
chemically based light amplification system and would remain little more than a scientific novelty until the 
concept of “caged” molecules would give this work broader implications5.   
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Scheme 5.1  The earliest caged enzymes.  (a) α-chymotrypsin (CM-OH) was modified with an activated 
cis-cinnamoyl ester capable of acylating active site serine residues, rendering the enzyme catalytically 
inactive.  Illumination with UV light caused a configuration of the appended moiety to switch from cis to 
trans which left the enzyme-cinnamate ester linkage vulnerable to rapid hydrolysis, restoring the parent 
enzyme1.  (b) In an analogous manner, α-thrombin was caged with an o-hydroxycinnamoyl ester on the 
catalytic serine residue in the enzyme active site.  Instead of using the catalytic action of the enzyme to 
remove the ester as in (a) this second strategy makes use of an intramolecular ring closure that generates 
a fluorescent coumarin reporter as a byproduct along with the wild type enzyme6.  When the R substituent 
is diethylamine the half-life of dark de-acylation is greater than 5 days and post photolysis lactone formation 
is complete in milliseconds7. 
  
a) 
b) 
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It would take fifteen years for the field biology to begin to find pragmatic applications for this technology.  In 
1986 Porter and colleagues modified the earlier caging technique to create light induced blood clots. They 
used a structurally similar cinnamoyl moiety (o-hydroxymethylcinnamate p-amidinophenyl ester) to cage α-
thrombin, a fibrinogen activator that triggers the formation of fibrin based blood clots, by means of a light 
reversible acylation6.  In living organisms, thrombin activates fibrinogen via proteolytic processing exposing 
ligand binding sites that facilitate self adhesion8.  Thrombin mediated proteolysis operates via the same 
mechanism as chymotrypsin, therefore, acylation of the crucial active site serine residue leads to 
deactivation of thrombin activity.  Scheme 5.1 demonstrates how photoisomerization of the o-
hydroxycinnamoyl adduct cleaves the enzyme ester linkage, creating a fluorescent reporter as a side 
product.  Modifications to the cinnamate extend the wavelength of photolysis into the blue spectrum, 
stabilizing the caged state of the enzyme for days, and reducing photolysis times to milliseconds7.  Porter 
and others would go on to fully describe this method as a general strategy for caging serine 
proteases9,10,11,12,13. 
 A more recent example of this basic caging strategy, where activity is temporarily halted by the 
covalent modification of a key active site functional group with a photocleavable alkylating agent appeared 
in 2011.  Priestman et al. were able to cage cGMP dependent protein kinase (PKG) by co-incubation of the 
catalytic subunit with a thiol reactive o-nitrobenzyl bromide.  This non-selective chemical reaction modified 
all solvent exposed cysteine residues on the enzyme, including Cys518, which is crucial for enzyme 
activity14.  Upon irradiation with UV light, the o-nitrobenzyl adducts were removed and activity was restored.  
By using site directed mutagenesis to generate a constitutively active PKG, this “caged” enzyme was 
introduced into a cellular environment via microinjection and the resulting phosphorylation was entirely 
dependent upon light as opposed to endogenous regulatory factors.  Using this technique they were able 
to discriminate the intracellular targets of PKG and the structurally similar PKA in living cells by selectively 
activating PKG using UV light14.  This method of caging by photoreversible alkylation (or acylation) of 
residues crucial for activity is generalizable as long as off target reactions are not a problem or can be 
minimized with site directed mutagenesis.  This technique has been used in the study of a broad range of 
enzymes such as proteases, kinases, acetocholinesterases, restriction enzymes, and 
methyltransferases15,16,17. 
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 Blocking key residues that are crucial for catalysis is by no means the only strategy available for 
caging a macromolecule.  Proteins are often regulated by conformational changes that have dramatic 
effects on their biological activity.  Photocleavable moieties can change activity of a biomacromolecule by 
triggering a light dependent change in conformation.  In the case of Ghosh et al., an acidic nitrobenzyl 
moiety was appended to the actin binding protein, cofilin, mimicking a negatively charged phosphate group 
causing the protein to enter an inactive conformation18,19.  Photolysis of this negatively charged light 
cleavable moiety caused cofilin to switch to an active conformation allowing it bind to and depolymerize 
actin filaments.  Microinjection of the caged protein into live cells had no effect on morphology.  Photolysis 
of the leading edge of the cell, however, caused lamellipodial protrusions and eventually cell migration in 
the direction of photolysis.  Location specific activation of this protein within the cell was key to the 
understanding of the ability of cofilin to steer cellular migration18.  This method was also been used by 
Imperali and colleagues in the construction of a light activated myosin motor protein.  They appended an 
o-nitrobenzyl moiety to a regulatory phosphoserine residue that led to an activating conformational change 
when cleaved20.  Finally, it is not necessary to rely on a naturally occurring conformational control 
mechanism to control enzyme activity with light.  Woolley and colleagues have repeatedly demonstrated 
that bi-functional azobenzene staples to protein backbones can use the force of photoisomerization to push 
and pull the secondary structure of α-helical subunits into and out of proper alignment causing proteins to 
fold and unfold in a light dependent manner, thus modulating their activity21,22,23. 
A more general approach is to think of a protein as a large scaffold to which ligands can be tethered 
to in a light dependent fashion.  Proteins often have reactive cysteine residues that are non-crucial to 
enzymatic activity but are close enough to a ligand binding pocket to act as a covalent attachment site.  
Even when this is not the case, site directed mutagenesis is readily able to provide such a site.  The small 
molecule or peptide agonist/antagonist must be able to effect enzyme activity at high local concentration 
but have little to no effect on the macromolecule if allowed to freely diffuse away or repositioned due to 
photoisomerization.  Lee et al. developed a peptide based protein kinase A (PKA) inhibitor that was tethered 
to the enzyme via a flexible photolabile linker, effectively increasing the local concentration of the inhibitor 
many fold.  This concentrating effect was sufficient to permanently affix the peptide in the active site 
(resulting in < 3% activity) until photolysis allowed the inhibitor to diffuse away, restoring 80% of the native  
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Figure 5.1.  The structure of PKA caging agent from Lee et al. While this caging agent appears structurally 
complex it can be broken down into four functional components.  (i) The PKI peptide reversibly binds the 
caging agent to the protein kinase active side via a flexible PEG linker.  (ii) The thiol reactive maleimide 
covalently links the caging agent to the protein.  (iii) A photolabile o-nitrobenzyl linker cleaves under UV 
light, to allow the PKI inhibitor to diffuse away.  (iiii)  A fluorophore/quencher pair reports the activation of 
the enzyme directly upon photolysis.  
 
Reprinted with permission from Lee, H. M.; Xu, W.; Lawrence, D. S. Construction of a Photoactivatable 
Profluorescent Enzyme via Propinquity Labeling. J. Am. Chem. Soc. 2011, 133, 2331–2333.© 2011 
American Chemical Society. 
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activity of the kinase24.  Furthermore, placing a fluorophore/quencher pair on either side of the 
photocleavable moiety allowed for the enzyme to emit a fluorescent signal when activated (Figure 5.2).  
This basic strategy was repeated with similar results using carbonic anhydrase and a small molecule 
inhibitor in 201325.  Finally, if a tether has the ability to photoisomerize then it is not necessary to have the 
small molecule diffuse away upon photolysis to affect activity of proteins.  The precision with which an 
azobenzene moiety can reposition a tethered ligand upon isomerization from cis to trans allows for a 
wavelength dependent binding or dissociation of ligands to receptors.  Thiol reactive azobenzene 
derivatized ligands have proven themselves useful in controlling ion channels23. 
Of course, one need not modify an enzyme in order to cage its activity.  If an inhibitor binds tightly 
enough to quench enzymatic activity it can be used to cage it.  Li et al. demonstrated this concept with Src 
kinase using a bidentate inhibitor peptide that contained active site and SH2 domain directed peptide 
ligands connected by a photolabile linker.  The binding avidity of these two binding sites created an inhibitor 
with an impressive IC50 of 18 nM, which allowed for complete cessation of Src activity at a peptide 
concentration of 2 µM.  Upon photolysis the active site targeted motif did not have sufficient binding affinity 
to maintain inhibition and 90% of activity was restored26.  This showed that in some cases one may not 
need to chemically modify an enzyme in order to cage it if one can produce a selective inhibitor with a 
sufficiently low IC50 value that can be degraded with light. 
Many modern caged enzymes are prepared by a hybrid of chemistry and molecular biology.  
Engineered “split” proteins are designed using circular permutation so that crucial peptide sequences 
missing from their primary structure causing them to fold improperly.  The sequence is chosen such that 
the missing peptide can reintroduced in solution and bind to the incomplete parent protein, allowing the 
protein to fold properly, and restoring function.  Synthetic peptides are easily modifiable in a site specific 
manner, one can append a photoprotecting group that prevents the split protein system from interacting 
until illumination, leaving the peptide free to bind and activating the protein27.  In a similar fashion, a naturally 
occurring RNAse requiring a separate peptide ligand to bind for activity was caged by using solid phase 
synthesis to modify the peptide sequence to include an o-nitrobenzyl derivative at specific sites.  This 
effectively blocked the peptide-protein interaction and prevented activity until photolysis with UV light  
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allowed for the formation of the holoenzyme28.  An alternative strategy seeks not to use light to recombine 
an incomplete protein with a missing peptide segment but to excise an unnecessary, interfering sequence 
of amino acids.  Recently, Wei et al. have devised a scheme of inserting an intein sequence into proteins, 
which excise themselves upon exposure to UV light.  This intein sequence relies on two flanking cysteine 
residues in order to self excise and splice adjacent N- and C- termini together, which generates a functional 
mCherry fluorescent protein and a functional Src kinase in living cells in seconds.  By protecting one of 
these residues with an o-nitrobenzyl group, this excision and ligation can only occur upon photolysis29.  This 
method is particularly promising because it is a single component system unlike split enzyme systems. 
In order to precisely place photolabile protecting groups at specific amino acid positions on a protein 
many have turned to the method developed by Schultz and colleagues to incorporate non-natural amino 
acids through mutated amber codons and synthetic tRNAs30.  These methods allow one to place an amino 
acid with a photolabile protecting group by inserting a modified amber stop codon into a protein sequence 
at the desired site of incorporation and introducing a modified tRNA that has been acylated with the amino 
acid of interest.  While this method can produce a caged protein in a cellular environment with more 
precision and control than standard chemical methods, the complex biology and chemistry that need to 
combine to incorporate new caging groups is out reach for most labs and so progress into longer 
wavelength activation has been slow.  However, many enzymes have been caged using the o-nitrobenzyl 
group in this way31,32,33. 
Still others have taken the field of caged enzymes and placed it solely in the hands of biologists 
using optogenetics.  Using light activated protein domains that can be fully expressed in living cells, a 
molecular biologist can now activate enzymes and other proteins without the need of chemistry at all.   
Cryptochrome (Cry2) proteins contain a bound FAD molecule that absorbs light and causes conformational 
changes that promote binding to a CIB1 binding partner.  Creating protein fusions with these binding pairs 
one can potentially associate most proteins with an intracellular target using light.  This blue-light induced 
dimerization has been used to control subcellular localization34, induce protein-protein interactions35, and 
associate transcription factors with promoters36.  A red light activated binding pair exists, Phytochrome B 
(PhyB) – PIF3, that behaves in the same manner as Cry2 - CIB1 with red light induced dimerization and 
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near IR disassociation, allowing one to work within the optical window of tissue37.  Another popular 
optogenetic tool is the light-oxygen-voltage (LOV) domain.  This domain contains a flavin moiety that that 
absorbs blue light and causes an α-helical region to dissociate and become disordered.  Careful 
computational engineering is required to use this action to cause a conformational change (leading to a 
change in activity) in a fused protein.  However, once engineered, this represents the only one component 
optogenetic technique38, simplifying kinetics of photoactivaton. 
In this chapter I employ the photolabile tethered inhibitor technique to cage PKA in an analogus 
manner to Lee et al.24  Of all the many enzyme caging techniques this strategy offers the advantage of 
offering a generalizable strategy for photoreversible inhibition of protein kinases.  While PKA natively 
possesses an optimal cysteine location for a maleimide attachment site, other enzymes can be modified to 
include such a residue.  Flexible tethers negate the need for overly precise positioning of this attachment 
site, removing the need for computational modeling.  This system also has the advantage of requiring 
peptide inhibitors of mediocre affinity (which are commonplace in the scientific literature) as they must freely 
dissociate from the enzyme once the photolabile tether is cleaved (Figure 5.2). 
  Cobalamin brings wavelength selectivity to this photoactivation39,40, potentially allowing future 
experiments that activate multiple caged enzymes at controlled intervals.  My goal was to create an 
inhibitor/substrate complex that was catalytically inert or caged (≤10% original activity) until photolysis 
whereupon a resumption in phosphorylation was expected.  While this may seem a departure from my 
claim that cobalamin is not a “caging agent” in the style of photoprotecting groups previously described in 
the literature, one can state the role of the cobalamin is not to cage the enzyme but to sequester an inhibitory 
peptide to an enzyme that cages the activity of PKA.   
5.2.  Design of a “Caged” PKA Activated by Green Light. 
 The basic design of the PKA caging agent incorporated a PKAc (PKA catalytic subunit) active site 
directing peptide (PKI)41 tethered to a thiol reactive maleimide moiety via a photolabile cobalamin based 
linker.  By attaching the peptide inhibitor to the photostable 5’ –OH ribose of cobalamin via a polyethylene 
glycol chain, only the maleimide β-axial ligand remained behind on the surface of PKAc after photolysis.  
(Figure 5.2 and Figure 5.3).  Upon incubation with PKAc, the PKI peptide segment of the caging agent (5c)  
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Figure 5.2. Structure of caging agent 5c.  The cobalamin caging agent (5c) has the following distinct 
sections: i) an active site-directed inhibitor with the sequence Ac-GRAGRRNAIHD ii) a maleimide residue 
to allow for covalent attachment of caging agent to PKAc  iii) a photolabile alkyl cobalamin linker able to 
sever the bond between the enzyme and inhibitor upon exposure to ≤ 577 nm light and iv) a PEG linker 
connecting sections i and iii that is slightly lengthened from Dr. Lee’s model (Figure 5.1) to compensate for 
steric hindrance of the Cbl as compared with the smaller nitrobenzyl moiety used previously.24  
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Figure 5.3.  A general schematic of the process of caging PKA.  i)  5c and PKAc are concentrated and 
incubated at 4 oC, leading to reversible binding of PKI to the enzymatic active site ii) the maleimide moiety 
of 5c clicks into Cys-343, permanently binding PKI to the active site until iii) illumination with < 577 nm light 
causes homolytic cleavage of cobalt-carbon bond.  After cleavage the enzyme is diluted 1000 fold and its 
activity is measured by the Deep Quench assay. 
 
i 
ii 
iii 
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targets the binding cleft of the enzyme active site and the photolabile maleimide ligand undergoes a click 
reaction with Cys – 343 via Michael addition.  Upon photolysis the Co-C bond undergoes homolytic 
cleavage, freeing the inhibitor-cobalamin complex to diffuse away from the active site of the enzyme 
(Figure 5.2 and Figure 5.3). 
The key innovation in the design of 5c that differs from previous chemically caged enzymes is the 
wavelength (577 nm) of activation.  Previous methods have only been able to initiate photolytic activation 
using UV and blue light (<450 nm).  At the time of this work, this represented the longest activating 
wavelength possible.  However, based on the discoveries that would follow (discussed in Chapters 1-3), 
one can easily imagine how this design could be made sensitive to near IR wavelength activation by 
incorporating a fluorophore to the β-axial ligand.  This would allow for both fluorescent labeling of the 
activated enzyme and a fluorescent indicator of cleavage due to the quenching effect of cobalamin. 
PKAc contains only two cysteine residues, Cys–199 and Cys–343.   Cys–199 resides in the active 
site cleft of the enzyme and alkylation of this position results in permanent loss of activity42,43 and must be 
avoided in order to restore catalysis post illumination.  Cys–343 is located approximately 2 nm from this 
site and modification of it is inconsequential to the catalytic function of the enzyme44 (Figure 5.3).  Normally 
the presence of two chemically equivalent reaction sites would present as a major obstacle for a caging 
strategy that relies on reaction selectivity.  However, this system overcomes the issue by selection of an 
inhibitor peptide that covers the active site, protecting Cys-199 from chemical modification.  Even so, the 
coupling reaction takes place at 4 oC, in order to cut the rate of off target maleimide alkylation in half from 
room temperature levels (according to the Arrhenius rate plot from Clarke et al.)45.  This cooler temperature 
simultaneously enhances the binding affinity of PKI to the active site of PKAc by nearly two and a half times 
as determined from the van’t Hoff plot provided by Kivi et al.46.  Furthermore, in order to get as near to 
100% binding as possible, PKAc and 5c are reacted at concentrations 1000 fold greater than what is 
needed to perform the activity assay.  Finally, due to the orientation of PKI bound to the PKAc active site, 
the effective concentration of the maleimide moiety is increased only with respect to Cys–343, selectively 
accelerating the reaction at the desired site.  The combination of tighter binding due to temperature, a  
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Figure 5.4.  The catalytic subunit of PKA is shown.  Cysteine 199 can be seen in the binding cleft of the 
active site, covered by PKI and cysteine 343 lies exposed 20 Å away. 
 
 
Reprinted with permission from Lee, H. M.; Xu, W.; Lawrence, D. S. Construction of a Photoactivatable 
Profluorescent Enzyme via Propinquity Labeling. J. Am. Chem. Soc. 2011, 133, 2331–2333.© 2011 
American Chemical Society. 
 
  
210 
 
slower off target reaction rate, and a selectively accelerated reaction rate at the desired reaction site, 
strongly bias the maleimide click reaction in favor of Cys-343. 
5.3.  Monitoring PKA Activity by Deep Quench 
 The Deep Quench assay47,48 was used to monitor the activity of PKA.  This is a simple assay 
designed by Sharma et al.47 and then refined by Dr. Melanie Priestmann into the form used in this work.  A 
positively charged peptide substrate (such as those favored by PKA) electrostatically attracts a negatively 
charged molecule in solution.   In this instance, the positively charged peptide (5e) is labeled with a 
fluorophore and the negatively charged small molecule is a quencher dye.  Proper selection of fluorophore 
and quencher leads to a sharp fluorescent decrease when the two associate in solution.  Catalytic addition 
of a negatively charged phosphoryl group by the kinase to peptide 5e weakens this electrostatic interaction.  
This results in a fluorescent increase as demonstrated by Scheme 5.2.  It is noteworthy to mention that 
according to Coulumb’s law, given below, the decrease of positive charge of the peptide to one third of its 
original value decreases the attractive force between the peptide and chromophore by the same amount. 
 =	
 ∗ 	
 ∗ 

 
Key advantages of the Deep Quench method are the continuous nature of the assay, the speed at 
which it can be performed, and the small amounts of substrate and enzyme required to detect activity (5 
µM and 25 nM respectively).  This allows for many trials from the same batch of caged enzyme.  
Fluorescence readouts like those demonstrated in Figure 5.5 could be obtained with much less material 
than a more traditional enzymatic coupled assay49.  One disadvantage of the Deep Quench assay is that 
there is as yet no way to generate quantitative reaction rates from it.  However, for the purposes of these 
experiments such data was not needed.  By comparing the relative activity of modified enzymes to wild 
type activity, a relative rate was obtained.  Figure 5.5 shows the fluorescent response from wild type enzyme 
and an equivalent amount of enzyme with activity extinguished by N-ethylmaleimide (NEM) treatment50.  
The negative control is necessary because any perturbation of the system could potentially change the 
interaction between peptide and quencher, changing the fluorescent intensity.  
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Scheme 5.2.  Mechanism of the Deep Quench assay.  The PKA substrate 5d (5-TAM-GRTGRRFSY-NH2) 
contains three basic arginine residues, giving it a charge of 3+.  The acidic aniline blue quencher has a 
charge of 3-. Electrostatic interactions are able to bring the two species together causing a quench.  Once 
phosphorylation occurs, the quencher can no longer bind as tightly to the dye and the substrate increases 
in fluorescence (ʎex: 555 nm, ʎem: 585 nm). 
 
  
5d 
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Figure 5.5.  Demonstration of the PKA-catalyzed fluorescent increase using Deep Quench.  The Deep 
Quench reaction buffer included 5 µM substrate, 1 mM MgCl2, 1 mM ATP, 30 µmol aniline blue, 25 mM Tris 
HCl pH 7.5 One can see the response to addition of wild type enzyme (blue) and catalytically dead PKA 
(orange).   Both WT and dead enzymes were present at a concentration of 25 nM.  The gaps in the continuity 
of the data at 300 s indicates the point at which measurements were halted for enzyme addition. 
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 In order to obtain the fluorescent increase due to catalytic activity, the fluorescent response needed 
to be subtracted by the observed increase in fluorescence triggered by a catalytically dead enzyme.  It is 
important to remember that this assay only measures the disruption of a peptide-quencher interaction and 
highly sensitive fluorimeters can detect the slightly fluorescent increase due to minute disruptions in binding 
that can occur with the addition of reagents (such as proteins).  The inactivated enzyme served as a control 
for changes in fluorescence due to non-catalytic disturbances to binding equilibria.  In order to obtain a 
relative rate, initial rates of modified enzymes were divided by the rate of unreacted, wild type PKA.  This 
allowed for rates to be reported as a percentage of wild type activity.  This procedure is illustrated in Figure 
5.6 with a generic caged enzyme used as an example.   
5.4.  Free Inhibitor Effect of Nonconjugated 5c on PKA 
 I began by testing the hypothesis that the enzyme must be covalently modified with caging agent 
5c in order to show a decrease in activity.  Thefore, 2 µM PKAc and 10 µM 5c were combined in the 
presence of 1 mM DTT.   These conditions did not allow for the formation of a maleimide-protein bond 
because DTT was present in 500 times the abundance of either of the cysteines on PKAc which is known 
to thwart maleimide couplings to proteins51.  This instead led to the formation of 5e (shown in Figure 5.7)51.  
After allowing the reaction to take place for 30 min at room temperature, the enzyme was diluted to 20 nM 
in Deep Quench buffer, leaving the inhibitor (5e) concentration at 100 nM (40% higher than in any of the 
caged enzyme studies). 
As seen in Figure 5.8, the relative activity of the enzyme with 100 nM inhibitor present was 96% ± 
4% that of wild type enzyme.  The enzymatic activities of the two reactions create almost parallel fluorescent 
responses.  In other words, the inhibition caused by freely associated inhibitor at a concentration of 100 nM 
is too slight to be accurately detected by this assay.  An inhibitor with a Ki large enough to be ineffective at 
blocking activity when not tethered to the enzyme (at concentrations encountered in the Deep Quench 
assay) is crucial to this design. 
5.5.  Enzyme Caging Reaction 
 While the design of the caging agent was fairly straightforward, reaction conditions had to be 
optimized to acheive the desired goal of <10% WT activity in the caged state and at least a 5 fold recovery  
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Figure 5.6.  Demonstration of the method of rate determination for modified PKAc by Deep Quench.  (top) 
The initial increase in TAMRA fluorescence is shown after the addition of catalytically “dead” enzyme (red), 
a caged enzyme (yellow), the same caged enzyme after photolysis (grey), and the wild type enzyme (blue).  
(bottom)  By subtracting out the fluorescent signal created by the addition of inactivated enzyme one is left 
with only the fluorescent increase due to the catalytic activity of PKA.  Dividing the slope of the activity of 
modified enzymes by the slope of wild type activity provides a relative rate.  The various curves in this figure 
represent a typical catalytic profile of a non-optimized caged enzyme before and after photolysis.  In this 
demonstration, the reaction conditions of PKA with 5c have generated a caged enzyme that displays a rate 
of 13% of WT and a recovery of 55% of WT activity upon photolysis.   
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Figure 5.7.  The structure of the DTT-Inhibitor conjugate, 5e.  In a PKA caging reaction, all unreacted 5c 
had to be reacted with DTT before photolysis could occur in order to prevent photolyzed maleimide from 
attacking the free enzyme.  This molecule was the product of the DTT quench at the end of every coupling 
reaction.  It can be seen from Figure 5.8 that 5e is not inhibitory at the concentrations found in the kinase 
assay.  
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Figure 5.8.  Wild type activity compared to enzymatic activity in the presence of 5e.  The initial activity of 
wild type PKAc (blue) compared with the same enzyme after a 30 min treatment with 5c in 1 mM DTT 
(orange).  DTT prevented the covalently linked enzyme inhibitor complex from forming.  The initial slope of 
the fluorescent response for wild type and treated enzyme were 115 ± 5.2 and 110.8 ± 0.4 respectively. 
  
40000
41000
42000
43000
44000
45000
46000
47000
48000
49000
0 10 20 30 40 50
Fl
u
o
re
sc
e
n
ce
 
/ a
.
u
.
Time / s
217 
 
  
 
 
 
 
 
 
 
Figure 5.9.  The fluorescent response of two modified enzymes by Deep Quench.  The activity of PKAc 
caged with 1.1 eq 5c is shown in grey.  The activity of PKAc caged with 2.5 eq 5c before (blue) and after 
(organge) 5 min photolysis under 577 nm light  The relative rates of these enzymes compared to wild type 
PKA is 51% ± 2%, 12% ± 1%, and 89% ± 4% respectively. 
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upon photolysis.  Enzyme concentration during the caging reaction was maintained at 21 µM while the 
concentration of the caging agent was varied.  Initially two concentrations of caging agent were employed 
1.1 eq 5c to enzyme and 2.5 eq.  The resulting catalytic activity can be seen in Figure 5.9.  At the end of a 
17 h coupling reaction, the coupling reaction was quenched with DTT and activity was assessed by Deep 
Quench.  With a 10% excess of caging agent to enzyme, PKAc activity was only cut in half (grey line).  
However at a 150% excess of caging agent, the picture looked very different.  Caged enzyme activity (blue) 
droped to nearly one tenth that of wild type and upon photolysis at 0 oC (577 nm light), the wild type activity 
was nearly restored.  This represented a promising first step in attaining a photoactivable PKAc. 
5.6.  Optimization of Enzyme Caging Reaction 
In order to affirm that enough time was being given to the enzyme-inhibitor conjgation, I repeated 
the 17 hour, 4 oC coupling reaction and then elevated the temperature to 22 oC for several hours.  By 
sampling the caged PKA activity at 1 h, 2 h, and 3.5 h after the temperature change the reaction 
completeness could be compared over time.  If the enzyme activity continued to change after the transistion, 
where the maleimide coupling reaction rate was doubled, it would indicate that 17 h was insufficienct time 
for the coupling reaction and more complete caging would take place with increased time rather than 
increased caging agent.  This took advantage of the relative thermal stability of PKAc, which can be 
exposed to room tempreature for hours without signficant loss of activity.   
When one compares the phosphorylation rate of each coupling reaction (1.1 and 2.5 eq), it clearly 
demonstrates that no further loss of activity is taking place.  In fact only the wild type PKA showed any loss 
of activity from being exposed to room temperature for 3.5 h (thermal deanturation).  The lack of diminished 
activity in the caged enzymes revealed that not only was no further coupling taking place but the binding of 
PKI to the active site of PKAc lent thermal stability to the enzyme52 as the only enzyme batch without PKI 
showed any signs of denaturation (Figure 5.10 and Table 5.1). 
After determining that additional reaction time made no difference to the initial rate of the caged 
PKA, other means of reducing dark activity were needed.  One solution suggested by the initial data was 
to simply increase the concentration of inhibitor.  Therefore the concentration of inhibitor in the caging 
reaction was increased to 3 and 4.5 eq with respect to PKA.  After 17 h of coupling at 4 oC the left over 5c  
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Figure 5.10.  Assessment of caging reaction completeness and the enchanced thermal stability of caged 
enzymes.  The first minute of PKAc activity, as assessed by Deep Quench, is shown for enzymes treated 
with (a) 2.5 eq, (b) 1.1 eq and (c) no amount of caging agent (5c).  In order to judge the completeness of 
the caging reaction in the time alotted in the standard protocol,  PKAc was allowed to couple with 5c for 17 
h at 4 oC in the dark.  Then, in order to acellerate the reaction of any uncoupled enzyme, the samples were 
allowed react at room temperature (22 oC) for a further 1 h (orange), 2 h (grey), or 3.5 h (blue).  In each 
case, the reaction was quenched by DTT and the Deep Quench assay was performed on 20 nM enzyme.  
A decrease in the initial slope of the kinase reaction over time would have revealed that either the enzymes 
were denaturing over time or the coupling was still proceeding after 17 h.  No such change is observed for 
enzymes treated with 5c, indicating that additional time would not enahnce the caging effect.  The wild type 
enzyme is less active after 3.5 h because it does not have the added thermal stability provided by the bound 
inhibitor. 
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[5c]  
Slope (a. u. / s) 
1 h 2 h 3.5 h 
0 eq 15 ± 0.5 14 ± 2 12 ± 4 
1 eq 7.8 ±0.3 8.4 ± 0.8 9.1 ± 0.9 
3 eq 4.6 ±0.3 4.6 ± 0.3 4.8 ± 1.2 
 
Table 5.1.  The slopes of enzymatic activity obtained by Deep Quench from Figure 5.9.  The different caging 
reactions were treated with for 17 h before being warmed to room temperature for 1 h, 2 h, and 3.5 h as 
shown.  Had the maleimide click reaction were not been finished, the reaction rates would have decreased 
over time as click reaction was given increased time to react at elevated temperatures that would double 
the rate of the micahel addiition.  However the only enzyme that lost activity over time was the wild type 
enzyme due to thermal denaturation.  Due to the the difference in denaturation rates it was not possible to 
convert these slopes into relative activities. 
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was converted to 5e with 0.5 mM DTT and activities were measured by Deep Quench.   The caged 
activites for 1.1 eq, 2.5 eq, 3 eq, and 4.5 eq were 51% ± 2%, 12% ± 1%, 10% ± 1% and 4% ± 1%, 
respectively.   
 The enzyme created by addition of 1.1 eq of inhibitor was not photolyzed because the caged activity 
before photolysis (>50%) was too large to be of use. The caged enzymes created by treatment with 2.5, 3, 
and 4.5 eq of 5c were photolyzed with 577 nm light for 5 min on ice and their activities jumped to 97% ± 
1%, 53% ± 4%, and 47% ± 1% of wild type PKA respectively post illumination.  Tabel 5.2 provides a 
summary of the activities of all caged enzyme batches before and after photolysis.  A maximal 
phototriggerable increase of 12 fold was obtained by coupling PKAc with 4.5 eq 5c.  Figure 5.11 clearly 
demonstrates that caging agent 5c is able to quench the activity of PKAc and then increase activity by an 
order of magnitude after photolysis. It is worth nothing that there is clear trade off between background 
activity for the caged state of PKAc and the amount of activity that can be recovered after photolysis.  
However, the important metric of a caged enzyme is the difference between caged and uncaged states.   
The decrease in the post photolysis restoration of enzyme activity that occurred as the 
concentration of 5c increased was not due to the effect of freely associating PKI.  I have demonstrated that 
even the highest concentrations of inhibitor used in these experiments had little to no effect on catalysis in 
the absense of covalent modification (See Figure 5.8).  Several factors could play a role in this decrease.  
The more alkyl radicals that one generates in solution, the more chance they have of abstracting hydrogens 
in crucial places on the enzyme.  Abstracting from the side chains of non-essential amino acids might not 
have much of an effect on PKA activity.  However, should a radical abstract a hydrogen directly from the 
amide backbone, this could lead to strand scission and a complete denaturation of the enzyme53.  If this 
were the cause of the unrecoverable PKA activity, one would not expect a mathematically inverse 
relationship between activity and free radical concentration because even damaged enzymes still function 
as a radical trap.  A cleaved and denatured enzyme can absorb free radicals and prevent damage to intact 
PKA, and in fact the decrease in restored activity does appear to level off after 3 eq. 
Another potential reason for loss of activity is the removal of the reducing agent, DTT, through 
generation of hydroxocobalamin, the byproduct of photolysis of the cobalt carbon bond in the presence of  
222 
 
 
 
 
 
 
 
 
 
 
Ratio of Caging Agent to PKAc 
 1.1 2.5 3 4.5 
Caged Activity 
(% of WT) 51 12 10 4 
Uncaged Activity 
(% of WT) n/a 97 53 47 
Fold Change 
After Photolysis n/a 8 5 12 
 
Table 5.2.  Extent of enzyme caging and fold change in activity after phototlysis vs concentration of caging 
agent 5c.  PKAc concentration was held at a constant 21 µM while the concentration of the caging agent 
was varied.  Coupling reactions took place for 17 h, in the dark, and at 4 oC.  The greatest recovery (% of 
WT activity after photolysis) occurred at 2.5 eq of caging agent, while the greatest fold change (ratio of 
uncaged to caged activity) occurred at 4.5 eq.   
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Figure 5.11.  The first 20 s of PKA activity resulting from four different coupling reactions between PKAc 
and 5c before (left) and after (right) photolysis.  (a) At 1.1 eq caging agent the activity of the enzyme dropped 
to 51% of wild type activity. (b) At 2.5 and (c) 3 eq the rate became 13% and 11% of wild type respectively.  
(d) At 4.5  eq the rate drops to 3.9% of wild type PKA, which is well below the stated goal of a caged activity 
of less than 10%.  The rate of catalysis after 5 min photolysis at 577 nm on ice was determined for enzymes 
treated with 2.5, 3, and 4.5 eq of inhibitor.  The relative initial rates for PKA after these caging conditions 
were (b) 97%, (c) 53%, and (d) 47% respectively.  
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Scheme 5.3. Mechanism of amide 
backbone scission by free radicals.   A 
primary carbon radical (a) is easily 
reactive enough to abstract a hydrogen 
from a nearby alpha carbon  on the 
amide backbone of a protein (b).  
Hyperconjugation with the amino acid 
side chain, resonance with a carbonyl, 
and a lone pair of electrons on an 
adjacent nitrogen are all stabilizing 
factors that make abstraction from this 
position more energetically favored 
than other places.  Interactions with 
molecular oxygen would lead to a 
peroxy radical (c) that would be 
eliminated (d) by the adjacent 
heteroatom.  Once this occurs, the 
protein backbone is vulnerable to 
scission via hydrolysis (e). 
a) 
b) 
c) 
d) 
e) 
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oxygen.  Hydroxocobalamin is well known to catalytically degrade aqueous DTT54.  If enough cobalamin 
were present to consume the majority of DTT before photolysis of the caged enzyme was complete, any 
alkyl radicals created after that point would be free to damage enzymes in solution because there would be 
fewer sulfhydryls in solution to act as a radical trap.  Scheme 5.2 demonstrates one mechanistic route for 
strand scission of the amide backbone of PKA.  In retrospect, using glutathione to quench the reaction 
would most likely avoid this problem because of the stability of the Co-S bond in glutathionyl cobalamin55.   
5.7.  Conclusion 
 I was able to synthesize a peptide based PKA caging agent with a photolabile tether that covalently 
binds to PKAc and inhibits activity until exposure 577 nm light.  Without covalent modification the presence 
of the peptide inhibitor provided no alteration in PKA activity.  Unfortunately, at present the technology does 
not exist to microinject this species into a living cell, as visible light is needed to guide the injection needle, 
which would lead to unintentional photolysis of the enzyme complex.  This limits the biological utility of this 
acheivement to a proof of principle for now. 
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5.8.  Materials and Methods 
3-aminopropylcobalamin (5a): Synthesized as reported by Shell et al.39 
Maleimidocobalamin (5b): 5a (100 mg, 72 µmol, mw=1385) was dissolved in 5 mL of DMF. To this solution 
3 eq of N-Succinimidyl 6-maleimidohexanoate (63 mg, 216 µmol, mw=292) was added along with 5 eq. 
DIPEA (65 µL, 360 µmol, mw =129) and allowed to react at r.t. under shaking for 4 h in the dark.  The 
product was recrystallized twice in either:chloroform (50 mL).  The resulting precipitate was collected by 
centrifugation and decantation.  The pellet was dried under vacuum and 10 mL EtOH was added. 5b was 
purified on a 100g C18 flash column with a linear gradient an H2O:MeOH (0.1% TFA) gradient from 0 – 
100% in 8 column volumes.   5b eluted at 65% MeOH.  Maleimidocobalamin (5b): orange solid, 70%, ESI 
MS calcd. for C75H107CoN15O17P (M2+) m/z = 790.84, found 791.0.  (M3+) m/z = 527.89, found 527.9. 
227 
 
 
Scheme 5.4 The structure and synthesis of 5a and 5b. 
 
PKA Caging Agent (5c) – PKI-PEG3-Lys peptide was synthesized using standard solid phase peptide 
synthesis on a Prelude peptide synthesizer from Protein Technology with Fmoc protected amino acids.  A 
0.21 mmol/g a NovaSyn TGR resin was employed with 5 eq amino acids, 4.9 eq HCTU, 10 eq DIPEA, 
double coupling (20 min each). 3 eq Fmoc-NH-PEG3-CH2CH2COOH.  Fmoc deprotection was performed 
in 20% piperidine (5 times for 3 min each).  The N-terminus was acetylated with acetic anhydride with 20% 
DIPEA.  Ac-GRAGRRNAIHD-PEG3-K-NH2.  Peptide cleavage took place in 95% TFA, 2.5% H2O, and 2.5% 
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TIS.  Crude peptide was purified by HPLC using a C18 column.  5b (16 mg, 10 µmol, mw=1580) was 
dissolved in 3 mL of anhydrous DMSO and 10 eq CDT (16 mg, 100 µmol, mw=164) was added. The solution 
was stirred for 45 min in the dark.  Excess CDT was removed by ether:chloroform (12 mL, 3x) 
recrystallization.  Recrystalized product dried under vacuum and combined with 5 mg of PKI-PEG3-Lys in 
with DIPEA (10 eq to peptide) in 1 mL DMSO and allowed to react in the dark with shaking over night.  Pure 
5c was obtained by HPLC purification. PKA Caging Agent (5c)- Red solid, ESI MS calcd. for 
C141H220CoN42O38P (M3+ + H2O) m/z = 1082.86, found 1082.8.  (M4+ + H2O) m/z = 812.15, found 812.3 (M4+ 
+ H2O) = 649.71 found, 649.2.   
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Scheme 5.5.  The structure and synthesis of 5c. 
 
PKA Substrate (5e) – PKA substrate was prepared as previously described in Oien et al.48 Briefly, peptide 
was synthesized using standard solid phase peptide synthesis on a Prelude peptide synthesizer from 
Protein Technology with Fmoc protected amino acids.  A 0.21 mmol/g a NovaSyn TGR resin was employed 
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with 5 eq amino acids, 4.9 eq HCTU, 10 eq DIPEA, double coupling (20 min each). Fmoc deprotection was 
performed in 20% piperidine (5 times for 3 min each).  The N-terminus was labeled with 5-TAM (double 
coupling, 4 h each) using a 2 fold excess of the fluorophore, 5 eq DIPEA, and 1.9 eq of HCTU. Peptide 
cleavage took place in 95% TFA, 2.5% H2O, and 2.5% TIS.  Crude peptide was purified by HPLC using a 
C18 column.   
Deep Quench Procedure   
A volume of 200 µL Deep Quench reaction buffer (5 µM 5e, 1 mM MgCl2, 1 mM ATP, 30 µmol aniline blue, 
25 mM Tris HCl pH 7.5) was added to a 200 µL quartz cuvette in a PTI fluorimeter with a heated temperature 
block set to 30 oC.  The fluorescence signal was allowed to equilibrate before 1 µL enzyme (25 nM) was 
added.  ʎEx = 555 nm, ʎEm = 585 nm. Rate data was taken from the initial linear portion of the fluorescent 
increase.  Baseline was determined by assaying an equivalent amount of catalytically inactive enzyme. 
Enzyme Caging Reaction 
PKA catalytic subunit was expressed in E. coli as described by Lee et al. Enzyme was diluted to a 
concentration of 21 µM in a buffer consisting of 10% glycerol, 10 mM ATP, 50 mM Tris HCl pH 7.5, and 
varying concentrations of 5c.  The reaction generally proceeded in the dark for 17 h at 4 oC, unless 
otherwise specified.  The reaction was quenched with 1 mM DTT, after which the enzyme was immediately 
ready for assaying.   
Enzyme Photolysis 
Sample was placed on ice in an insulated chamber capped by a 532 ± 10 nm filter 1 in away.  Photolysis 
was performed using a 20 W compact fluorescent bulb positioned as close to the filter as possible without 
touching.  Photolysis was complete after 30 min.    
Generation of Catalytically Inactive PKA 
 PKA catalytic subunit (20 µM) was treated with 4 mM NEM in buffer containing 10 mM ATP, 10 mM MgCl2, 
25 mM Tris pH 7.5.  The reaction took place at r. t. for 4 h.  Maleimide was quenched with 4 mM DTT. 
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